Lens ID,Source Country,ISSNs,Publisher,Source Title,Title,Fields of Study,Date Published,Publication Year,Publication Type,Keywords,Funding,Issue Number,Start Page,End Page,Author/s,Abstract,Volume,MeSH Terms,Chemicals,Source URLs,External URL,Patent Citation Count,PMID,DOI,Microsoft Academic ID,PMCID,References,Scholarly Citation Count
000-831-233-186-748,Germany,00320943; 14390221,Georg Thieme Verlag,Planta Medica,A Compound Isolated from Phyllanthus tenellus Demonstrates Metabolic and Vascular Effects In Vitro,Adenosine; Pinocembrin; Phenylephrine; Metabolic syndrome; Tenellus; Endothelial dysfunction; Biochemistry; Diabetes mellitus; Biology; Platelet; Pharmacology,2020-01-01,2020,journal article,,,01,78,84,Omar Estrada; Camilo Di Giulio; Radharani Dorta-Ledezma; Freddy González-Mujica; Norma Motta; Elsa Zea; Nelson Cupitra; Whendy Contreras; Raul Narvaez-Sanchez; Juan C. Calderón,"Common chronic conditions such as metabolic syndrome and diabetes are increasingly associated to metabolic and cardiovascular complications. Although Phyllanthus tenellus leaves have been used in decoctions as a popular remedy to control blood glucose levels and hypertension, its use needs a scientific basis. This study was therefore undertaken to report a phytochemical analysis of P. tenellus leaves and to test if the main active compound has potential to simultaneously tackle several pathophysiological features of metabolic syndrome and diabetes-related metabolic and vascular disorders such as hyperglycaemia, increased platelet activation, and endothelial dysfunction. We performed a partition of the methanolic extract of P. tenellus leaves among different organic solvents followed by chromatographic separation guided by the rat liver microsomal glucose-6-phosphatase assay. Two known tannins were identified by spectroscopic methods as pinocembrin-7-O-[3″-O-galloyl-4″,6″-(S)-hexahydroxydiphenoyl]-α-D-glucose, named P7OG by us, and gemin D. The structural determination of the isolated compounds was based on spectral data. The ability of the main active component, P7OG, to inhibit human platelet aggregation and to modify vascular reactivity of rat aortic rings incubated with high glucose (D-glucose 55 mM) was then evaluated. P7OG was further able to inhibit platelet aggregation induced by adenosine 5′-diphosphate and collagen, showed vasorelaxant effects in arteries precontracted with phenylephrine, and reverted the endothelium-dependent impairment effect of high glucose in rat aortic rings. In conclusion, one tannin isolated from P. tenellus showed promising metabolic, antiaggregant, and vascular effects, which suggests the potential beneficial use of P. tenellus to tackle complex cardiometabolic diseases.",86,,,https://www.thieme-connect.de/products/ejournals/abstract/10.1055/a-1019-9401 https://www.ncbi.nlm.nih.gov/pubmed/31652477 https://www.thieme-connect.com/products/ejournals/abstract/10.1055/a-1019-9401,https://www.thieme-connect.de/products/ejournals/abstract/10.1055/a-1019-9401,0,,,2982035470,,007-612-990-766-584; 008-723-667-219-351; 010-395-554-708-45X; 012-150-150-835-097; 012-511-171-882-301; 017-708-334-525-925; 018-844-331-664-973; 024-926-890-681-549; 030-206-765-383-747; 032-916-563-639-758; 033-248-893-305-174; 034-391-860-970-002; 042-105-410-174-56X; 042-972-959-342-968; 062-428-460-451-715; 064-596-063-485-431; 069-451-062-509-096; 071-715-345-524-374; 076-822-580-638-676; 113-604-922-638-436; 129-727-072-973-844; 136-007-285-226-218; 160-008-130-484-524; 180-510-575-051-86X; 196-495-618-343-212,0
002-315-999-739-942,United States,03008177; 15734919,Springer Netherlands,Molecular and Cellular Biochemistry,"Effect of high doses of vitamin D supplementation on dengue virus replication, Toll-like receptor expression, and cytokine profiles on dendritic cells",Innate immune system; Molecular biology; Calcitriol receptor; Immunology; Virus; Toll-like receptor; Inflammation; TLR3; Cytokine; Dengue virus; Biology,2020-01-01,2020,journal article,,,1,169,180,Jahnnyer Martínez-Moreno; Juan C. Hernandez; Silvio Urcuqui-Inchima,"Dengue, caused by dengue virus (DENV) infection, is a public health problem worldwide. Although DENV pathogenesis has not yet been fully elucidated, the inflammatory response is a hallmark feature in severe DENV infection. Although vitamin D (vitD) can promote the innate immune response against virus infection, no studies have evaluated the effects of vitD on DENV infection, dendritic cells (DCs), and inflammatory response regulation. This study aimed to assess the impact of oral vitD supplementation on DENV-2 infection, Toll-like receptor (TLR) expression, and both pro- and anti-inflammatory cytokine production in monocyte-derived DCs (MDDCs). To accomplish this, 20 healthy donors were randomly divided into two groups and received either 1000 or 4000 international units (IU)/day of vitD for 10 days. During pre- and post-vitD supplementation, peripheral blood samples were taken to obtain MDDCs, which were challenged with DENV-2. We found that MDDCs from donors who received 4000 IU/day of vitD were less susceptible to DENV-2 infection than MDDCs from donors who received 1000 IU/day of vitD. Moreover, these cells showed decreased mRNA expression of TLR3, 7, and 9; downregulation of IL-12/IL-8 production; and increased IL-10 secretion in response to DENV-2 infection. In conclusion, the administration of 4000 IU/day of vitD decreased DENV-2 infection. Our findings support a possible role of vitD in improving the innate immune response against DENV. However, further studies are necessary to determine the role of vitD on DENV replication and its innate immune response modulation in MDDCs.",464,,,https://link.springer.com/article/10.1007/s11010-019-03658-w,https://link.springer.com/article/10.1007/s11010-019-03658-w,0,,,2990191413,,000-032-277-008-029; 001-823-423-805-534; 003-893-793-149-788; 005-273-518-596-837; 005-643-213-843-820; 006-848-395-684-247; 008-507-963-048-239; 008-946-160-115-017; 009-697-137-423-822; 010-025-756-498-413; 012-638-527-655-74X; 016-144-954-235-737; 018-506-811-294-842; 020-075-841-189-541; 021-267-138-187-096; 021-397-574-269-122; 024-519-559-748-725; 024-928-888-377-723; 025-500-457-369-480; 026-378-500-518-729; 028-471-499-451-780; 028-738-102-757-563; 030-088-110-400-396; 031-186-659-098-53X; 033-967-017-985-326; 037-285-998-932-308; 039-207-167-051-63X; 041-385-014-942-902; 043-309-635-059-002; 044-113-378-565-378; 046-317-865-996-80X; 046-384-126-100-512; 046-698-920-067-416; 047-168-570-469-21X; 050-199-593-369-107; 050-587-754-989-564; 051-002-156-129-193; 051-170-771-162-772; 051-684-390-771-257; 051-800-896-011-98X; 051-970-504-157-536; 055-038-906-045-643; 056-245-106-531-721; 056-575-862-391-834; 058-036-696-291-255; 058-902-531-035-163; 059-507-473-765-091; 067-944-980-636-564; 068-371-826-260-58X; 072-250-458-566-940; 075-892-281-492-627; 079-334-019-031-525; 080-869-733-328-111; 082-595-124-944-039; 095-249-902-768-28X; 096-155-411-213-158; 098-464-783-758-978; 098-900-298-398-620; 123-796-911-062-840; 124-048-202-948-49X,0
002-660-837-045-478,United States,02719142; 15732592,Springer New York,Journal of Clinical Immunology,Human Inborn Errors of Immunity: 2019 Update on the Classification from the International Union of Immunological Societies Expert Committee,Medical microbiology; Immunology; Disease; Immunity; Rapid identification; Computational biology; Biology,2020-01-17,2020,journal article,IUIS; autoinflammatory disorders; immune dysregulation; inborn errors of immunity; next-generation sequencing; primary immune deficiency,,,1,41,Stuart G. Tangye; Waleed Al-Herz; Aziz Bousfiha; Talal A. Chatila; Charlotte Cunningham-Rundles; Amos Etzioni; José Luis Franco; Steven M. Holland; Christoph Klein; Tomohiro Morio; Hans D. Ochs; Eric Oksenhendler; Capucine Picard; Jennifer M. Puck; Troy R. Torgerson; Jean-Laurent Casanova; Kathleen E. Sullivan,"We report the updated classification of Inborn Errors of Immunity/Primary Immunodeficiencies, compiled by the International Union of Immunological Societies Expert Committee. This report documents the key clinical and laboratory features of 416 inborn errors of immunity, including 64 gene defects that have either been discovered in the past 2 years since the previous update (published January 2018) or were characterized earlier but have since been confirmed or expanded upon in subsequent studies. The application of next-generation sequencing continues to expedite the rapid identification of novel gene defects, rare or common; broaden the immunological and clinical phenotypes of conditions arising from known gene defects and even known variants; and implement gene-specific therapies. These advances are contributing to greater understanding of the molecular, cellular, and immunological mechanisms of disease, thereby enhancing immunological knowledge while improving the management of patients and their families. This report serves as a valuable resource for the molecular diagnosis of individuals with heritable immunological disorders and also for the scientific dissection of cellular and molecular mechanisms underlying inborn errors of immunity and related human diseases.",,,,https://link.springer.com/article/10.1007/s10875-019-00737-x,http://dx.doi.org/10.1007/s10875-019-00737-x,0,31953710,10.1007/s10875-019-00737-x,3000301584,,000-763-425-467-323; 001-337-648-985-560; 002-223-953-163-900; 002-684-655-228-413; 003-716-097-297-296; 003-901-423-657-432; 004-726-101-512-012; 007-941-154-448-000; 008-050-219-698-770; 010-040-780-423-88X; 011-107-403-507-308; 013-007-808-594-803; 013-187-480-649-663; 013-661-721-804-827; 015-038-327-936-635; 016-211-163-206-726; 016-310-302-322-852; 016-405-032-216-401; 016-626-372-573-527; 016-709-010-268-086; 016-986-575-720-792; 017-572-462-827-418; 018-479-665-041-423; 018-704-155-034-416; 018-883-363-596-778; 018-925-733-813-323; 019-362-073-397-028; 019-597-403-871-113; 019-691-167-547-768; 020-017-280-169-085; 020-445-642-698-859; 021-859-383-064-881; 023-032-160-485-221; 023-348-855-588-455; 024-476-581-443-98X; 024-538-718-169-493; 024-738-311-170-798; 025-233-713-296-601; 025-829-822-240-647; 026-313-799-369-360; 027-680-166-121-622; 028-270-833-148-496; 028-391-785-811-96X; 030-229-848-598-809; 031-295-113-376-06X; 031-763-526-735-467; 032-334-587-928-722; 034-007-958-149-248; 034-527-678-823-583; 034-664-266-344-464; 034-909-095-541-051; 035-082-587-304-937; 035-144-049-346-305; 035-267-512-142-022; 036-038-852-964-740; 037-048-352-624-358; 037-463-542-061-427; 037-798-019-546-686; 038-996-447-184-742; 039-113-690-672-492; 040-859-901-747-471; 043-589-363-800-088; 043-868-370-193-396; 046-734-843-240-259; 047-888-605-644-424; 048-202-819-690-896; 049-964-334-276-096; 052-660-015-237-925; 053-122-347-678-303; 053-214-692-980-587; 053-523-920-590-636; 054-677-159-805-219; 055-003-230-378-068; 058-566-995-831-301; 059-598-948-074-275; 062-019-418-472-216; 065-715-741-272-757; 065-717-826-510-557; 065-807-598-064-397; 068-748-244-560-58X; 070-379-914-776-453; 074-058-141-278-230; 076-020-434-389-216; 082-549-637-508-438; 083-267-844-985-158; 085-292-314-627-326; 085-453-405-937-017; 088-131-843-196-818; 090-584-812-288-06X; 091-045-114-919-788; 099-024-861-134-069; 104-842-372-327-584; 110-453-610-064-088; 114-883-250-924-560; 119-625-769-310-709; 123-749-332-445-407; 124-106-244-858-225; 124-135-057-322-655; 127-266-304-139-356; 129-211-580-274-647; 130-144-089-592-723; 130-173-048-818-899; 130-643-312-283-525; 154-851-779-305-422; 171-167-097-140-558,0
005-665-008-526-380,United States,1525755x; 15257541,American Meteorological Society,Journal of Hydrometeorology,Two-Layer Dynamic Recycling Model (2L-DRM): Learning from Moisture Tracking Models of Different Complexity,Geology; Water cycle; Monsoon; Meteorology; Moisture,2020-01-01,2020,journal article,,National Science Foundation; U.S. Department of Energy Office of Science Biological and Environmental Research; Comite Desarrollo Investicacion,1,3,16,Francina Dominguez; H. Hu; J. A. Martinez,AbstractAtmospheric moisture tracking models are used to identify and quantify sources and sinks of water in the atmospheric branch of the hydrologic cycle. These models are primarily used to inves...,21,,,https://journals.ametsoc.org/doi/full/10.1175/JHM-D-19-0101.1,http://dx.doi.org/10.1175/jhm-d-19-0101.1,0,,10.1175/jhm-d-19-0101.1,2989261267,,005-007-326-139-074; 008-187-675-033-411; 009-677-722-455-835; 010-107-803-453-015; 015-332-986-540-498; 019-059-788-204-187; 026-478-095-764-456; 032-630-558-240-917; 042-341-206-704-169; 043-616-274-093-626; 049-138-567-706-363; 049-485-531-933-923; 049-494-859-758-924; 049-853-902-816-926; 050-780-038-232-143; 051-536-096-197-640; 052-132-887-030-754; 055-836-704-511-710; 056-796-718-214-066; 059-094-637-270-499; 060-759-132-116-241; 073-283-931-629-888; 075-633-955-288-010; 080-654-559-998-268; 083-885-610-509-86X; 095-326-572-969-287; 097-761-424-239-839; 099-099-382-020-079; 100-095-730-897-973; 105-974-438-542-107; 112-513-188-565-040; 118-341-732-550-740; 118-524-375-595-909; 122-338-847-884-473; 130-503-979-114-75X; 135-493-176-171-043; 137-344-883-122-949; 142-377-080-044-272; 145-731-413-880-219; 147-709-618-133-390; 158-008-128-594-837; 160-708-763-271-550; 161-632-429-560-734; 187-887-271-426-065,0
005-881-779-937-635,United States,08852308; 10958363,Academic Press Inc.,Computer Speech & Language,Principal component analysis of the spectrogram of the speech signal: Interpretation and application to dysarthric speech,Principal component analysis; Connected speech; Close vowel; Speech recognition; Dysarthric speech; Signal interpretation; Computer science; Spectrogram; Vocal tract; Linear combination,2020-01-01,2020,journal article,,,,114,122,Abdellah Kacha; Francis Grenez; Juan Rafael Orozco-Arroyave; Jean Schoentgen,Abstract The article concerns the interpretation of the principal components of the spectrogram of the speech signal and its application to the description of dysarthric speech. Each principal component is a linear combination of the frame spectra. We show that the first principal component of the spectrogram is closely related to the long-term average spectrum (LTAS) and the second principal component is the difference of two weighted sums of frame spectra reporting open and close vowel frame spectra respectively. We investigate articulation deficits in dysarthric speakers via cues obtained from principal components of the spectrogram of connected speech because long-term average spectra have been claimed to inform about speaker settings of the vocal tract.,59,,,https://www.sciencedirect.com/science/article/pii/S0885230819301111,http://dx.doi.org/10.1016/j.csl.2019.07.001,0,,10.1016/j.csl.2019.07.001,2954911682,,002-576-098-897-56X; 006-366-437-379-75X; 008-673-787-746-049; 009-774-153-089-525; 013-437-875-698-151; 016-474-485-555-448; 017-886-993-865-28X; 018-609-023-584-234; 027-235-028-460-25X; 028-332-745-625-580; 034-867-380-109-994; 038-482-060-504-133; 044-597-678-552-003; 055-447-867-781-804; 068-056-759-737-084; 068-261-286-469-587; 071-626-337-830-043; 076-284-574-503-446; 106-322-331-808-393; 107-378-799-330-857; 125-123-160-480-369; 151-444-568-077-645; 156-071-496-007-180; 156-686-521-551-147; 166-922-771-645-757; 169-172-209-133-577; 178-562-440-045-14X; 189-911-264-549-518,0
006-871-828-157-123,United States,00143820; 15585646,Wiley-Blackwell,Evolution,Signal evolution and morphological complexity in hummingbirds (Aves: Trochilidae),Ecology; Iridescence; Ornaments; Macroevolution; Evolutionary biology; Biology,2020-01-10,2020,journal article,Iridescence; macroevolution; melanosomes; ornaments,AFOSR (FA9550-18-1-0477); HFSP (RGY 0083); HFSP (RGP 0047); Colombian Administrative Department for Science and Technology - Colciencias (111571250482),,,,Chad M. Eliason; Rafael Maia; Juan L. Parra; Matthew D. Shawkey,"Understanding how animal signals are produced is critical for understanding their evolution because complexity and modularity in the underlying morphology can affect evolutionary patterns. Hummingbird feathers show some of the brightest and most iridescent colors in nature. These are produced by optically complex stacks of hollow, platelet-shaped organelles called melanosomes. Neither how these morphologies produce colors nor their evolution has been systematically studied. We first used nanoscale morphological measurements and optical modeling to identify the physical basis of color production in 34 hummingbird species. We found that, in general, the melanosome stacks function as multilayer reflectors, with platelet thickness and air space size explaining variation in hue (color) and saturation (color purity). Additionally, light rays reflected from the outer keratin surface interact with those reflected by small, superficial melanosomes to cause secondary reflectance peaks, primarily in short (blue) wavelengths. We then compared variation of both the morphological components and the colors they produce. The outer keratin cortex evolves independently and is more variable than other morphological traits, possibly due to functional constraints on melanosome packing. Intriguingly, shorter wavelength colors evolve faster than longer wavelength colors, perhaps due to developmental processes that enables greater lability of the shapes of small melanosomes. Together, these data indicate that increased structural complexity of feather tissues is associated with greater variation in morphology and iridescent coloration.",,,,https://onlinelibrary.wiley.com/doi/pdf/10.1111/evo.13893,http://dx.doi.org/10.1111/evo.13893,0,31922617,10.1111/evo.13893,3000473418,,000-037-644-647-002; 000-531-577-299-389; 001-211-720-132-818; 001-861-496-182-961; 002-297-909-805-357; 004-200-460-198-540; 005-008-228-599-952; 007-561-402-546-087; 009-309-744-667-223; 015-227-305-346-637; 018-089-353-646-972; 018-183-594-293-734; 018-754-991-850-887; 021-699-375-898-499; 022-436-533-877-127; 023-729-400-207-31X; 026-441-979-000-532; 026-596-169-891-886; 027-972-990-895-065; 032-127-437-739-473; 034-585-191-625-388; 034-590-883-631-486; 035-481-253-901-967; 037-820-808-798-358; 037-910-968-149-479; 042-424-500-628-244; 044-863-909-419-04X; 046-595-017-262-264; 048-726-350-120-008; 049-466-468-851-808; 052-502-752-808-958; 056-219-923-972-827; 056-340-181-638-946; 057-356-061-537-537; 058-435-677-898-666; 064-322-379-039-683; 066-599-452-691-876; 068-459-435-061-889; 071-265-920-325-350; 072-038-822-922-887; 076-025-325-960-439; 077-229-774-939-214; 077-659-627-943-547; 078-340-485-754-16X; 087-584-223-234-700; 088-794-516-421-317; 095-401-037-094-770; 097-389-126-648-29X; 106-524-694-696-39X; 109-927-290-815-845; 133-328-923-282-950; 133-583-891-755-810; 145-531-248-714-658; 154-117-665-509-754; 167-275-555-617-549,0
008-407-040-285-211,United States,10795642; 15244636,Lippincott Williams and Wilkins,"Arteriosclerosis, Thrombosis, and Vascular Biology",Genetically Determined ABO Blood Group and its Associations With Health and Disease,ABO blood group system; Disease; Physiology; Biochemistry; Diabetes mellitus; Biology,2020-01-23,2020,journal article,ABO; aging; blood; genetics; hypertension; phenotype,,,ATVBAHA119313658,,Hilde E. Groot; Laura E. Villegas Sierra; M. Abdullah Said; Erik Lipsic; Jacco C. Karper; Pim van der Harst,"Objective: To determine the spectrum of phenotypes linked to the ABO blood group system, using genetic determinants of the ABO blood group system. Approach and Results: We assessed the risk of 41 h...",,,,https://www.ahajournals.org/doi/abs/10.1161/ATVBAHA.119.313658,http://dx.doi.org/10.1161/atvbaha.119.313658,0,31969017,10.1161/atvbaha.119.313658,3000971549,,001-272-667-580-53X; 005-620-345-994-944; 007-698-069-148-014; 008-141-944-121-185; 008-964-061-671-500; 010-087-238-158-500; 012-063-413-553-337; 014-643-355-701-680; 015-218-343-804-104; 016-441-435-849-105; 025-376-946-112-859; 034-028-431-967-861; 037-060-876-513-749; 038-838-511-037-293; 041-593-348-719-256; 042-137-905-950-969; 043-552-349-809-140; 046-120-666-878-705; 046-543-047-501-874; 046-718-041-032-044; 054-957-420-442-578; 058-750-716-937-42X; 060-683-604-069-423; 075-955-542-075-553; 077-277-956-689-937; 081-011-443-050-587; 092-768-633-817-674; 096-217-262-497-361; 115-391-153-995-813; 119-824-885-451-797,0
008-786-606-452-49X,Germany,18149324; 18149332,European Geosciences Union,Climate of The Past,South Pacific Subtropical High from the late Holocene to the end of the 21st century: insights from climate proxies and general circulation models,Global warming; Geology; Intertropical Convergence Zone; Climate change; Westerlies; Subtropical ridge; Climate model; Tropical climate; Paleoclimatology; Climatology,2020-01-10,2020,journal article,,,1,79,99,Valentina Flores-Aqueveque; Maisa Rojas; Catalina Aguirre; Paola A. Arias; Charles González,"Abstract. The South Pacific Subtropical High (SPSH) is a; predominant feature of the South American climate. The variability of this; high-pressure center induces changes in the intensity of coastal alongshore; winds and precipitation, among others, over southwestern South America. In; recent decades, strengthening and expansion of the SPSH have been observed; and attributed to the current global warming. These changes have led to an; intensification of the southerly winds along the coast of northern to; central Chile and a decrease in precipitation from central to southern; Chile. Motivated by improving our understanding about the regional impacts; of climate change in this part of the Southern Hemisphere, we analyzed SPSH; changes during the two most extreme climate events of the last millennium,; the Little Ice Age (LIA) and the Current Warm Period (CWP: 1970–2000), based; on paleoclimate records and CMIP5/PMIP3 model simulations. In order to; assess the level of agreement of general circulation models, we also compare; them with ERA-Interim reanalysis data for the 1979–2009 period as a; complementary analysis. Finally, with the aim of evaluating future SPSH; behavior, we include 21st century projections under a Representative Concentration Pathway (RCP8.5) scenario in; our analyses. Our results indicate that during the relative warm (cold); period, the SPSH expands (contracts). Together with this change, alongshore; winds intensify (weaken) south (north) of ∼35 ∘  S; also, southern westerly winds become stronger; (weaker) and shift southward (northward). Model results generally; underestimate reanalysis data. These changes are in good agreement with; paleoclimate records, which suggest that these variations could be related; to tropical climate dynamics but also to extratropical phenomena. However,; although models adequately represent most of the South American climate; changes, they fail to represent the Intertropical Convergence Zone–Hadley cell system dynamics, emphasizing the importance of improving; tropical system dynamics in simulations for a better understanding of its; effects on South America. Climate model projections indicate that changes; recently observed will continue during the next decades, highlighting the need; to establish effective mitigation and adaptation strategies against their; environmental and socioeconomic impacts.",16,,,https://www.clim-past.net/16/79/2020/ https://noa.gwlb.de/receive/cop_mods_00050018 https://www.clim-past-discuss.net/cp-2019-69/cp-2019-69.pdf https://www.clim-past-discuss.net/cp-2019-69/,http://dx.doi.org/10.5194/cp-16-79-2020,0,,10.5194/cp-16-79-2020,2955439468,,000-215-924-058-711; 001-041-370-399-520; 004-394-057-622-725; 004-895-562-647-283; 005-252-925-625-946; 005-458-709-846-481; 005-912-515-496-935; 005-949-967-026-124; 005-974-484-495-780; 006-333-129-852-137; 006-846-939-789-903; 007-019-444-668-883; 007-680-572-155-793; 008-190-119-365-500; 009-684-688-554-156; 010-012-018-619-292; 010-773-444-925-723; 011-140-312-510-127; 011-529-198-504-836; 013-758-539-614-403; 014-607-014-939-633; 015-438-849-512-154; 015-721-771-599-379; 016-201-780-377-249; 016-579-612-324-484; 017-985-504-423-573; 018-408-551-268-955; 018-649-936-649-502; 020-454-539-951-793; 022-675-043-027-654; 022-916-513-589-585; 023-467-499-656-520; 023-708-678-662-779; 024-981-219-193-41X; 025-093-906-189-456; 025-223-757-177-824; 028-738-235-318-679; 031-286-354-993-056; 031-770-960-024-655; 032-340-617-365-168; 034-155-333-679-550; 035-047-765-721-95X; 037-095-879-675-655; 037-804-363-524-732; 038-280-063-607-546; 038-559-374-506-935; 039-224-101-095-458; 039-744-181-351-026; 040-062-682-029-470; 040-719-809-981-391; 040-723-577-891-451; 042-774-399-921-699; 043-268-795-561-60X; 045-064-672-345-489; 045-661-843-477-431; 046-160-553-751-595; 046-863-224-843-369; 047-864-732-606-221; 048-336-295-718-184; 049-800-015-187-474; 050-757-475-942-295; 051-746-310-905-026; 051-910-912-342-082; 052-873-280-827-087; 054-184-790-893-243; 059-016-688-661-023; 061-040-232-972-853; 062-571-893-761-884; 063-456-242-396-521; 064-227-848-342-250; 065-286-451-032-47X; 065-830-453-674-253; 066-678-945-550-639; 066-800-044-946-827; 067-266-278-309-176; 068-360-530-458-550; 069-314-378-892-561; 070-153-861-668-624; 074-505-505-069-045; 075-270-413-462-74X; 076-612-202-010-616; 078-587-049-003-102; 078-903-019-092-249; 079-561-102-621-075; 080-162-405-578-016; 080-361-718-055-226; 081-292-265-833-899; 082-248-503-880-358; 083-250-718-062-546; 087-374-371-247-241; 087-416-813-441-985; 089-531-115-537-476; 090-601-249-947-338; 091-111-568-833-367; 092-378-400-301-155; 095-684-869-654-331; 098-142-676-037-92X; 099-708-826-203-900; 100-243-257-277-905; 100-696-053-391-919; 101-542-743-771-50X; 104-574-970-094-532; 106-848-273-738-230; 107-216-873-203-37X; 107-978-935-463-080; 109-080-935-845-283; 111-012-385-693-728; 115-467-732-537-102; 116-688-914-896-662; 117-368-376-988-335; 121-211-450-636-08X; 125-482-534-265-482; 126-665-376-864-321; 128-340-902-070-407; 130-562-830-638-512; 132-178-624-413-722; 134-182-792-940-905; 136-991-245-789-84X; 137-389-002-114-164; 137-581-071-484-927; 138-377-900-346-360; 139-017-364-228-949; 141-689-127-356-000; 150-713-069-124-028; 151-026-227-849-465; 159-639-150-658-806; 165-400-694-253-084; 166-272-769-014-022; 168-738-556-814-389; 176-452-115-799-28X; 176-486-846-537-852; 180-300-859-103-03X; 190-804-345-467-014; 196-375-574-850-75X,0
010-515-831-913-333,Netherlands,0001706x; 18736254,Elsevier,Acta Tropica,VENOM DIVERSITY IN THE NEOTROPICAL SCORPION GENUS TITYUS: IMPLICATIONS FOR ANTIVENOM DESIGN EMERGING FROM MOLECULAR AND IMMUNOCHEMICAL ANALYSES ACROSS ENDEMIC AREAS OF SCORPIONISM,Antivenom; Envenomation; Virology; Phylogenetic tree; Scorpion; Panama; Venom; Antigenic Diversity; Amazon rainforest; Biology; Zoology,2020-01-23,2020,journal article,Tityus; antivenom; immunochemical; neurotoxin; scorpion; venom,,,105346,,Adolfo Borges; Bruno Lomonte; Yamileth Angulo; Hildaura Acosta de Patiño; Juan M. Pascale; Rafael Otero; Roberto J. Miranda; Leonardo De Sousa; Matthew J. Graham; Aarón Gómez; Pedro Pereira de Oliveira Pardal; Edna Aoba Yassui Ishikawa; Fabián Bonilla; Adolfo Castillo; Ricardo A. Machado de Avila; Juan Pablo Gómez; Jorge A. Caro-López,"ABSTRACT Scorpions of the Neotropical genus Tityus are responsible for most severe envenomations in the Caribbean, South America, and Lower Central America (LCA). Although Tityus is taxonomically complex, contains high toxin polymorphism, and produces variable clinical manifestations, treatment is limited to antivenoms produced against species with restricted distributions. In this study, we explored the compositional and antigenic diversity of Tityus venoms to provide improved guidelines for the use of available antivenoms at a broader geographic scale. We used immunoblotting, competitive ELISA, and in vivo studies to compare reactivity against commercial antivenoms from Brazil, Venezuela, and Mexico, as well as MALDI-TOF mass spectrometry, cDNA sequencing, and phylogenetic analyses to assess venom sodium channel-active toxin (NaTx) content from medically important Tityus populations inhabiting Brazil, Colombia, Costa Rica, Ecuador, Panama, Trinidad and Tobago, and Venezuela. Additionally, we raised rabbit antibodies against Tityus venoms from LCA to test for cross-reactivity with congeneric species. The results suggest that Tityus spp. possess high venom antigenic diversity, underlying the existence of four toxinological regions in Tropical America, based on venom composition and immunochemical criteria: LCA/Colombia/Amazonia (Region I), Venezuela (Region II), southeast South America (Region III), and a fourth region encompassing species related to toxinologically divergent Tityus cerroazul. Importantly, our molecular and cross-reactivity results highlight the need for new antivenoms against species inhabiting Region I, where scorpions may produce venoms that are not significantly reactive against available antivenoms.",,,,https://www.sciencedirect.com/science/article/pii/S0001706X19314780,http://dx.doi.org/10.1016/j.actatropica.2020.105346,0,31982434,10.1016/j.actatropica.2020.105346,3003048841,,000-036-544-586-957; 000-356-435-975-016; 000-471-066-016-680; 002-021-250-096-080; 005-827-924-382-887; 006-439-361-893-553; 007-110-615-470-810; 007-146-134-970-333; 007-854-131-859-864; 008-520-676-216-240; 011-645-951-225-043; 013-126-038-657-880; 013-403-473-211-130; 013-572-453-503-15X; 015-384-496-461-222; 016-004-141-124-592; 020-797-669-931-605; 024-701-444-415-614; 025-735-270-899-04X; 026-965-307-434-132; 027-774-718-202-461; 028-275-357-615-470; 032-506-096-317-896; 037-899-351-631-869; 038-424-556-999-402; 039-591-738-165-825; 039-772-716-762-541; 040-132-978-778-658; 041-149-194-783-245; 041-554-595-182-765; 043-622-776-825-867; 045-474-818-703-595; 046-332-945-675-163; 046-644-862-576-613; 047-124-401-731-884; 047-534-193-919-55X; 048-069-314-247-127; 051-655-307-780-206; 052-215-353-741-23X; 052-438-399-713-881; 053-679-108-506-246; 054-175-888-175-923; 054-839-784-274-192; 056-170-146-907-582; 057-382-947-776-923; 058-346-620-752-944; 059-014-985-469-397; 059-498-629-833-758; 059-797-215-055-511; 060-154-831-670-063; 060-680-130-679-137; 061-241-284-233-199; 061-958-581-000-55X; 062-778-833-385-109; 063-753-221-932-71X; 064-183-441-447-825; 065-195-594-043-295; 066-724-824-519-293; 067-979-808-905-670; 068-262-741-760-718; 068-342-308-986-898; 070-163-495-034-11X; 070-327-602-090-976; 072-660-848-691-132; 074-335-610-937-343; 075-536-012-803-545; 079-571-287-506-928; 080-933-682-260-105; 083-796-921-750-285; 086-748-085-798-664; 087-047-720-794-908; 087-370-136-458-702; 088-116-957-096-350; 096-126-708-473-986; 098-589-983-993-779; 103-865-632-161-644; 107-173-786-917-166; 116-405-521-761-326; 124-099-060-365-730; 126-156-557-261-970; 135-798-866-326-089; 143-340-981-915-44X; 145-663-820-940-694; 147-062-353-951-739; 169-157-778-533-487; 191-880-691-137-617,0
011-676-210-735-224,,,,,Estrategias financieras para el fútbol como generador de valor,Humanities; Political science,2020-01-14,2020,,,,2,,,Laura Juliana Franco Montoya; Laura Cadavid Silva; Leidy Johana Orozco Grisales; Diego Alonso Ramírez Gómez,"El desarrollo del presente articulo esta orientado a establecer las estrategias financieras que requiere llevar a cabo el Club Rionegro Aguilas Doradas en el marco del Objetivo Basico Financiero (OBF). Para esto se realizo un diagnostico de los estados financieros del equipo deportivo; adicionalmente se hizo una investigacion documental mediante la cual se establecieron los antecedentes sobre el tema, se realizaron entrevistas a algunos profesionales del area financiera para obtener el conocimiento de las posibles estrategias que se pueden implementar; y finalmente se establecieron algunas estrategias que pueden ayudar al equipo a alcanzar el Objetivo Basico Financiero frente a la optimizacion de los ingresos, evaluacion permanente del flujo de caja y la gestion eficiente de costos y gastos.",4,,,https://www.funlam.edu.co/revistas/index.php/SHA/article/view/3493,https://www.funlam.edu.co/revistas/index.php/SHA/article/view/3493,0,,,2999074159,,,0
011-866-405-708-389,Netherlands,03702693,Elsevier,Physics Letters B,Search for light pseudoscalar boson pairs produced from decays of the 125 GeV Higgs boson in final states with two muons and two nearby tracks in pp collisions at s=13TeV,Pseudoscalar; Particle physics; Physics; Higgs boson; Lepton; Muon; Branching fraction; Standard Model; Fermion; Boson,2020-01-01,2020,journal article,,"Türkiye Atom Enerjisi Kurumu; CERN; State Fund for Fundamental Research of Ukraine; Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul; Academy of Finland; U.S. Department of Energy; Department of Atomic Energy, Government of India; Austrian Science Fund; University of South Alabama; National Natural Science Foundation of China; Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional; Ministry of Education and Science; European Regional Development Fund; National Research Center ""Kurchatov Institute""; Fonds De La Recherche Scientifique - FNRS; Fonds Wetenschappelijk Onderzoek; Welch Foundation; Instituto Nazionale di Fisica Nucleare; National Research Foundation of Korea; Departamento Administrativo de Ciencia, Tecnología e Innovación (COLCIENCIAS); Fonds pour la Formation à la Recherche dans l’Industrie et dans l’Agriculture; Alexander von Humboldt-Stiftung; Science Foundation Ireland; Российский Фонд Фундаментальных Исследований (РФФИ); Nemzeti Kutatási, Fejlesztési és Innovaciós Alap; Nemzeti Kutatási, Fejlesztési és Innovaciós Alap; Nemzeti Kutatási, Fejlesztési és Innovaciós Alap; Nemzeti Kutatási, Fejlesztési és Innovaciós Alap; Nemzeti Kutatási, Fejlesztési és Innovaciós Alap; Nemzeti Kutatási, Fejlesztési és Innovaciós Alap; Nemzeti Kutatási, Fejlesztési és Innovaciós Alap; Nemzeti Kutatási, Fejlesztési és Innovaciós Alap; National Academy of Sciences of Ukraine; Fundacja na rzecz Nauki Polskiej; Ministerstwo Nauki i Szkolnictwa Wyższego; Ministerstwo Nauki i Szkolnictwa Wyższego; Ministerstwo Nauki i Szkolnictwa Wyższego; Ministerstwo Nauki i Szkolnictwa Wyższego; Ministerstwo Nauki i Szkolnictwa Wyższego; Fundação para a Ciência e a Tecnologia; Ministry of Science,Technology and Research; Conselho Nacional de Desenvolvimento Científico e Tecnológico; Qatar National Research Fund; European Regional Development Fund; National Science and Technology Development Agency; Secretaría de Estado de Investigación, Desarrollo e Innovación; A.G. Leventis Foundation; Belgian Federal Science Policy Office; Agentschap voor Innovatie door Wetenschap en Technologie; Ministry of Education and Science; Chinese Academy of Sciences; Science and Technology Facilities Council; Magyar Tudományos Akadémia; Research Promotion Foundation; State Atomic Energy Corporation ROSATOM; Secretaría de Educación Superior, Ciencia, Tecnología e Innovación; European Commission; Institute for Research in Fundamental Sciences; General Secretariat for Research and Technology; Fundação de Amparo à Pesquisa do Estado de São Paulo; Bundesministerium für Bildung, Wissenschaft und Forschung; Helmholtz-Gemeinschaft; Ministerstvo Školství, Mládeže a Tělovýchovy; Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro; Weston Havens Foundation; Alfred P. Sloan Foundation; Ministry of Business, Innovation and Employment; Pakistan Atomic Energy Commission; European Research Council; European Research Council; European Research Council; Secretaría de Educación Pública; Consejo Nacional de Ciencia y Tecnología; Department of Science and Technology, Ministry of Science and Technology; Ministry of Science, ICT and Future Planning; Russian Academy of Sciences; Benemérita Universidad Autónoma de Puebla; Coordenação de Aperfeiçoamento de Pessoal de Nível Superior; Deutsche Forschungsgemeinschaft; Bundesministerium für Bildung und Forschung; Ministry of Science and Technology of the People's Republic of China; Joint Institute for Nuclear Research; MSES; CSF; MoER; ERC IUT; PUT; MEC; HIP; CEA and CNRS/IN2P3; MES; LAS; MOE; UM; LNS; UASLP-FAI; MOS; MSHE; NSC; MON; MESTD; CPAN; PCTI; Swiss Funding Agencies; MST; ThEPCenter; IPST; STAR; TUBITAK; NSF; Beijing Municipal Science & Technology Commission; Council of Science and Industrial Research; Programa Estatal de Fomento de la Investigación Científica y Técnica de Excelencia María de Maeztu; EU-ESF and the Greek NSRF; Rachadapisek Sompot Fund for Postdoctoral Fellowship, Chulalongkorn University",,135087,,A. M. Sirunyan; Armen Tumasyan; Wolfgang Adam; Federico Ambrogi; Ece Aşılar; Thomas Bergauer; Johannes Brandstetter; Marko Dragicevic; Janos Erö; A. Escalante Del Valle; Martin Flechl; R. Frühwirth; V. M. Ghete; Josef Hrubec; Manfred Jeitler; Natascha Krammer; Ilse Krätschmer; Dietrich Liko; Thomas Madlener; Ivan Mikulec; Navid Rad; Herbert Rohringer; Jochen Schieck; Robert Schöfbeck; Markus Spanring; Daniel Spitzbart; Wolfgang Waltenberger; Johannes Wittmann; C.-E. Wulz; Mateusz Zarucki; Vladimir Chekhovsky; V. Mossolov; J. Suarez Gonzalez; E. A. De Wolf; D. Di Croce; Xavier Janssen; Jasper Lauwers; Aleksandra Lelek; Maxim Pieters; H. Van Haevermaet; P. Van Mechelen; N. Van Remortel; Freya Blekman; Jorgen D'Hondt; J. De Clercq; Kevin Deroover; Giannis Flouris; Denys Lontkovskyi; Steven Lowette; Ivan Marchesini; Seth Moortgat; Lieselotte Moreels; Quentin Python; K. Skovpen; Stefaan Tavernier; W. Van Doninck; P. Van Mulders; I. Van Parijs; Diego Beghin; Bugra Bilin; Hugues Brun; Barbara Clerbaux; G. De Lentdecker; Hugo Delannoy; Brian Dorney; Giuseppe Fasanella; Laurent Favart; Anastasia Grebenyuk; Amandeep Kaur Kalsi; Jelena Luetic; Andrey Popov; Nicolas Postiau; Elizabeth Starling; Laurent Thomas; C. Vander Velde; Pascal Vanlaer; David Vannerom; Qun Wang; Tom Cornelis; Didar Dobur; Alexis Fagot; Muhammad Gul; Illia Khvastunov; Christos Roskas; Daniele Trocino; Michael Tytgat; Willem Verbeke; Basile Vermassen; Martina Vit; N. Zaganidis; O. Bondu; Giacomo Bruno; Claudio Caputo; Pieter David; Christophe Delaere; Martin Delcourt; Andrea Giammanco; Georgios Krintiras; Vincent Lemaitre; Alessio Magitteri; Krzysztof Piotrzkowski; Alessia Saggio; M. Vidal Marono; Pietro Vischia; Joze Zobec; Fábio Lúcio Alves; G. A. Alves; G. Correia Silva; C. Hensel; Arthur Moraes; M. E. Pol; P. Rebello Teles; E. Belchior Batista Das Chagas; W. Carvalho; Jose Chinellato; Eduardo Coelho; E. M. Da Costa; G. G. Da Silveira; D. De Jesus Damiao; C. De Oliveira Martins; S. Fonseca De Souza; L. M. Huertas Guativa; Helena Malbouisson; D. Matos Figueiredo; M. Melo De Almeida; C. Mora Herrera; Luiz Mundim; Helio Nogima; W. L. Prado Da Silva; L. J. Sanchez Rosas; A. Santoro; A. Sznajder; Mauricio Thiel; E. J. Tonelli Manganote; F. Torres Da Silva De Araujo; A. Vilela Pereira; Sudha Ahuja; Cesar Augusto Bernardes; Luigi Calligaris; T. R. Fernandez Perez Tomei; Eduardo De Moraes Gregores; P. G. Mercadante; S. F. Novaes; Sandra S. Padula; Aleksandar Aleksandrov; R. Hadjiiska; P. Iaydjiev; Andrey Marinov; Milena Misheva; M. Rodozov; Mariana Shopova; G. Sultanov; A. Dimitrov; Leander Litov; B. Pavlov; P. Petkov; Wenxing Fang; Xinlei Gao; Li Yuan; M. Ahmad; J. G. Bian; G. M. Chen; H. S. Chen; M. Chen; Y. C. Chen; C. H. Jiang; Duncan Leggat; H. Liao; Z. K. Liu; S. M. Shaheen; Aniello Spiezia; J. Tao; E. Yazgan; H. Zhang; S. Zhang; J. Zhao; Y. Ban; G. Chen; Andrew Levin; Jing Li; Liang Li; Q. Li; Y. J. Mao; S. J. Qian; Dong Wang; Y. Wang; C. Avila; A. Cabrera; C. A. Carrillo Montoya; L. F. Chaparro Sierra; C. Florez; C. F. González Hernández; M. A. Segura Delgado; J. D. Ruiz Alvarez; Nikola Godinovic; Damir Lelas; Ivica Puljak; Toni Sculac; Z. Antunovic; Marko Kovac; V. Brigljevic; D. Ferencek; K. Kadija; Benjamin Mesic; Matej Roguljic; A. Starodumov; Tatjana Susa; Mohsan Waseem Ather; Alexandros Attikis; Marina Kolosova; Georgios Mavromanolakis; Jehad Mousa; C. Nicolaou; Fotios Ptochos; P. A. Razis; Hans Rykaczewski; M. Finger; Edy Ayala; E. Carrera Jarrin; A. A. Abdelalim; Yasser Assran; M. A. Mahmoud; Sandeep Bhowmik; A. Carvalho Antunes De Oliveira; Ram Krishna Dewanjee; Karl Ehataht; M. Kadastik; M. Raidal; Christian Veelken; Paula Eerola; Henning Kirschenmann; Juha Pekkanen; M. Voutilainen; Joona Havukainen; Jaana Kristiina Heikkilä; Terhi Jarvinen; Veikko Karimäki; Ritva Kinnunen; Tapio Lampén; Kati Lassila-Perini; Santeri Laurila; Sami Lehti; Tomas Lindén; Panja-Riina Luukka; Teppo Mäenpää; Hannu Siikonen; Eija Tuominen; Jorma Tuominiemi; Tuure Tuuva; Marc Besancon; Fabrice Couderc; M. Dejardin; D. Denegri; Jérôme Faure; F. Ferri; S. Ganjour; A. Givernaud; P. Gras; G. Hamel de Monchenault; P. Jarry; Clément Leloup; E. Locci; J. Malcles; J. Rander; A. Rosowsky; M. Ö. Sahin; A. Savoy-Navarro; M. Titov; Chiara Amendola; Florian Beaudette; P. Busson; C. Charlot; Batoul Diab; R. Granier de Cassagnac; Inna Kucher; Artur Lobanov; J. Martin Blanco; C. Martin Perez; M. Nguyen; C. Ochando; Giacomo Ortona; P. Paganini; Jonas Rembser; R. Salerno; J. B. Sauvan; Yves Sirois; Alexandre Zabi; Amina Zghiche; J. L. Agram; J. Andrea; D. Bloch; Guillaume Bourgatte; J. M. Brom; E. C. Chabert; Vladimir Cherepanov; Caroline Collard; E. Conte; J. C. Fontaine; D. Gelé; U. Goerlach; Markéta Jansová; A. C. Le Bihan; Nicolas Tonon; P. Van Hove; Sébastien Gadrat; Stephanie Beauceron; Colin Bernet; G. Boudoul; N. Chanon; R. Chierici; D. Contardo; P. Depasse; H. El Mamouni; J. Fay; S. Gascon; Maxime Gouzevitch; G. J. Grenier; B. Ille; Francois Lagarde; I. B. Laktineh; Hugues Lattaud; M. Lethuillier; L. Mirabito; S. Perries; V. Sordini; Gaël Touquet; M. Vander Donckt; Sébastien Viret; Arsen Khvedelidze; Zviad Tsamalaidze; C. Autermann; L. Feld; M. K. Kiesel; K. Klein; Martin Lipinski; Marius Preuten; Max Philip Rauch; Christian Schomakers; Johannes Schulz; Marius Teroerde; B. Wittmer; Andreas Albert; M. Erdmann; Sören Erdweg; Thomas Esch; R. Fischer; Saranya Ghosh; T. Hebbeker; Carsten Heidemann; K. Hoepfner; Henning Keller; Luca Mastrolorenzo; Markus Merschmeyer; Andreas Bernhard Meyer; Philipp Millet; Swagata Mukherjee; Andrzej Novak; Tobias Pook; Andrey Pozdnyakov; Markus Radziej; H. Reithler; Marcel Rieger; Alexander Schmidt; Archana Sharma; D. Teyssier; Sebastian Thüer; G. Flügge; Olena Hlushchenko; T. Kress; Thomas Müller; Alexander Nehrkorn; A. Nowack; Claudia Pistone; O. Pooth; Dennis Roy; Hale Sert; A. Stahl; M. Aldaya Martin; Till Arndt; C. Asawatangtrakuldee; Illia Babounikau; H. Bakhshiansohi; Kelly Beernaert; Olaf Behnke; U. Behrens; A. Bermúdez Martínez; David Bertsche; A. A. Bin Anuar; Kerstin Borras; Valeria Botta; A. J. Campbell; Patrick Connor; S. Consuegra Rodríguez; Christian Contreras-Campana; Vladyslav Danilov; A. De Wit; Matteo Maria Defranchis; C. Diez Pardos; D. Domínguez Damiani; G. Eckerlin; Thomas Eichhorn; Adam Elwood; Engin Eren; Elisabetta Gallo; A. Geiser; J. M. Grados Luyando; Alexander Grohsjean; Moritz Guthoff; Mykyta Haranko; Ali Harb; Nur Zulaiha Jomhari; H. Jung; M. Kasemann; James Keaveney; C. Kleinwort; Joscha Knolle; D. Krücker; W. Lange; Teresa Lenz; J. Leonard; K. Lipka; W. Lohmann; R. Mankel; Isabell-Alissandra Melzer-Pellmann; A. B. Meyer; M. Meyer; Marino Missiroli; Gregor Mittag; J. Mnich; Volodymyr Myronenko; D. Pérez Adán; Svenja Karen Pflitsch; D. Pitzl; Alexei Raspereza; Andrej Saibel; Mykola Savitskyi; Pooja Saxena; Paul Schütze; C. Schwanenberger; Rostyslav Shevchenko; A. P. Singh; Heiner Tholen; Oleksii Turkot; Antonio Vagnerini; M. Van De Klundert; G. P. Van Onsem; R. Walsh; Y. Wen; Katarzyna Wichmann; Christoph Wissing; O. Zenaiev; Robin Aggleton; Samuel Bein; Lisa Benato; Anna Benecke; Volker Blobel; Torben Dreyer; Aliakbar Ebrahimi; Erika Garutti; D. Gonzalez; P. Gunnellini; Johannes Haller; Andreas Hinzmann; Anastasia Karavdina; Gregor Kasieczka; R. Klanner; Roman Kogler; Nataliia Kovalchuk; Simon Kurz; Viktor Kutzner; J. C. Lange; Daniele Marconi; Jens Multhaup; Marek Niedziela; C. E. N. Niemeyer; Dominik Nowatschin; Adrian Perieanu; Arne Reimers; Oliver Rieger; Christian Scharf; P. Schleper; Svenja Schumann; J. Schwandt; Jory Sonneveld; Hartmut Stadie; G. Steinbrück; F. M. Stober; Marc Stöver; Benedikt Vormwald; Irene Zoi; Melike Akbiyik; C. Barth; Marta Baselga; Sebastian Baur; Thomas Berger; Erik Butz; René Caspart; Thorsten Chwalek; W. De Boer; A. Dierlamm; K. El Morabit; Nils Faltermann; M. Giffels; Marco Alexander Harrendorf; F. Hartmann; U. Husemann; I. Katkov; Simon Kudella; Soureek Mitra; M. U. Mozer; Th. Müller; M. Musich; G. Quast; Klaus Rabbertz; M. Schröder; Ivan Shvetsov; H. J. Simonis; Ralf Ulrich; M. Weber; Clemens Wöhrmann; Roger Wolf; G. Anagnostou; G. Daskalakis; T. Geralis; A. Kyriakis; D. Loukas; Garyfallia Paspalaki; Antonis Agapitos; George Karathanasis; Pantelis Kontaxakis; A. D. Panagiotou; Ioanna Papavergou; Niki Saoulidou; Konstantinos Vellidis; Georgios Bakas; Konstantinos Kousouris; Ioannis Papakrivopoulos; Georgios Tsipolitis; I. Evangelou; C. Foudas; Paraskevas Gianneios; Panagiotis Katsoulis; P. Kokkas; Stavros Mallios; Kalliopi Manitara; N. Manthos; I. Papadopoulos; Evangelos Paradas; John Strologas; Frixos A Triantis; Dimitrios Tsitsonis; Márton Bartók; Mate Csanad; Nicolas Filipovic; Péter Major; Koushik Mandal; Ankita Mehta; Marton Imre Nagy; Gabriella Pasztor; Olivér Surányi; Gabor Istvan Veres; G. Bencze; C. Hajdu; D. Horvath; Ádám Hunyadi; F. Sikler; Tamás Álmos Vámi; Viktor Veszpremi; G. Vesztergombi; N. Beni; S. Czellar; János Karancsi; Alajos Makovec; J. Molnar; Z. Szillasi; P. Raics; Z. L. Trocsanyi; Balazs Ujvari; Samrat Choudhury; Jyothsna Rani Komaragiri; Praveen Chandra Tiwari; Seema Bahinipati; Chandiprasad Kar; Prolay Mal; A. Nayak; S. Roy Chowdhury; D. K. Sahoo; S. K. Swain; Sunil Bansal; S. B. Beri; V. Bhatnagar; Shubhanshu Chauhan; Ridhi Chawla; Nitish Dhingra; Ruchi Gupta; A. Kaur; M. Kaur; Sandeep Kaur; Priyanka Kumari; Manisha Lohan; Meena Meena; Kaur Sandeep; Samandeep Sharma; J. B. Singh; A. K. Virdi; Genius Walia; A. Bhardwaj; B. C. Choudhary; R. B. Garg; Mohit Gola; Sumit Keshri; Ashok Kumar; Shivali Malhotra; M. Naimuddin; Priyanka Priyanka; K. Ranjan; Aashaq Shah; R. Sharma; Rishika Bhardwaj; Monika Bharti; Rajarshi Bhattacharya; S. Bhattacharya; U. Bhawandeep; Debabrata Bhowmik; Sourav Dey; Suneel Dutt; Suchandra Dutta; Manas Maity; Kuntal Mondal; Saswati Nandan; Arnab Purohit; Prasant Kumar Rout; A. Roy; Gourab Saha; S. Sarkar; Tanmay Sarkar; Manoj Sharan; Bipen Singh; Shalini Thakur; Prafulla Kumar Behera; Alibordi Muhammad; Ruchi Chudasama; D. Dutta; Vishwajeet Jha; V. Kumar; Dipak Kumar Mishra; Pawan Kumar Netrakanti; L. M. Pant; P. Shukla; Praveenkumar Suggisetti; T. Aziz; Muzamil Ahmad Bhat; S. R. Dugad; G. B. Mohanty; Nairit Sur; Ravindra Ravindra Kumar Verma; Sunanda Banerjee; S. Chatterjee; Pallabi Das; M. Guchait;  Jain; Saikat Karmakar; Sanjeev Kumar; G. Majumder; K. Mazumdar; Niladribihari Sahoo; Siddhesh Sawant; Sourabh Dube; Vinay Hegde; A. Kapoor; Kunal Kothekar; Shubham Pandey; Aditee Rane; Angira Rastogi; Shirin Chenarani; E. Eskandari Tadavani; S. M. Etesami; Mohsen Khakzad; M. Mohammadi Najafabadi; M. Naseri; F. Rezaei Hosseinabadi; Batool Safarzadeh; Maryam Zeinali; M. Felcini; M. W. Grünewald; M. Abbrescia; C. Calabria; A. Colaleo; D. Creanza; Leonardo Cristella; N. De Filippis; M. De Palma; A. Di Florio; Filippo Errico; L. Fiore; Andrea Gelmi; G. Iaselli; Merve Ince; Samet Lezki; G. Maggi; Mario Maggi; Giorgia Miniello; S. My; S. Nuzzo; Alexis Pompili; Gabriella Pugliese; R. Radogna; A. Ranieri; G. Selvaggi; L. Silvestris; R. Venditti; P. Verwilligen; G. Abbiendi; Carlo Battilana; D. Bonacorsi; Lisa Borgonovi; S. Braibant-Giacomelli; Renato Campanini; P. Capiluppi; A. Castro; F. R. Cavallo; Simranjit Singh Chhibra; G. Codispoti; M. Cuffiani; G. M. Dallavalle; F. L. Fabbri; A. Fanfani; Elisa Fontanesi; P. Giacomelli; C. Grandi; L. Guiducci; Fabio Iemmi; S. Lo Meo; S. Marcellini; Gianni Masetti; A. Montanari; F. L. Navarria; Andrea Perrotta; Federica Primavera; A. M. Rossi; T. Rovelli; G. P. Siroli; Nicolò Tosi; Sebastiano Albergo; A. Di Mattia; Renato Potenza; A. Tricomi; C. Tuve; Giuseppe Barbagli; Kalyanmoy Chatterjee; V. Ciulli; C. Civinini; R. D'Alessandro; E. Focardi; G. Latino; P. Lenzi; M. Meschini; S. Paoletti; Lorenzo Russo; G. Sguazzoni; D. M. Strom; Lorenzo Viliani; L. Benussi; Stefano Bianco; D. Piccolo; Fabrizio Ferro; Roberto Mulargia; Enrico Robutti; S. Tosi; Andrea Benaglia; Andrea Beschi; Francesco Brivio; Vincenzo Ciriolo; S. Di Guida; Mauro Emanuele Dinardo; Sara Fiorendi; S. Gennai; A. Ghezzi; P. Govoni; Martina Malberti; S. Malvezzi; D. Menasce; Fabio Monti; L. Moroni; M. Paganoni; D. Pedrini; S. Ragazzi; T. Tabarelli de Fatis; Davide Zuolo; S. Buontempo; N. Cavallo; A. De Iorio; A. Di Crescenzo; Francesco Fabozzi; Francesco Fienga; Giuliana Galati; Alberto Orso Maria Iorio; L. Lista; Sabino Meola; P. Paolucci; C. Sciacca; Elena Voevodina; Patrizia Azzi; Nicola Bacchetta; D. Bisello; Alessio Boletti; Alberto Bragagnolo; Roberto Carlin; P. Checchia; Martino Dall'Osso; P. De Castro Manzano; T. Dorigo; Umberto Dosselli; F. Gasparini; Ugo Gasparini; Andrea Gozzelino; S. Y. Hoh; S. Lacaprara; Paul Lujan; Martino Margoni; A. T. Meneguzzo; Jacopo Pazzini; Matteo Presilla; P. Ronchese; Roberto Rossin; Franco Simonetto; Andres Tiko; E. Torassa; Mia Tosi; Marco Zanetti; P. Zotto; Gianni Zumerle; Alessandro Braghieri; Alice Magnani; Paolo Montagna; S. P. Ratti; V. Re; Martina Ressegotti; C. Riccardi; Paola Salvini; I. Vai; P. Vitulo; M. Biasini; G. M. Bilei; Claudia Cecchi; Diego Ciangottini; L. Fanò; Paolo Lariccia; Roberto Leonardi; Elisa Manoni; G. Mantovani; Valentina Mariani; M. Menichelli; Antonio Rossi; Attilio Santocchia; Daniele Spiga; Konstantin Androsov; P. Azzurri; G. Bagliesi; L. Bianchini; T. Boccali; Laura Borrello; R. Castaldi; Ma Ciocci; R. Dell'Orso; G. Fedi; Francesco Fiori; Leonardo Giannini; A. Giassi; M. T. Grippo; F. Ligabue; Elisabetta Manca; Giulio Mandorli; A. Messineo; Fabrizio Palla; A. Rizzi; G. Rolandi; A. Scribano; P. Spagnolo; R. Tenchini; G. Tonelli; A. Venturi; P. G. Verdini; L. Barone; F. Cavallari; Marco Cipriani; D. Del Re; E. Di Marco; M. Diemoz; Simone Gelli; Egidio Longo; Badder Marzocchi; P. Meridiani; G. Organtini; F. Pandolfi; R. Paramatti; Federico Preiato; Claudio Quaranta; S. Rahatlou; Carlo Rovelli; Francesco Santanastasio; N. Amapane; R. Arcidiacono; S. Argiro; M. Arneodo; Nazar Bartosik; R. Bellan; C. Biino; Alessandra Cappati; N. Cartiglia; F. Cenna; Simona Cometti; M. Costa; R. Covarelli; Natale Demaria; Bilal Kiani; C. Mariotti; S. Maselli; E. Migliore; V. Monaco; Ennio Monteil; M. Monteno; M. M. Obertino; Luca Pacher; N. Pastrone; Mario Pelliccioni; G. L. Pinna Angioni; A. Romero; M. Ruspa; R. Sacchi; Riccardo Salvatico; Ksenia Shchelina; Valentina Sola; Ada Solano; Dario Soldi; A. Staiano; S. Belforte; V. Candelise; M. Casarsa; F. Cossutti; A. Da Rold; G. Della Ricca; Federico Vazzoler; A. Zanetti; Dh Kim; G. N. Kim; Min Suk Kim; Jsh Lee; S. W. Lee; C. S. Moon; Y. D. Oh; S. I. Pak; Sezen Sekmen; D. C. Son; Y. C. Yang; Hyunyong Kim; Dong Ho Moon; Geonhee Oh; Brieuc Francois; Junghwan Goh; Tae Jeong Kim; Sungwoong Cho; S. Choi; Yeonju Go; Dooyeon Gyun; Seungkyu Ha; B. Hong; Youngkwon Jo; K. S. Lee; Kisung Lee; Soon-Gul Lee; J. K. Lim; S. K. Park; Youn Roh; H. S. Kim; John Almond; J. S. Kim; Jongjeong Kim; H. S. Lee; Kyungwook Nam; S. B. Oh; Benjamin Charles Radburn-Smith; S. h. Seo; U. K. Yang; H. D. Yoo; Geum Bong Yu; D. Jeon; J. H. Kim; J. S. H. Lee; I. C. Park; Y. Choi; Chanwook Hwang; I. Yu; Viesturs Veckalns; Vytautas Dudenas; Andrius Juodagalvis; J. Vaitkus; Z. A. Ibrahim; M. A. B. Md Ali; F. Mohamad Idris; W. A. T. Wan Abdullah; Mohd Nizam Yusli; Zukhaimira Zolkapli; Jose F Benitez; A. M. Castaneda Hernandez; J. A. Murillo Quijada; Heriberto Castilla-Valdez; E. De La Cruz-Burelo; M. C. Duran-Osuna; I. Heredia-De La Cruz; Ricardo Lopez-Fernandez; J. Mejia Guisao; Raúl Iraq Rabadán-Trejo; Gabriel Ramirez-Sanchez; Rogelio Reyes-Almanza; A. Sanchez-Hernandez; S. Carrillo Moreno; C. Oropeza Barrera; M. Ramirez-Garcia; F. Vazquez Valencia; Jan Eysermans; Isabel Pedraza; H. A. Salazar Ibarguen; C. Uribe Estrada; A. Morelos Pineda; Natasa Raicevic; D. Krofcheck; Srinidhi Bheesette; P. H. Butler; Ashfaq Ahmad; M. I. Asghar; Qamar Hassan; H. R. Hoorani; W. A. Khan; Mehar Ali Shah; Muhammad Shoaib; Muhammad Waqas; Helena Bialkowska; M. Bluj; Bozena Boimska; Tomasz Frueboes; M. Górski; Malgorzata Kazana; Michal Szleper; P. Traczyk; P. Zalewski; K. Bunkowski; Adrian Byszuk; K. Doroba; A. Kalinowski; M. Konecki; J. Krolikowski; Maciej Misiura; M. Olszewski; Andrzej Pyskir; Marek Walczak; Mariana Araujo; Pedrame Bargassa; C. Beirão Da Cruz E Silva; A. Di Francesco; P. Faccioli; Bruno Galinhas; M. Gallinaro; Jj Hollar; Nuno Leonardo; J. Seixas; Giles Strong; Oleksii Toldaiev; Joao Varela; Vadim Alexakhin; Pavel Bunin; I. Golutvin; Ilya Gorbunov; A. Kamenev; Vladimir Karjavine; I. Kashunin; Vladimir Korenkov; A. Lanev; Alexander Malakhov; V. A. Matveev; P. Moisenz; V. Palichik; V. Perelygin; S. Shmatov; Siarhei Shulha; Nikolay Voytishin; Bekhzod S Yuldashev; A. Zarubin; V. Golovtsov; Y. Ivanov; V. Kim; Ekaterina Kuznetsova; P. Levchenko; Victor Murzin; Vadim Oreshkin; I. Smirnov; Dmitry Sosnov; V. Sulimov; L. Uvarov; Sergey Vavilov; A. Vorobyev; Yu. Andreev; Alexander Dermenev; S. Gninenko; N. Golubev; Anton Karneyeu; M. Kirsanov; N. Krasnikov; A. Pashenkov; Arseniy Shabanov; D. Tlisov; A. Toropin; Vladimir Epshteyn; Vladimir Gavrilov; Natalia Lychkovskaya; Vladimir Popov; Ivan Pozdnyakov; Grigory Safronov; Alexander Spiridonov; Anton Stepennov; V. Stolin; Maria Toms; Evgueni Vlasov; Alexander Zhokin; T. Aushev; Marina Chadeeva; Sergey Polikarpov; E. Popova; Vladimir Rusinov; Valeri Andreev; Maksim Azarkin; Igor Dremin; Martin Kirakosyan; Adel Terkulov; Alexey Baskakov; Alexander Belyaev; E. E. Boos; V. Bunichev; Mikhail Dubinin; L. V. Dudko; A. Gribushin; Vyacheslav Klyukhin; O. Kodolova; I. Lokhtin; Stepan Obraztsov; S. Petrushanko; V. Savrin; Alexander Barnyakov; V. E. Blinov; Tatyana Dimova; L. V. Kardapoltsev; Yuri Skovpen; Igor Azhgirey; Igor Bayshev; Sergei Bitioukov; Vassili Kachanov; Alexey Kalinin; Dmitri Konstantinov; Petr Mandrik; V. Petrov; Roman Ryutin; Sergei Slabospitskii; Andrei Sobol; Sergey Troshin; Nikolay Tyurin; Andrey Uzunian; A.E. Volkov; Anton Babaev; Sergei Baidali; Aleksandr Iuzhakov; Vitalii Okhotnikov; P. Adzic; Predrag Cirkovic; Damir Devetak; Milos Dordevic; Predrag Milenovic; Jovan Milosevic; J. Alcaraz Maestre; A. Álvarez Fernández; Irene Bachiller; M. Barrio Luna; J. A. Brochero Cifuentes; Marcos Cerrada; N. Colino; B. De La Cruz; A. Delgado Peris; C. Fernandez Bedoya; J. P. Fernández Ramos; Jose Flix; M. C. Fouz; O. Gonzalez Lopez; S. Goy Lopez; J. M. Hernandez; M. I. Josa; Dermot Moran; A. Pérez-Calero Yzquierdo; J. Puerta Pelayo; I. Redondo; L. Romero; S. Sánchez Navas; Mara Senghi Soares; Andrea Triossi; C. Albajar; J. F. de Trocóniz; J. Cuevas; Carlos Erice; J. Fernandez Menendez; Santiago Folgueras; I. Gonzalez Caballero; J. R. González Fernández; E. Palencia Cortezon; V. Rodríguez Bouza; S. Sanchez Cruz; J. M. Vizan Garcia; Iban Jose Cabrillo; A. Calderon; B. Chazin Quero; J. Duarte Campderros; M. Fernandez; P. J. Fernández Manteca; A. García Alonso; Juan Garcia-Ferrero; G. Gomez; A. Lopez Virto; J. Marco; C. Martinez Rivero; P. Martinez Ruiz del Arbol; F. Matorras; J. Piedra Gomez; Cédric Prieels; T. Rodrigo; Alberto Ruiz-Jimeno; L. Scodellaro; Nicolò Trevisani; Ivan Vila; R. Vilar Cortabitarte; Nadeesha Wickramage; D. Abbaneo; Bora Akgun; Etiennette Auffray; Georg Auzinger; Paul Baillon; A. H. Ball; David Barney; Joshua Bendavid; Michele Bianco; Andrea Bocci; C. Botta; Erica Brondolin; Tiziano Camporesi; M. Cepeda; Gianluca Cerminara; Emilien Chapon; Giacomo Cucciati; D. d’Enterria; A. Dabrowski; Nadir Daci; Vincenzo Daponte; A. David; A. De Roeck; Nikkie Deelen; Marc Dobson; Marc Dünser; Niels Dupont; A. Elliott-Peisert; Francesco Fallavollita; Daniele Fasanella; G. Franzoni; J. Fulcher; W. Funk; D. Gigi; Andrew Gilbert; K. Gill; F. Glege; Marek Gruchala; Maxime Guilbaud; Doga Gulhan; Jeroen Hegeman; Constantin Heidegger; Yutaro Iiyama; V. Innocente; Gian Michele Innocenti; Abideh Jafari; P. Janot; Olena Karacheban; Jan Kieseler; Andreas Kornmayer; Manfred Krammer; Clemens Lange; P. Lecoq; Carlos Lourenco; L. Malgeri; M. Mannelli; A. Massironi; F. Meijers; J. A. Merlin; S. Mersi; E. Meschi; F. Moortgat; M. Mulders; Jennifer Ngadiuba; Shervin Nourbakhsh; Styliani Orfanelli; L. Orsini; Felice Pantaleo; L. Pape; Emmanuelle Perez; M. Peruzzi; A. Petrilli; G. Petrucciani; Andreas Pfeiffer; M. Pierini; Florian Michael Pitters; Dinyar Rabady; A. Racz; M. Rovere; H. Sakulin; C. Schäfer; C. Schwick; Michele Selvaggi; Pedro Silva; P. Sphicas; Anna Stakia; Jan Steggemann; D. Treille; A. Tsirou; Adish Vartak; Mauro Verzetti; Wolfram Dietrich Zeuner; Lea Caminada; K. Deiters; W. Erdmann; R. Horisberger; Q. Ingram; H. C. Kaestli; D. Kotlinski; U. Langenegger; T. Rohe; Stephan Albert Wiederkehr; Malte Backhaus; Pirmin Berger; Nadezda Chernyavskaya; G. Dissertori; M. Dittmar; M. Donegà; Christian Dorfer; T. A. Gómez Espinosa; Christoph Grab; D. Hits; Thomas Klijnsma; W. Lustermann; Riccardo Andrea Manzoni; M. Marionneau; Maren Tabea Meinhard; F. Micheli; P. Musella; F. Nessi-Tedaldi; F. Pauss; Gaël Perrin; L. Perrozzi; Simone Pigazzini; Michael Reichmann; Christina Reissel; Thomas Reitenspiess; Daniele Ruini; D. A. Sanz Becerra; Myriam Schönenberger; Lesya Shchutska; V. R. Tavolaro; K. Theofilatos; M. L. Vesterbacka Olsson; R. Wallny; D. H. Zhu; T. K. Aarrestad; C. Amsler; Danyyl Brzhechko; M. F. Canelli; A. De Cosa; R. Del Burgo; Silvio Donato; Camilla Galloni; Tomas Hreus; B. Kilminster; Stefanos Leontsinis; Vinicius Massami Mikuni; Izaak Neutelings; Giorgia Rauco; P. Robmann; Daniel Salerno; Korbinian Schweiger; Claudia Seitz; Yuta Takahashi; Sébastien Wertz; Alberto Zucchetta; Thi Hien Doan; C. M. Kuo; W.T. Lin; S. S. Yu; P. Chang; Y. Chao; K. F. Chen; Po-Hsun Chen; W. S. Hou; Y. F. Liu; R.-S. Lu; Efstathios Paganis; Andreas Psallidas; Arnaud Steen; Burin Asavapibhop; Norraphat Srimanobhas; Narumon Suwonjandee; A. Bat; Fatma Boran; S. Cerci; Serdal Damarseckin; Zuhal Seyma Demiroglu; Furkan Dolek; Candan Dozen; Isa Dumanoglu; Gul Gokbulut; E. Gurpinar Guler; Yalcin Guler; Ilknur Hos; Candan Isik; E. E. Kangal; Ozgun Kara; A. Kayis Topaksu; Ugur Kiminsu; Mehmet Oglakci; Gulsen Onengut; Kadri Ozdemir; Sertac Ozturk; D. Sunar Cerci; Bayram Tali; Ufuk Guney Tok; Semra Turkcapar; Ibrahim Soner Zorbakir; Caglar Zorbilmez; B. Isildak; Guler Karapinar; Metin Yalvac; M. Zeyrek; Ismail Okan Atakisi; E. Gülmez; M. Kaya; O. Kaya; Özlem Özçelik; Suat Ozkorucuklu; Sevgi Tekten; Elif Asli Yetkin; Altan Cakir; Kerem Cankocak; Yildiray Komurcu; S. Sen; Boris Grynyov; L. Levchuk; Fionn Ball; J. J. Brooke; Dustin Burns; Emyr Clement; D. Cussans; Olivier Davignon; Henning Flacher; J. Goldstein; G. P. Heath; H. F. Heath; L. Kreczko; D. M. Newbold; Sudarshan Paramesvaran; Bjoern Penning; T. Sakuma; David J. Smith; V. J. Smith; Joseph Taylor; Alexander Titterton; K. W. Bell; C. Brew; R. M. Brown; Davide Cieri; David Ja Cockerill; J. A. Coughlan; Kristian Harder; S. Harper; Jacob Linacre; Konstantinos Manolopoulos; E. O. Olaiya; David Petyt; Thomas Reis; Thomas Schuh; C. H. Shepherd-Themistocleous; Alessandro Thea; I. R. Tomalin; Thomas Williams; William John Womersley; R. Bainbridge; Philippe Bloch; Johan Borg; Shane Breeze; O. Buchmuller; Aaron Bundock; D. Colling; P. D. Dauncey; G. Davies; M. Della Negra; R. Di Maria; Pieter Everaerts; G. Hall; G. Iles; Thomas James; Matthias Komm; Christian Laner; L. Lyons; Anne-Marie Magnan; S. Malik; Arabella Martelli; Vukasin Milosevic; J. A. Nash; A. Nikitenko; Vito Palladino; M. Pesaresi; D. M. Raymond; Alexander Richards; A. Rose; Edward Scott; C. Seez; Antoni Shtipliyski; Gurpreet Singh; M. Stoye; Thomas Strebler; Sioni Summers; A. Tapper; Kirika Uchida; T. Virdee; N. Wardle; Daniel Winterbottom; Jack Wright; Seth Conrad Zenz; J. E. Cole; Peter R Hobson; A. Khan; Paul Kyberd; C. K. Mackay; Alexander Morton; I. D. Reid; L. Teodorescu; Sema Zahid; Kenneth Call; J. R. Dittmann; K. Hatakeyama; Hongxuan Liu; Christopher Madrid; Brooks McMaster; Nathaniel Pastika; Caleb Smith; Rachel Bartek; A. Dominguez; Andrew Buccilli; Otman Charaf; Seth Cooper; C. Henderson; P. Rumerio; C. West; Daniel Arcaro; T. Bose; Zeynep Demiragli; Daniel Gastler; Semiray Girgis; Deborah Pinna; Clint Richardson; J. Rohlf; D. Sperka; Indara Suarez; L. R. Sulak; David Zou; Gabriele Benelli; Bjorn Burkle; Xavier Coubez; D. Cutts; Mary Hadley; John Hakala; U. Heintz; Julie Managan Hogan; K. H. M. Kwok; E. Laird; G. Landsberg; Z. Mao; M. Narain; Sinan Sagir; Rizki Syarif; Emanuele Usai; David Yu; Reyer Band; Christopher Brainerd; R. Breedon; M. Calderon De La Barca Sanchez; M. Chertok; J. Conway; Rylan Conway; P. T. Cox; R. Erbacher; Chad Flores; Garrett Funk; W. Ko; Ota Kukral; R. L. Lander; Michael Mulhearn; D. E. Pellett; J. Pilot; M. Shi; Dustin Stolp; Devin Taylor; Kyle Tos; M. Tripathi; Zhixing Wang; Fengwangdong Zhang; Michail Bachtis; Cameron Bravo; R. Cousins; Abhigyan Dasgupta; Alice Florent; J. Hauser; M. Ignatenko; Nickolas Mccoll; Simon Regnard; D. Saltzberg; Christian Schnaible; V. Valuev; Elvire Bouvier; Kira Burt; R. Clare; J. W. Gary; S. M. A. Ghiasi Shirazi; Gail Hanson; Georgia Karapostoli; Elizabeth Kennedy; O. R. Long; M. Olmedo Negrete; Mirena Ivova Paneva; W. Si; Long Wang; H. Wei; S. J. Wimpenny; Brent Yates; J. G. Branson; S. Cittolin; Mark Derdzinski; Raffaele Gerosa; Dylan Gilbert; Bobak Hashemi; A. Holzner; Daniel Klein; Gouranga Kole; V. Krutelyov; J. Letts; Mario Masciovecchio; S. May; Dominick Olivito; Sanjay Padhi; M. Pieri; V. Sharma; Matevz Tadel; John Wood; F. Würthwein; A. Yagil; G. Zevi Della Porta; Nick Amin; Rohan Bhandari; C. Campagnari; Matthew Citron; Valentina Dutta; M. Franco Sevilla; Loukas Gouskos; Ryan Heller; J. Incandela; Hualin Mei; Ana Ovcharova; H. Qu; J. D. Richman; D. Stuart; Sicheng Wang; J. Yoo; Dana Z. Anderson; A. Bornheim; Jay Mathew Lawhorn; Nan Lu; H. B. Newman; Thong Nguyen; Joosep Pata; Maria Spiropulu; J. R. Vlimant; R. Wilkinson; Si Xie; Zhicai Zhang; R. Y. Zhu; Michael Benjamin Andrews; T. Ferguson; Tanmay Mudholkar; Manfred Paulini; M. Sun; I. Vorobiev; M. Weinberg; J. P. Cumalat; W. T. Ford; Frank Jensen; Andrew Johnson; Emily MacDonald; Troy Mulholland; Rishi Patel; Alexx Perloff; K. Stenson; K. A. Ulmer; S. R. Wagner; J. P. Alexander; Jorge Chaves; Yangyang Cheng; J. Chu; Abhisek Datta; Kevin Mcdermott; Nathan Mirman; Jose Monroy; J. R. Patterson; D. Quach; Aurelijus Rinkevicius; A. Ryd; Louise Skinnari; Livia Soffi; S. M. Tan; Z. Tao; J. Thom; J. Tucker; P. Wittich; Margaret Zientek; S. Abdullin; Michael Albrow; Maral Alyari; Giorgio Apollinari; Artur Apresyan; A. Apyan; L. A. T. Bauerdick; A. Beretvas; Jeffrey Berryhill; P. C. Bhat; K. Burkett; J. N. Butler; A. Canepa; Giuseppe Benedetto Cerati; H. W. K. Cheung; Frank Chlebana; Matteo Cremonesi; Javier Duarte; V. D. Elvira; J. C. Freeman; Zoltan Gecse; Erik Gottschalk; L. Gray; D. R. Green; Stefan Grünendahl; O. Gutsche; J. Hanlon; R. M. Harris; S. Hasegawa; James Hirschauer; Z. Hu; Bodhitha Jayatilaka; S. Jindariani; M. Johnson; U. Joshi; B. Klima; Matti J. Kortelainen; Benjamin Kreis; S. Lammel; Don Lincoln; R. Lipton; Miaoyuan Liu; T. Liu; J. Lykken; Kaori Maeshima; John Michael Marraffino; D. Mason; P. McBride; P. Merkel; S. Mrenna; S. Nahn; V. O'Dell; Kevin Pedro; Cristian Pena; O. Prokofyev; G. Rakness; Fabio Ravera; Allison Reinsvold; L. Ristori; Basil Schneider; E. Sexton-Kennedy; Aron Soha; W. J. Spalding; L. Spiegel; S. Stoynev; James Strait; Nadja Strobbe; L. Taylor; S. Tkaczyk; N. V. Tran; Lorenzo Uplegger; E. W. Vaandering; Caterina Vernieri; Marco Verzocchi; R. Vidal; M. H. L. S. Wang; Hannsjoerg Artur Weber; D. Acosta; P. Avery; Pierluigi Bortignon; D. Bourilkov; Andrew Brinkerhoff; Luca Cadamuro; A. Carnes; D. Curry; R. D. Field; Sergei Gleyzer; Bhargav Madhusudan Joshi; J. Konigsberg; A. Korytov; Kin Ho Lo; P. Ma; K. Matchev; Nicholas Menendez; G. Mitselmakher; Daniel Rosenzweig; K. Shi; Jing Wang; X. Zuo; Yagya Raj Joshi; S. Linn; Todd Adams; Andrew Askew; S. Hagopian; V. Hagopian; K. F. Johnson; Raman Khurana; Ted Kolberg; German Martinez; T. Perry; H. B. Prosper; Anirban Saha; Catherine Schiber; Rachel Yohay; M. M. Baarmand; Vallary Bhopatkar; Stefano Colafranceschi; Marcus Hohlmann; D. Noonan; Mehdi Rahmani; Titas Roy; Mark Saunders; F. Yumiceva; M. R. Adams; Leonard Apanasevich; Douglas Berry; R. R. Betts; R. Cavanaugh; Xuan Chen; Susan Dittmer; O. Evdokimov; C. E. Gerber; Dhanush Anil Hangal; D. J. Hofman; Kurt Jung; Corrinne Mills; Marguerite Tonjes; N. Varelas; Hui Wang; Xiao Wang; Z. Wu; Jian Zhang; Mohammad Alhusseini; Burak Bilki; Warren Clarida; Kamuran Dilsiz; Süleyman Durgut; R. P. Gandrajula; Maksat Haytmyradov; Viktor Khristenko; Ohannes Kamer Köseyan; Jean-Pierre Merlo; A. Mestvirishvili; Anthony Moeller; J. Nachtman; Hasan Ogul; Y. Onel; Ferhat Ozok; A. Penzo; Christina Snyder; E. Tiras; James Wetzel; B. Blumenfeld; Alice Cocoros; Nicholas Eminizer; David Fehling; Lei Feng; A. V. Gritsan; W. T. Hung; P. Maksimovic; Jeffrey Roskes; Ulascan Sarica; Melody A. Swartz; Meng Xiao; Ayman Al-bataineh; Philip Baringer; A. Bean; Samuel Boren; James Bowen; Alexander Bylinkin; James Castle; S. Khalil; Anna Kropivnitskaya; Devdatta Majumder; William Mcbrayer; M. Murray; Christopher Rogan; S. Sanders; Erich Schmitz; J. D. Tapia Takaki; Senka Duric; Andrew Ivanov; Ketino Kaadze; Doyeong Kim; Yurii Maravin; Dalath Rachitha Mendis; Tyler Mitchell; Atanu Modak; Abdollah Mohammadi; Finn Rebassoo; D. M. Wright; A. Baden; Owen Baron; Alberto Belloni; S. C. Eno; Y. Feng; Charles Ferraioli; N. J. Hadley; Shabnam Jabeen; Geng-Yuan Jeng; R. G. Kellogg; Joshua Kunkle; A. C. Mignerey; Sara Nabili; Francesca Ricci-Tam; Markus Seidel; Y. H. Shin; Andris Skuja; Suresh C Tonwar; Kak Wong; Daniel Abercrombie; Brandon Allen; Virginia Azzolini; Austin Baty; Ran Bi; Stephanie Brandt; Wit Busza; I. A. Cali; Mariarosaria D'Alfonso; G. Gomez Ceballos; Maxim Goncharov; Philip Harris; Dylan Hsu; Miao Hu; Markus Klute; Dmytro Kovalskyi; Yen-Jie Lee; P. D. Luckey; Benedikt Maier; Andrea Carlo Marini; Christopher Mcginn; Camelia Mironov; Siddharth Narayanan; Xinmei Niu; C. Paus; Dylan Rankin; C. Roland; G. Roland; Z. Shi; George Stephans; Konstanty Sumorok; Kaya Tatar; Dragos Velicanu; T. W. Wang; Bolek Wyslouch; A. C. Benvenuti; Rajdeep Mohan Chatterjee; Andrew Evans; Peter Hansen; Joshua Hiltbrand; Sh. Jain; Sean Kalafut; Michael Krohn; Y. Kubota; Zachary Lesko; J. Mans; R. Rusack; Mohammad Abrar Wadud; John Gabriel Acosta; Sandra Oliveros; Ekaterina Avdeeva; Kenneth Bloom; D. R. Claes; Caleb Fangmeier; Linda Finco; Frank Golf; R. Gonzalez Suarez; Rami Kamalieddin; I. Kravchenko; Joaquin Emilo Siado; G. R. Snow; Benjamin Stieger; Andrew Godshalk; Charles Harrington; I. Iashvili; Avto Kharchilava; Christine Mclean; Duong Nguyen; A. Parker; S. Rappoccio; Bahareh Roozbahani; G. Alverson; E. Barberis; Chad Freer; Yacine Haddad; Apichart Hortiangtham; Gabriel Madigan; D. M. Morse; T. Orimoto; Abraham Tishelman-Charny; Tanvi Wamorkar; Baokai Wang; Andrew Wisecarver; D. R. Wood; James Bueghly; Thoth Gunter; Kristan Allan Hahn; Nathaniel Odell; Michael Henry Schmitt; Kevin Sung; Marco Trovato; M. Velasco; Rachael Bucci; Nabarun Dev; Reza Goldouzian; M. D. Hildreth; K. Hurtado Anampa; Colin Jessop; D. J. Karmgard; K. Lannon; Wei Li; Nikitas Loukas; N. Marinelli; F. Meng; Charles Mueller; Y. Musienko; Michael Planer; R. Ruchti; Prasanna Siddireddy; Graeme Smith; Silvia Taroni; M. Wayne; Andrew Wightman; M. Wolf; Anna Woodard; Juliette Alimena; Louis Antonelli; Ben Bylsma; L. S. Durkin; Sean Flowers; B. Francis; C. Hill; Weifeng Ji; Anthony Lefeld; T. Y. Ling; Wuming Luo; Brian L Winer; Stephane Cooperstein; Gage Dezoort; P. Elmer; Joshua Hardenbrook; Nicholas Haubrich; Samuel Higginbotham; Alexis Kalogeropoulos; Stephanie Kwan; D. Lange; Marco Toliman Lucchini; J. Luo; Daniel Marlow; Kelvin Mei; Isabel Ojalvo; James Olsen; C. Palmer; P.A. Piroué; Jakob Salfeld-Nebgen; D.P. Stickland; C. Tully; Scarlet Norberg; Anthony Barker; V. E. Barnes; Souvik Das; L.J. Gutay; M. Jones; Aw Jung; Ajeeta Khatiwada; Bibhuprasad Mahakud; D. H. Miller; Giulia Negro; N. Neumeister; Cheng-Chieh Peng; Stefan Piperov; H. Qiu; Jan-Frederik Schulte; J. Sun; Fuqiang Wang; Rui Xiao; W. Xie; Tongguang Cheng; James Dolen; N. Parashar; Zhenyu Chen; K. M. Ecklund; Sarah Freed; F. J. M. Geurts; Matthew Kilpatrick; Arun Kumar; B. P. Padley; Jay Roberts; Jamal Rorie; W. Shi; A. G. Stahl Leiton; Z. Tu; A. Zhang; A. Bodek; P. de Barbaro; Regina Demina; Y. t. Duh; Joseph Lynn Dulemba; Colin Fallon; T. Ferbel; M. Galanti; Aran Garcia-Bellido; J. Y. Han; Otto Hindrichs; Aleko Khukhunaishvili; Evan Ranken; P. Tan; Rhys Taus; Brandon Chiarito; John Paul Chou; Yuri Gershtein; Eva Halkiadakis; Andrew Hart; Maximilian Heindl; Elliot Hughes; Steven Kaplan; Savvas Kyriacou; Ian Laflotte; Amitabh Lath; Roy Montalvo et al.,"Abstract A search is presented for pairs of light pseudoscalar bosons, in the mass range from 4 to 15 GeV, produced from decays of the 125 GeV Higgs boson. The decay modes considered are final states that arise when one of the pseudoscalars decays to a pair of tau leptons, and the other one either into a pair of tau leptons or muons. The search is based on proton-proton collisions collected by the CMS experiment in 2016 at a center-of-mass energy of 13 TeV that correspond to an integrated luminosity of 35.9 fb − 1 . The 2 μ 2 τ and 4τ channels are used in combination to constrain the product of the Higgs boson production cross section and the branching fraction into 4τ final state, σ B , exploiting the linear dependence of the fermionic coupling strength of pseudoscalar bosons on the fermion mass. No significant excess is observed beyond the expectation from the standard model. The observed and expected upper limits at 95% confidence level on σ B , relative to the standard model Higgs boson production cross section, are set respectively between 0.022 and 0.23 and between 0.027 and 0.19 in the mass range probed by the analysis.",800,,,http://inspirehep.net/record/1744267 https://authors.library.caltech.edu/100865/ https://www.research-collection.ethz.ch/handle/20.500.11850/382131 https://www.sciencedirect.com/science/article/pii/S0370269319308093 https://aisberg.unibg.it/handle/10446/149086 http://cds.cern.ch/record/2682977 https://boa.unimib.it/handle/10281/253167 https://bura.brunel.ac.uk/handle/2438/19944 https://publikationen.bibliothek.kit.edu/1000099733,http://dx.doi.org/10.1016/j.physletb.2019.135087,0,,10.1016/j.physletb.2019.135087,2964534193,,001-717-766-573-633; 005-559-875-444-640; 008-061-828-995-74X; 012-284-173-029-913; 012-956-424-349-428; 013-755-871-777-382; 013-931-738-233-167; 015-568-991-767-700; 017-193-576-454-314; 019-258-182-288-576; 019-814-274-922-84X; 020-679-662-024-124; 022-067-924-411-518; 022-666-412-811-07X; 024-491-646-673-723; 026-634-122-118-591; 029-299-446-092-977; 029-992-588-626-925; 032-773-974-508-191; 034-725-391-895-712; 035-222-701-055-674; 044-601-876-979-242; 046-592-043-774-411; 046-837-099-887-733; 049-131-497-493-611; 049-528-108-375-52X; 052-033-590-781-625; 052-615-869-832-645; 053-038-778-199-353; 060-496-395-052-233; 062-475-505-388-29X; 068-343-767-725-894; 069-918-857-416-455; 070-140-657-941-520; 071-144-488-357-212; 071-635-574-646-279; 075-691-443-442-577; 080-004-651-933-534; 081-580-025-360-03X; 086-506-566-507-408; 088-150-939-459-516; 090-532-748-614-953; 092-496-255-061-681; 098-760-887-695-883; 099-676-699-775-493; 102-196-801-947-401; 106-546-685-213-613; 108-246-538-618-061; 109-214-022-927-373; 112-470-333-324-079; 113-853-159-058-741; 119-990-219-766-66X; 120-377-603-658-479; 125-282-177-439-926; 125-866-981-890-952; 131-452-884-865-162; 132-457-807-647-451; 135-205-606-849-768; 142-142-334-508-553; 143-995-959-320-084; 146-434-989-971-872; 147-398-702-033-901; 150-262-121-858-425; 160-813-316-281-938; 164-769-438-021-827; 166-365-709-244-195; 166-782-833-552-109; 167-026-440-903-898; 168-805-669-830-825; 173-762-797-631-357; 186-173-945-057-235; 187-903-305-703-073,0
016-309-408-157-375,United Kingdom,14752875,BioMed Central,Malaria Journal,"Quantification of malaria antigens PfHRP2 and pLDH by quantitative suspension array technology in whole blood, dried blood spot and plasma.",Virology; Whole blood; Dried blood spot; Suspension array technology; Lactate dehydrogenase; Malaria; Plasmodium falciparum; Rapid diagnostic test; Point-of-care testing; Biology,2020-01-09,2020,journal article,Histidine-rich protein 2; Luminex; Malaria; Parasite lactate dehydrogenase; Quantitative suspension array technology; Rapid diagnostic test,European and Developing Countries Clinical Trials Partnership; Australian Government; Department d’Universitats i Recerca de la Generalitat de Catalunya,1,12,,Xavier Martiáñez-Vendrell; Alfons Jiménez; Ana María Vásquez; Ana Campillo; Sandra Incardona; Raquel González; Dionicia Gamboa; Katherine Torres; Wellington Oyibo; Babacar Faye; Eusebio Macete; Clara Menéndez; Xavier C. Ding; Alfredo Mayor,"Background; Malaria diagnostics by rapid diagnostic test (RDT) relies primarily on the qualitative detection of Plasmodium falciparum histidine-rich protein 2 (PfHRP2) and Plasmodium spp lactate dehydrogenase (pLDH). As novel RDTs with increased sensitivity are being developed and implemented as point of care diagnostics, highly sensitive laboratory-based assays are needed for evaluating RDT performance. Here, a quantitative suspension array technology (qSAT) was developed, validated and applied for the simultaneous detection of PfHRP2 and pLDH in a variety of biological samples (whole blood, plasma and dried blood spots) from individuals living in different endemic countries.",19,,,https://link.springer.com/article/10.1186%2Fs12936-019-3083-5 https://www.ncbi.nlm.nih.gov/pubmed/31918718,http://dx.doi.org/10.1186/s12936-019-3083-5,0,31918718,10.1186/s12936-019-3083-5,2998820455,,002-903-922-148-694; 003-110-516-599-007; 003-438-977-217-218; 004-392-494-281-851; 005-012-161-569-960; 005-138-374-726-951; 005-198-563-803-754; 006-269-740-325-258; 008-029-214-087-27X; 008-532-043-218-594; 010-092-283-789-906; 011-087-198-036-82X; 012-082-199-132-729; 013-966-947-169-368; 021-186-410-157-087; 027-988-309-476-916; 028-606-725-486-646; 030-705-057-798-139; 031-280-201-140-741; 032-482-605-579-63X; 032-505-610-811-893; 034-053-739-346-513; 035-178-176-222-167; 037-806-252-224-410; 038-953-006-285-257; 046-317-683-776-136; 047-433-535-372-978; 058-682-514-577-436; 064-049-437-534-371; 066-590-376-490-835; 072-468-842-543-454; 073-784-006-456-890; 076-962-284-870-504; 084-080-479-008-506; 085-489-427-517-173; 091-119-464-969-442; 092-993-472-249-872; 098-947-523-436-477; 105-858-715-645-860; 142-077-039-211-601,0
018-638-630-949-373,United Kingdom,00981354,Elsevier BV,Computers & Chemical Engineering,Dynamic modeling and experimental validation of essential oils fractionation: application for the production of phenylpropanoids,Mathematical optimization; Distillation; Process engineering; Essential oil; Lippia origanoides; Mathematics; Experimental data; Batch distillation; System dynamics; Fractionation,2020-01-01,2020,journal article,,"Departamento Administrativo de Ciencia, Tecnología e Innovación (COLCIENCIAS); Universidad Industrial de Santander; Universidad de Antioquia",,106738,,Julián Arias; Daniel Casas-Orozco; Andrés Cáceres-León; Jairo René Martínez; Elena E. Stashenko; Aída-Luz Villa,"Abstract Batch distillation is useful in the essential oil (EO) industry to standardize and improve EO properties. Using the Lippia origanoides EO as a source of phenylpropanoids, a methodology was developed to solve and experimentally validate a batch distillation model, which described separation of EO major constituents over time. Nine EOs were distilled and their composition and distillation products were determined. Seven major constituents were used to represent the EOs and their distillation products in the mathematical analyses performed, namely, data reconciliation to modify the streams compositions in order to meet material balances, and a rigorous distillation model to describe the system dynamics. Statistical parameters ( r 2 = 0.95 , M S E = 0.002 ) were calculated to compare predicted and experimental data, showing that the model can accurately predict the composition of distillation cuts. This methodology can be extended to other EOs of industrial interest to support their fractionation processes.",135,,,https://www.sciencedirect.com/science/article/pii/S009813541931049X,http://dx.doi.org/10.1016/j.compchemeng.2020.106738,0,,10.1016/j.compchemeng.2020.106738,3001264016,,003-618-309-509-993; 008-446-137-295-004; 010-272-887-145-94X; 011-576-417-785-087; 011-877-390-271-420; 011-945-643-740-830; 012-515-073-672-51X; 015-524-732-731-127; 015-555-046-117-743; 016-487-360-202-588; 018-570-033-618-826; 020-209-441-726-767; 022-732-865-822-76X; 022-989-154-400-150; 025-120-898-972-520; 026-732-623-331-584; 027-033-023-017-341; 028-079-188-445-539; 030-944-786-652-517; 031-118-368-422-091; 032-017-817-006-207; 036-740-591-994-166; 036-747-498-958-728; 037-320-160-658-473; 037-841-408-138-599; 043-803-879-684-14X; 045-167-716-462-305; 050-629-724-023-948; 061-552-004-133-301; 062-624-786-783-128; 066-088-970-768-998; 069-172-817-170-835; 072-128-223-783-298; 074-304-430-949-898; 076-510-283-556-612; 076-800-791-185-470; 084-326-125-343-099; 085-846-261-160-874; 092-581-647-676-147; 096-863-486-272-686; 102-665-069-411-022; 102-945-909-132-592; 104-627-783-755-469; 112-164-942-109-758; 116-768-083-659-69X; 117-281-818-610-89X; 119-252-413-514-71X; 123-095-943-782-285; 127-261-155-112-690; 129-991-126-810-366; 136-531-228-394-830; 139-357-565-697-523; 140-384-061-035-787; 142-326-416-875-708; 149-341-594-513-988; 158-489-090-723-567; 159-831-245-873-322; 160-913-679-206-521; 170-276-761-510-331; 171-307-087-154-982; 177-707-410-832-28X; 189-034-208-679-543; 191-282-640-074-37X; 191-880-625-388-004,0
019-734-813-869-647,Netherlands,02540584,Elsevier BV,Materials Chemistry and Physics,New powder material obtained from spent coffee ground and whey protein; Thermal and morphological analysis,Isothermal process; Moisture; Inorganic chemistry; Materials science; Water content; Whey protein; Spray drying; Food industry; Pulp and paper industry; Water activity; Bulk density,2020-01-01,2020,journal article,,"Departamento Administrativo de Ciencia, Tecnología e Innovación (COLCIENCIAS); Departamento Administrativo de Ciencia, Tecnología e Innovación (COLCIENCIAS); Universidad de Antioquia; COLOIDES",,122171,,J. Osorio-Arias; S. Delgado-Arias; Y. Duarte-Correa; E. Largo-Ávila; D. Montaño; Ricardo Simpson; Oscar Vega-Castro,"Abstract Currently, the food industry generates large amounts of agroindustry waste. Specifically, the coffee and cheese industry produce spent coffee ground and whey respectively. Therefore, it is important to find applications for these residues allowing the food industry to be friendly with the environment. The main goal of this research was to evaluate some morphological and thermodynamic properties of a powder product obtained by spray drying, from the mixture of Spent Coffee Ground (SCG) with Whey Concentrated (WC). The methodology includes the mixture of different combinations of SCG (4, 10 & 16%) with WC; afterward, the mixture was spray dried using an inlet temperature of 170 °C. The powder characterization includes: Moisture, Water Activity (Aw), Glass Transition temperature (Tg). In addition, isothermal curves were obtained. As a result, the moisture content and Aw of the powder were 3.25 ± 0.18 and 0.252 ± 0.01, while the bulk density was 0.495 ± 0.10 g/cm3, showing a significant correlation (p",240,,,https://www.sciencedirect.com/science/article/pii/S0254058419309885,http://dx.doi.org/10.1016/j.matchemphys.2019.122171,0,,10.1016/j.matchemphys.2019.122171,2973093073,,001-054-379-235-074; 001-418-480-188-545; 002-149-656-709-660; 004-504-735-156-415; 005-139-459-736-483; 006-498-580-746-182; 006-962-668-513-531; 008-614-223-474-818; 013-722-006-972-051; 014-274-859-435-493; 019-069-702-991-992; 019-762-672-628-898; 021-502-493-143-669; 021-848-469-818-767; 021-897-905-434-104; 024-701-911-135-604; 026-999-877-644-380; 029-863-290-203-937; 031-475-274-050-720; 032-166-731-014-74X; 032-716-297-451-405; 033-026-422-280-640; 034-031-054-647-789; 034-186-009-862-179; 035-596-538-942-252; 037-350-344-412-90X; 041-050-083-749-087; 045-381-514-887-96X; 046-249-055-538-987; 048-794-206-361-530; 050-329-828-677-351; 051-795-555-347-828; 051-818-013-387-330; 051-831-476-416-288; 052-898-604-001-021; 054-557-767-315-401; 056-790-462-541-831; 058-378-128-399-84X; 059-083-947-489-847; 060-739-917-892-074; 064-779-997-056-077; 066-578-641-453-807; 066-584-019-414-761; 068-870-837-410-949; 069-724-518-864-725; 072-417-568-328-929; 075-659-991-341-267; 077-128-871-665-953; 081-684-734-176-004; 082-343-922-727-548; 089-607-275-827-200; 090-525-702-907-085; 091-109-699-432-691; 095-036-418-529-86X; 095-438-106-131-053; 096-059-318-040-707; 101-353-313-920-410; 113-915-060-478-165; 117-767-919-241-245; 124-379-380-560-363; 129-213-492-336-982; 146-319-598-137-924; 152-830-905-896-310; 181-629-612-715-691; 184-177-511-654-011; 190-581-734-382-510,0
020-714-281-149-880,United States,00029637,American Society of Tropical Medicine and Hygiene,American Journal of Tropical Medicine and Hygiene,"First Report of an Urban Case of Canine Visceral Leishmaniasis in the Municipality of Cali, Colombia.",Virology; Visceral leishmaniasis; Biology,2020-02-05,2020,journal article,,,2,289,293,Natalia Arbeláez; Jaime Moreno; Javier Murillo; Andrés Montoya; Sara M. Robledo; Andrés Vélez; Iván Darío Vélez,"American visceral leishmaniasis (VL) is a vector-borne disease caused by <i>Leishmania infantum</i> (syn. <i>chagasi</i>) and transmitted by <i>Lutzomyia longipalpis</i> and <i>Lutzomyia evansi</i> phlebotomine sand flies. Dogs not only are the main host reservoirs of the parasite but also suffer the disease; therefore, canine VL (CVL) has assumed an important role in public health. In Colombia, human and CVL are restricted to two transmission foci: one in the north region (Caribbean coast) and other in the central south region (middle Magdalena River Valley). We present a CVL case involving a 2-year-old male dog with a history of lack of appetite, general weakness, and progressive loss of weight. A diagnosis of CVL was obtained using the direct parasitological examination in spleen and bone marrow samples stained with Giemsa and RT-qPCR. The infecting <i>Leishmania</i> species was identified as <i>L. infantum</i> by PCR-restriction fragment length polymorphism amplifying the <i>Hsp70</i> gene from bone marrow and spleen samples and confirming by sequencing. The patient responded favorably to treatment with intramuscular meglumine antimoniate at a dose of 100 mg/kg daily for 8 weeks and oral allopurinol at a dose of 10 mg/kg every 12 hours until new indication. This is the first report of urban CVL in the city of Cali, Colombia, highlighting the need for surveillance and control programs in the municipalities of the department of Valle del Cauca, a region where VL has not been informed before. The findings also indicate the need to reinforce the surveillance programs in other rural and urban regions of the country where favorable eco-epidemiological conditions exist.",102,,,https://www.ncbi.nlm.nih.gov/pubmed/31802736,http://dx.doi.org/10.4269/ajtmh.19-0515,0,31802736,10.4269/ajtmh.19-0515,2992149817,,000-298-903-931-59X; 003-003-449-686-720; 003-867-209-024-611; 010-677-628-470-444; 012-204-491-568-485; 013-987-454-595-513; 017-111-576-177-693; 034-270-955-273-858; 041-748-766-115-360; 042-659-360-056-358; 095-993-055-637-566; 145-161-657-675-56X,0
021-341-260-075-883,Spain,1699258x,"Ediciones Doyma, S.L.",ReumatologÃ­a ClÃ­nica,Differences between patients with sarcoidosis with and without joint involvement treated for fifteen years in a third level hospital,Internal medicine; Etiology; Medical record; Disease; Concomitant; Sarcoidosis; Medicine,2020-01-01,2020,journal article,,,1,45,48,Carolina Muñoz; Mauricio Restrepo-Escobar; Manuel Martínez-Muñoz; Andrés Echeverri; Javier Marquez; Luis Fernando Pinto,"Abstract Introduction Sarcoidosis is a complex disease of unknown aetiology, with a variable course and highly different forms of presentation. Our objective was to characterize all our patients with sarcoidosis with emphasis on their clinical presentation and to establish differences between patients with sarcoidosis with and without joint involvement. Methods We reviewed the medical records of all patients with a diagnosis of sarcoidosis who were treated at the outpatient or inpatient services of the Pablo Tobon Uribe Hospital in Medellin, Colombia, from January 2002 to April 2017. Results We identified 22 patients with sarcoidosis. There were joint symptoms in 13 of them. All but one of the patients with sarcoidosis affecting the joints had concomitant skin involvement (92%), which was much less frequent in patients without joint involvement (22%) (odds ratio = 4.2; P  Conclusions Patients with sarcoidosis who have joint involvement have a much higher frequency of concomitant skin involvement. The absence of cutaneous findings in a patient with joint symptoms decreases the likelihood of sarcoidosis.",16,,,https://www.sciencedirect.com/science/article/pii/S2173574319300541,http://dx.doi.org/10.1016/j.reumae.2018.01.004,0,,10.1016/j.reumae.2018.01.004,2944990148,,004-651-345-349-449; 022-936-086-313-880; 046-340-546-178-098; 048-676-590-915-43X; 060-335-414-560-931; 063-017-819-058-865; 069-955-602-136-577; 070-202-534-901-423; 080-575-139-146-039; 095-623-486-187-693; 099-097-629-497-671; 130-250-987-097-184; 140-380-709-559-332,0
023-022-185-504-610,United Kingdom,00404039,Elsevier Limited,Tetrahedron Letters,Improved Synthesis of Natural Isomeric Naphthoxanthenones,Intercalation (chemistry); Organic chemistry; Chemistry; Structural isomer; Musa acuminata; Wachendorfia thyrsiflora; DNA,2020-01-01,2020,journal article,,Universidad de Antioquia,1,151359,,Julian Barrera; Edwin Patiño; Felipe Otálvaro,"Abstract 5-methoxy-1H-naphtho[2,1,8-mna]xanthen-1-one (1) and 5-methoxy-3H-naphtho[2,1,8-mna]xanthen-3-one (musafluorone 2), a pair of positional isomers isolated from Wachendorfia thyrsiflora and Musa acuminata, were synthesized in six steps in an overall yield of 53 % and 59 % starting from the corresponding methoxyphenalenones and employing an acid mediated cyclocondensation strategy. Preliminary assays demonstrated the intercalation ability of compounds 1 and 2 into DNA.",61,,,https://www.sciencedirect.com/science/article/pii/S0040403919311505,http://dx.doi.org/10.1016/j.tetlet.2019.151359,0,,10.1016/j.tetlet.2019.151359,2984651795,,002-261-164-833-470; 012-692-294-904-959; 012-782-867-578-249; 013-225-970-044-83X; 018-489-019-552-930; 020-180-856-972-883; 022-595-458-745-287; 024-627-758-025-712; 024-834-881-042-317; 056-636-790-240-557; 064-868-092-355-43X; 069-961-411-504-542; 075-627-669-809-507,0
026-905-725-739-591,United Kingdom,14786419; 14786427,Taylor and Francis Ltd.,Natural Product Research,Insecticidal activity of two essential oils used in perfumery (ylang ylang and frankincense),Chemistry; Frankincense; Ylang-ylang; Cananga odorata; Botany,2020-01-22,2020,journal article,Boswellia spp; Cananga odorata; commercial essential oils; housefly; insecticide; mosquito larvicide,,,1,7,Roman Pavela; Filippo Maggi; Cristiano Giordani; Loredana Cappellacci; Riccardo Petrelli; Angelo Canale,"AbstractNowadays, only a little part of essential oils produced at an industrial level is employed for insecticidal formulations, while thousand tons are used for perfumery purposes. This research ...",,,,https://www.tandfonline.com/doi/full/10.1080/14786419.2020.1715403,http://dx.doi.org/10.1080/14786419.2020.1715403,0,31965826,10.1080/14786419.2020.1715403,3002468654,,001-632-277-764-348; 015-726-127-497-067; 016-699-220-084-318; 022-455-775-990-695; 022-962-478-857-093; 025-987-872-417-432; 031-246-322-328-477; 035-625-926-031-266; 037-714-249-505-096; 046-498-709-137-355; 047-373-559-139-896; 055-579-303-822-134; 062-648-722-219-217; 063-264-662-966-133; 075-273-874-929-182; 083-778-426-534-498; 098-916-268-226-031; 108-932-396-071-039; 148-479-714-592-138; 168-370-992-610-400,0
027-102-895-465-180,United States,00927872; 15324125,Taylor and Francis Ltd.,Communications in Algebra,"Jordan superalgebra of type JPn,n≥3 and the Wedderburn principal theorem",Algebra; Superalgebra; Pure mathematics; Decomposition theorem; Mathematics,2020-01-10,2020,journal article,,,,1,9,F. A. Gómez-González; J. A. Ramírez Bermúdez,"AbstractWe investigate an analog to the Wedderburn Principal Theorem (WPT) for a finite-dimensional Jordan superalgebra J with solvable radical N such that N 2=0 and J/N≅JPn,n≥3. We consider N as a...",,,,https://www.tandfonline.com/doi/full/10.1080/00927872.2019.1711104,http://dx.doi.org/10.1080/00927872.2019.1711104,0,,10.1080/00927872.2019.1711104,2999524290,,006-951-478-242-167; 018-806-745-376-376; 025-717-848-698-713; 037-734-675-598-22X; 043-080-035-558-534; 056-336-820-229-646; 074-002-639-707-714; 074-888-262-552-235; 079-680-255-195-419; 085-487-595-714-556; 090-881-962-943-497; 122-544-780-255-45X; 138-336-111-048-466; 143-691-435-161-542,0
032-111-314-253-899,,01232576; 25007106,EDIMECO,Medicina y Laboratorio,"Profilaxis combinada con inmunoglobulina intravenosa y plasmaféresis en pacientes altamente sensibilizados, receptores de trasplante renal o combinado hígado-riñón: experiencia en un centro médico colombiano",Internal medicine; Etiology; Kidney disease; Plasmapheresis; Kidney; Immunosuppression; Kidney transplantation; Population; Medicine; Cohort,2020-01-01,2020,journal article,,,1,57,67,Dabely A. Palacios-Ramírez; Jorge E. Henao-Sierra; Mario A. Arbeláez-Gómez; Joaquín R. Rodelo-Ceballos; Luis Fernando Arias-Restrepo; Victoria I. Bedoya-Escobar; Julián Bustamante-Mira,"Introduction. Kidney transplantation is the best treatment option for patients with terminal chronic kidney disease, regardless of the etiology, making graft survival an important feature, which may be affected by immunological or non-immunological factors. This, added to the increasing number of patients on waiting lists, makes it necessary to define management strategies for these patients that allow better long-term results. Objectives. To determine the clinical, humoral and outcome characteristics in highly sensitized recipients of kidney and simultaneous kidney- liver transplant who received combined prophylaxis with intravenous immunoglobulin and plasmapheresis therapy in a Colombian medical center. Materials and methods. A retrospective, observational, descriptive study was carried out that included the transplanted patients between July 4, 2010 and April 19, 2017. Variables included the etiology of chronic kidney disease, the type of therapy received, and waiting time in days, among others. As outcomes, the presence of rejection, type of rejection, graft loss, complications and death were evaluated. Results. From a total of 25 patients, 100% received intravenous immunoglobulin and 84% plasmapheresis. Twelve percent presented graft rejection, all humoral, and 20% lost the graft. Discussion. Despite the great variety of protocols proposed in the literature, an optimal immunosuppression protocol has not been established for this particular population. The protocol in our small cohort did not have a negative impact on the percentage of post-transplant infections nor in the loss of the renal graft, but it did reduce waiting time; therefore, additional studies are required to confirm the findings in this study.",24,,,https://medicinaylaboratorio.com/index.php/myl/article/view/14,http://dx.doi.org/10.36384/01232576.14,0,,10.36384/01232576.14,2980736721,,008-338-480-313-101; 010-675-015-632-464; 010-902-239-207-800; 019-193-197-233-16X; 020-425-973-706-333; 023-458-865-436-305; 025-925-589-737-824; 030-433-352-838-678; 031-600-017-697-419; 031-807-507-472-050; 034-037-520-366-907; 036-354-971-849-352; 043-634-390-197-202; 046-881-015-422-25X; 049-871-693-340-659; 050-404-430-972-42X; 052-340-325-604-505; 053-707-273-780-666; 054-334-375-323-48X; 061-192-358-320-677; 064-053-205-043-954; 069-288-344-591-043; 073-796-732-951-130; 074-397-561-003-299; 079-699-340-653-912; 079-996-718-354-879; 090-014-543-144-732; 091-695-649-369-844; 114-642-931-715-994; 115-260-870-742-667; 119-282-523-560-044; 134-289-689-614-597,0
032-167-034-318-179,Netherlands,0169555x; 1872695x,Elsevier,Geomorphology,Influence of hydraulic properties on physically modelling slope stability and the definition of rainfall thresholds for shallow landslides,Precipitation; Slope stability analysis; Slope stability; Geology; Pressure head; Infiltration (HVAC); Factor of safety; Landslide; Hydrology; Hydraulic conductivity,2020-02-01,2020,journal article,,,,106976,,Roberto J. Marín; María Fernanda Velásquez,"Abstract Physically-based models are recognized as a good tool for slope stability analysis and have been implemented for the definition of rainfall thresholds for landslides. In this study, a methodology for estimating rainfall intensity and duration thresholds for shallow sliding failure, using the physical model TRIGRS, was implemented in a tropical mountainous basin of the Valle de Aburra (Colombia). The variation of pressure head and factor of safety during different rainfall events and hydraulic conditions is studied for specific grid cells. Steady state and a maximum pressure head were reached for each grid cell regardless of the different rainfall intensities and hydraulic conductivities simulated, but the time in which this condition is reached depends on these variables and occurs faster for steeper slopes. The influence of hydraulic properties on the stability results and the position of the rainfall intensity and duration thresholds were studied with parametric analysis. Very low values of saturated hydraulic conductivity do not allow rainfall intensity and duration thresholds to be developed. The rainfall threshold position also has a greater variation with respect to the parameters of the soil water retention curve and the initial infiltration rate (or long-term background rainfall rate) for low values of saturated hydraulic conductivity.",351,,,https://www.sciencedirect.com/science/article/pii/S0169555X19304672,http://dx.doi.org/10.1016/j.geomorph.2019.106976,0,,10.1016/j.geomorph.2019.106976,2990426357,,000-373-969-307-527; 000-855-976-665-885; 001-151-189-830-272; 001-156-681-667-940; 001-880-458-634-641; 003-714-197-515-781; 009-559-094-475-722; 014-661-534-231-003; 017-035-110-460-479; 017-924-206-672-388; 026-124-531-704-436; 029-064-907-341-483; 031-740-239-384-72X; 032-624-257-992-073; 033-683-753-367-644; 034-021-086-767-882; 034-400-531-393-605; 035-466-831-675-995; 037-486-804-879-838; 039-679-441-057-213; 040-484-733-670-832; 042-646-115-493-463; 048-010-475-790-861; 049-013-909-522-750; 050-985-703-951-148; 051-061-396-471-49X; 052-558-355-621-041; 053-994-332-783-619; 054-754-094-847-341; 055-074-457-522-982; 058-047-649-155-174; 058-523-488-371-718; 058-689-091-037-180; 059-981-592-904-03X; 060-334-090-756-879; 061-136-229-767-505; 067-302-982-746-447; 068-544-592-245-418; 068-576-240-816-746; 070-084-127-957-10X; 070-386-386-716-443; 073-225-220-023-534; 080-896-588-799-18X; 082-367-691-037-959; 086-079-737-805-300; 088-160-198-111-908; 088-634-989-630-140; 092-898-428-287-438; 093-316-067-744-78X; 093-464-662-345-171; 094-705-392-184-398; 107-470-921-519-998; 107-486-191-673-323; 109-113-804-221-68X; 114-121-108-379-53X; 114-588-831-913-366; 118-612-695-945-234; 118-912-527-799-092; 121-236-149-099-394; 124-841-446-992-749; 125-851-525-624-018; 131-034-647-694-070; 134-127-026-832-831; 134-292-428-108-597; 134-487-316-234-521; 141-386-813-760-224; 142-687-223-888-725; 144-313-811-021-18X; 146-794-961-518-784; 162-074-867-646-653; 166-424-170-069-254; 171-670-014-591-993; 182-127-242-522-986; 187-417-218-433-913; 187-637-173-034-883,0
036-091-096-032-405,Germany,00209910; 14321297,Springer New York,Inventiones Mathematicae,Singularity formation for the two-dimensional harmonic map flow into \(S^2\),Combinatorics; Mathematical analysis; Singularity; Finite set; Omega; Finite time; Mathematics; Bounded function; Nabla symbol; Harmonic map; Codimension,2020-02-01,2020,journal article,,,2,1,122,Juan Dávila; Manuel del Pino; Juncheng Wei,"We construct finite time blow-up solutions to the 2-dimensional harmonic map flow into the sphere \(S^2\), ; ; $$\begin{aligned} u_t&= \Delta u + |\nabla u|^2 u \quad \text {in } \Omega \times (0,T)\\ u&= \varphi \quad \text {on } \partial \Omega \times (0,T)\\ u(\cdot ,0)&= u_0 \quad \text {in } \Omega , \end{aligned}$$; ; where \(\Omega \) is a bounded, smooth domain in \(\mathbb {R}^2\), \(u: \Omega \times (0,T)\rightarrow S^2\), \(u_0:\bar{\Omega } \rightarrow S^2\) is smooth, and \(\varphi = u_0\big |_{\partial \Omega }\). Given any k points \(q_1,\ldots , q_k\) in the domain, we find initial and boundary data so that the solution blows-up precisely at those points. The profile around each point is close to an asymptotically singular scaling of a 1-corotational harmonic map. We build a continuation after blow-up as a \(H^1\)-weak solution with a finite number of discontinuities in space–time by “reverse bubbling”, which preserves the homotopy class of the solution after blow-up. Furthermore, we prove the codimension one stability of the one point blow-up phenomenon.",219,,,https://link.springer.com/article/10.1007/s00222-019-00908-y https://open.library.ubc.ca/cIRcle/collections/48630/items/1.0355888 https://researchportal.bath.ac.uk/en/publications/singularity-formation-for-the-two-dimensional-harmonic-map-flow-i,https://link.springer.com/article/10.1007/s00222-019-00908-y,0,,,2964809261,,004-677-868-113-297; 006-254-675-217-434; 007-233-388-216-010; 008-702-584-989-403; 013-122-907-159-886; 013-221-340-203-543; 024-648-041-733-642; 029-006-235-504-263; 031-953-680-116-629; 040-874-505-323-613; 044-610-143-099-672; 047-701-364-556-606; 050-368-009-466-130; 058-035-084-024-530; 058-209-872-576-739; 059-185-751-693-202; 062-830-513-273-218; 072-074-767-106-630; 080-763-503-713-481; 083-668-901-879-27X; 099-679-581-047-937; 099-821-194-161-814; 109-553-662-738-083; 118-364-751-045-119; 126-323-786-260-774; 135-681-160-819-421; 144-124-515-483-15X; 158-142-408-902-15X; 162-510-579-183-517; 166-981-686-155-622; 188-624-667-980-785; 196-519-369-370-853,3
038-764-576-953-576,Spain,16977912; 16977920,Universidad Politecnica de Valencia,Revista Iberoamericana De Automatica E Informatica Industrial,Sistema de posicionamiento en interiores utilizando señales de radio estaciones FM comerciales y Deep Learning,Engineering; Humanities; Control theory,2020-01-01,2020,journal article,,,1,34,,Julian Román; David Andrés Márquez Viloria; Ricardo A. Velásquez; Juan Botero Valencia,"El problema de posicionamiento en interiores se ha abordado con soluciones basadas en diferentes tipos de tecnologia. Las tecnicas varian desde las usadas con pseudolites, ultra-sonido, vision, magneticas, hasta tecnicas que hacen uso de tecnologias de radiofrecuencia principalmente haciendo uso de las senales WiFi. Las alternativas anteriormente mencionadas cuentan con la dificultad de requerir en su mayoria de una infraestructura o equipos especiales propios en el sitio de la aplicacion, lo que puede conllevar a que si en medio de una catastrofe alguno de los equipos es afectado, el posicionamiento sera afectado tambien. Para dar solucion a este problema hemos propuesto a traves de este trabajo una metodologia de posicionamiento en interiores que hace uso de las radio estaciones FM existentes, presentes en la gran mayoria de ciudades. La metodologia propuestas utilizan algoritmos de aprendizaje profundo y su desempeno fue comparado con el del algoritmo de posicionamiento KNN Regresivo, el cual es comunmente utilizado para posicionamiento en interiores.",17,,,https://polipapers.upv.es/index.php/RIAI/article/view/10894 https://polipapers.upv.es/index.php/RIAI/article/download/10894/11510,http://dx.doi.org/10.4995/riai.2019.10894,0,,10.4995/riai.2019.10894,2955556557,,,0
041-255-270-479-86X,United States,19490976; 19490984,Landes Bioscience,Gut microbes,"Gut microbiota profiles in critically ill patients, potential biomarkers and risk variables for sepsis",Intensive care medicine; Intensive care unit; Sepsis; Critically ill; Antibiotics; Gut flora; Medicine; Biomarker (medicine),2020-01-10,2020,journal article,Intestinal microbiota; antibiotics; critically ill patient; intensive care unit; sepsis,,,1,16,Gloria M. Agudelo-Ochoa; Beatriz E. Valdés-Duque; Nubia A. Giraldo-Giraldo; Ana M. Jaillier-Ramírez; Adriana Giraldo-Villa; Irene Acevedo-Castaño; Mónica A. Yepes-Molina; Janeth Barbosa-Barbosa; Alfonso Benítez-Páez,ABSTRACTCritically ill patients are physiologically unstable and recent studies indicate that the intestinal microbiota could be involved in the health decline of such patients during ICU stays. Th...,,,,https://www.tandfonline.com/doi/full/10.1080/19490976.2019.1707610,http://dx.doi.org/10.1080/19490976.2019.1707610,0,31924126,10.1080/19490976.2019.1707610,3000570416,,000-239-423-757-342; 002-282-465-694-593; 003-194-655-863-104; 003-947-607-029-071; 004-748-410-569-060; 007-123-977-084-960; 007-349-953-877-319; 007-869-499-607-368; 008-563-063-024-086; 009-362-368-504-043; 009-824-342-528-956; 009-951-694-644-071; 011-592-201-871-787; 015-253-961-711-734; 016-202-025-473-75X; 016-440-650-134-298; 017-102-804-120-96X; 018-396-607-316-237; 023-400-939-840-019; 024-252-684-489-46X; 029-172-299-986-584; 029-283-809-567-956; 031-502-978-648-617; 031-626-372-960-942; 033-543-476-254-89X; 035-286-939-174-318; 036-075-937-986-546; 036-999-375-233-445; 040-107-316-239-060; 040-271-673-295-401; 044-024-808-317-40X; 045-862-805-567-752; 047-254-514-788-428; 047-746-970-739-591; 049-891-441-563-344; 055-098-259-934-114; 060-722-126-508-864; 069-469-927-955-884; 070-431-968-555-213; 073-740-942-732-902; 074-353-427-078-762; 081-262-017-519-027; 081-999-926-038-657; 084-638-840-010-042; 085-714-558-963-008; 087-178-726-387-422; 087-330-539-163-232; 088-561-209-940-70X; 096-246-945-902-912; 098-164-185-640-959; 099-464-390-298-110; 103-849-528-825-13X; 112-397-017-997-396; 112-535-674-656-551; 116-661-965-783-908; 127-768-921-061-793; 129-268-082-407-002,0
042-309-985-614-137,Peru,02549247; 22233733,Sistema de Bibliotecas PUCP,Revista de Psicología,Perfiles de riesgo de deserción en estudiantes de las sedes de una universidad colombiana,,2020-01-01,2020,journal article,,,1,275,297,Sandra Milena Rueda Ramírez; Diana Urrego Velásquez; Esteban Páez Zapata; Carlos Alberto Agudelo Velásquez; Eliana María Hernández Ramírez,,38,,,http://revistas.pucp.edu.pe/index.php/psicologia/article/view/21586,http://dx.doi.org/10.18800/psico.202001.011,0,,10.18800/psico.202001.011,2994897927,,,0
042-314-017-884-419,South Africa,00068241,National Botanical Institute,Bothalia,"Garrapatas duras (Acari: Ixodidae) de Colombia, una revisión a su conocimiento en el país",Humanities; Ixodidae; Rhipicephalus; Amblyomma; Haemaphysalis; Dermacentor; Acari; Botany; Biology,2020-01-01,2020,journal article,,,1,126,139,Leidy Y. Acevedo-Gutiérrez; Luis E. Paternina; Juan Camilo Perez-Peréz; Andrés F. Londoño; Gustavo López; Juan D Rodas,"Las garrapatas son artropodos de gran impacto sobre la economia pecuaria y la salud humana debido a las perdidas generadas en la produccion, y a su capacidad de transmitir microorganismos. Pese a la evidencia de circulacion de una gran diversidad de garrapatas en Colombia, no se cuenta con compilaciones actualizadas de la variedad de especies presentes, por lo cual los autores presentan una revision de literatura sobre las garrapatas de la familia Ixodidae reportadas en Colombia incluyendo su distribucion geografica, sus hospederos y los microorganismos reportados en aquellas especies registradas en este pais. En la recopilacion se evidencio la presencia en Colombia de diferentes especies de garrapatas de los generos Amblyomma, Ixodes, Haemaphysalis, Rhipicephalus y Dermacentor. El genero con mayor variedad fue Amblyomma con 29 especies, seguido de Ixodes con 11 especies, y de los generos Dermacentor, Haemaphysalis y Rhipicephalus se reportaron dos especies para cada uno. Las especies se distribuyeron en la mayoria de los departamentos de Colombia y en una amplia diversidad de hospederos entre los cuales se incluyen animales domesticos, sinantropicos y silvestres. Adicionalmente se encontro que algunas garrapatas reportadas podrian jugar un papel como vectores potenciales de diversos microorganismos que pueden afectar a la salud publica y veterinaria. Esperamos que este trabajo sea un aporte para apoyar la investigacion en garrapatas y el estudio de los agentes transmitidos por estas en Colombia.",25,,,https://revistas.unal.edu.co/index.php/actabiol/article/view/75252,http://dx.doi.org/10.15446/abc.v25n1.75252,0,,10.15446/abc.v25n1.75252,2967406428,,,0
043-688-716-517-741,United States,00029173; 19437722,American Society of Clinical Pathologists,American Journal of Clinical Pathology,Utility of Routine Frozen Section of Thyroid Nodules Classified as Follicular NeoplasmMeta-Analysis of Diagnostic Tests,Pathology; Follicular phase; Thyroid nodules; Follicular neoplasms; Intraoperative care; Medicine; Diagnostic test; Frozen section procedure,2020-01-02,2020,journal article,Frozen section; Thyroid neoplasm; eta-analysis,,2,210,220,Jhorman Grisales; Álvaro Sanabria,"<AbstractText Label=""OBJECTIVES"" NlmCategory=""OBJECTIVE"">To evaluate the diagnostic performance of frozen section in thyroid nodules classified as follicular neoplasm.</AbstractText>;           <AbstractText Label=""METHODS"" NlmCategory=""METHODS"">A diagnostic test meta-analysis was designed. Studies that assessed frozen section in patients with thyroid nodules and a fine-needle aspiration biopsy result of Bethesda IV were selected. The outcomes measured were the number of false- and true-positive and -negative results. We used the Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2) instrument for methodological quality assessment and a bivariate mixed-effects regression framework and a likelihood-based estimation of the exact binomial approach.</AbstractText>;           <AbstractText Label=""RESULTS"" NlmCategory=""RESULTS"">Forty-six studies from 1991 to 2018 were included. Most studies had moderate methodological quality. The overall sensitivity and specificity were 43% (95% confidence internal [CI], 0.34-0.53) and 100% (95% CI, 0.99-1.00), respectively. The hierarchic summary receiver operating characteristic curve showed an area under the curve of 0.91 (95% CI, 0.80-0.97).</AbstractText>;           <AbstractText Label=""CONCLUSIONS"" NlmCategory=""CONCLUSIONS"">Frozen section demonstrates moderate diagnostic performance in patients with follicular neoplasm, and its utility for making intraoperative decisions is limited. Its routine use should be discouraged.</AbstractText>;           <CopyrightInformation>© American Society for Clinical Pathology, 2019. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.</CopyrightInformation>",153,,,https://academic.oup.com/ajcp/article/153/2/210/5626498,http://dx.doi.org/10.1093/ajcp/aqz152,0,31732728,10.1093/ajcp/aqz152,2988849533,,000-554-267-176-465; 003-412-985-480-774; 003-660-119-567-50X; 005-495-554-830-380; 006-161-994-153-682; 008-121-652-348-144; 010-032-781-018-798; 010-342-671-078-726; 010-387-551-812-569; 010-978-418-628-222; 011-420-304-244-689; 012-340-651-017-225; 014-653-842-843-829; 016-641-461-083-592; 017-686-306-642-193; 018-574-396-672-125; 018-764-173-315-62X; 020-479-514-546-485; 020-611-070-240-797; 020-637-231-533-335; 023-302-099-745-895; 023-373-743-705-180; 023-712-922-210-814; 025-047-138-155-052; 025-192-371-075-359; 026-457-299-640-911; 027-655-139-446-312; 027-976-183-731-820; 028-865-389-799-104; 029-277-201-750-807; 032-780-992-648-871; 033-386-537-031-547; 033-652-882-295-091; 035-954-880-916-276; 036-388-463-653-586; 036-451-397-830-984; 040-120-993-373-132; 042-835-413-940-914; 043-634-415-803-062; 044-835-962-626-402; 047-277-255-236-152; 047-977-276-702-711; 049-487-587-408-393; 052-285-569-826-21X; 054-809-811-878-366; 057-012-250-444-891; 057-075-056-237-870; 059-716-789-204-160; 064-989-304-092-696; 065-529-214-170-530; 069-673-862-413-010; 071-854-621-406-797; 074-213-379-924-295; 076-364-462-770-750; 083-328-936-402-868; 083-730-741-421-378; 094-257-664-463-977; 097-954-819-548-899; 099-993-498-730-415; 100-161-220-083-753; 101-373-234-476-495; 103-411-589-329-141; 107-706-692-382-155; 109-487-226-194-814; 117-317-447-476-08X; 128-562-239-699-762; 146-033-274-757-584; 152-467-074-352-115,0
047-521-560-729-633,United States,19373341; 1937335x,Mary Ann Liebert Inc.,Tissue Engineering Part A,Polyplexes system to enhance the LL-37 antimicrobial peptide expression in human skin cells,Molecular biology; Human skin; Peptide expression; Antimicrobial; Biology; Microbiology,2020-02-05,2020,journal article,CAMP gene; LL 37; fibroblast; keratinocytes; polyplexes,,,,,Maria Isabel Patiño Vargas; Monica Mesa Cadavid; Claudia Marcela Arenas Gómez; Johnatan Diosa Arango; Luz Marina Restrepo Múnera; Natalia Yiset Becerra Colorado,"Inefficient autologous tissue recovery in diverse skin injuries increases the susceptibility of patients to infections caused by multiresistant microorganisms, resulting in a high mortality rate. N...",,,,https://www.scilit.net/article/0147097b8575e9be42976b9e6e8f7a22 https://www.liebertpub.com/doi/10.1089/ten.TEA.2019.0196,http://dx.doi.org/10.1089/ten.tea.2019.0196,0,31805827,10.1089/ten.tea.2019.0196,2993333120,,001-243-567-753-218; 004-035-636-907-448; 005-323-119-176-782; 006-960-717-353-601; 007-658-351-440-020; 008-232-626-367-351; 011-725-101-475-353; 013-625-767-985-338; 014-829-032-243-908; 015-827-463-898-866; 019-065-788-148-50X; 019-291-747-192-673; 023-782-660-069-489; 024-494-826-886-906; 029-279-954-362-218; 029-375-469-732-035; 029-521-275-716-646; 031-793-424-117-884; 044-960-660-942-963; 048-896-193-407-567; 050-533-318-251-287; 053-376-015-911-412; 054-983-365-499-078; 055-768-401-680-689; 055-791-274-788-747; 059-387-438-840-312; 059-776-143-439-045; 063-653-689-053-333; 064-093-150-998-708; 066-446-791-271-393; 067-929-454-539-654; 069-527-825-268-752; 070-681-848-587-562; 084-597-906-230-761; 091-458-323-614-302; 091-574-884-037-144; 093-576-927-961-436; 110-853-359-439-232; 114-104-775-052-309; 114-698-931-424-989; 137-567-411-600-349; 143-360-612-615-909,0
049-831-738-973-219,United Kingdom,07487983; 15322157,W.B. Saunders Ltd,Ejso,The role of radioactive iodine in the management of patients with differentiated thyroid cancer – An oncologic surgical perspective,Biopsy; Adjuvant; Adjuvant therapy; Malignancy; Thyroid cancer; Radioactive iodine; Risk groups; Thyroid carcinoma; General surgery; Medicine,2020-01-09,2020,journal article,Adjuvant; Radioactive iodine; Thyroid cancer; Thyroidectomy,,,,,Iain J. Nixon; Jatin P. Shah; Mark Zafereo; Ricard Simo; I.D. Hay; Carlos Suárez; Peter Zbären; Alessandra Rinaldo; Álvaro Sanabria; Carl E. Silver; Antti Mäkitie; V. Vander Poorten; L.P. Kowalski; Ashok R. Shaha; Gregory W. Randolph; Alfio Ferlito,"Abstract With improved understanding of the biology of differentiated thyroid carcinoma its management is evolving. The approach to surgery for the primary tumour and elective nodal surgery is moving from a “one size -fits-all” recommendation to a more personalised approach based on risk group stratification. With this selective approach to initial surgery, the indications for adjuvant radioactive iodine (RAI) therapy are also changing. This selective approach to adjuvant therapy requires understanding by the entire treatment team of the rationale for RAI, the potential for benefit, the limitations of the evidence, and the potential for side-effects. This review considers the evidence base for the benefits of using RAI in the primary and recurrent setting as well as the side-effects and risks from RAI treatment. By considering the pros and cons of adjuvant therapy we present an oncologic surgical perspective on selection of treatment for patients, both following pre-operative diagnostic biopsy and in the setting of a post-operative diagnosis of malignancy.",,,,https://www.sciencedirect.com/science/article/pii/S0748798320300147?dgcid=rss_sd_all,http://dx.doi.org/10.1016/j.ejso.2020.01.010,0,31952928,10.1016/j.ejso.2020.01.010,2999242292,,000-893-485-456-621; 001-579-485-681-125; 002-093-869-080-974; 003-258-847-141-835; 004-514-137-903-221; 005-019-867-025-457; 005-025-426-781-493; 005-127-515-636-244; 005-870-467-389-98X; 006-589-504-420-694; 007-667-731-049-503; 007-874-811-079-165; 008-668-548-146-496; 008-753-219-518-849; 008-779-921-042-874; 009-134-077-288-470; 009-204-730-397-41X; 009-930-220-495-438; 010-122-513-020-452; 012-048-623-443-851; 013-382-969-895-206; 013-812-668-332-802; 014-085-656-005-917; 014-568-266-379-75X; 016-312-000-702-63X; 017-123-534-640-772; 017-136-520-663-132; 017-974-129-129-589; 018-233-233-185-394; 018-381-233-923-03X; 018-415-407-963-561; 019-615-035-213-278; 019-691-383-008-70X; 021-031-702-626-512; 021-475-358-583-417; 024-266-847-904-443; 024-911-964-188-174; 025-723-417-235-064; 027-511-491-385-907; 028-103-831-941-10X; 029-431-586-465-769; 029-601-234-803-33X; 031-159-813-164-774; 031-421-200-427-093; 031-781-035-963-86X; 033-657-312-922-498; 034-719-769-032-134; 035-683-467-522-220; 038-713-118-292-862; 040-636-351-951-583; 041-444-365-066-198; 042-704-386-166-694; 043-075-656-947-966; 043-175-154-035-690; 045-138-381-616-065; 046-592-626-130-765; 047-135-982-227-531; 048-802-434-482-032; 049-207-774-015-22X; 049-572-678-765-026; 050-864-827-105-92X; 052-188-849-458-832; 056-078-355-043-037; 057-710-537-628-063; 059-341-674-145-270; 061-443-354-726-526; 061-628-055-284-394; 062-944-628-636-459; 063-638-154-523-858; 067-977-844-137-382; 069-709-844-968-508; 070-785-264-578-634; 071-319-824-955-599; 071-783-338-487-055; 074-700-112-506-615; 077-061-364-074-979; 078-897-756-437-077; 079-582-984-006-463; 080-946-212-120-143; 082-186-263-025-748; 084-000-482-082-704; 084-748-630-557-557; 085-603-719-407-79X; 093-731-707-912-955; 094-880-771-045-898; 097-954-819-548-899; 099-176-828-595-480; 100-292-494-048-584; 100-459-997-426-489; 101-358-269-919-852; 101-801-127-879-30X; 105-096-655-318-340; 105-531-984-104-03X; 107-477-666-888-99X; 118-611-001-317-512; 137-523-228-642-634; 143-389-375-875-06X; 145-031-028-721-37X; 146-720-572-519-511,0
050-854-008-537-324,United Kingdom,14712288,BioMed Central,BMC Medical Research Methodology,Reliability and validity of a sedentary behavior questionnaire for South American pediatric population: SAYCARE study,Econometrics; Population; Sedentary behavior; Medicine; Gerontology,2020-01-10,2020,journal article,Methods; Sedentary behavior; Youth,Conselho Nacional de Desenvolvimento Científico e Tecnológico (471266/2013-2); Conselho Nacional de Desenvolvimento Científico e Tecnológico (313772/2014-2); Conselho Nacional de Desenvolvimento Científico e Tecnológico (200340/2015-8); Conselho Nacional de Desenvolvimento Científico e Tecnológico (304003/2014-0); Conselho Nacional de Desenvolvimento Científico e Tecnológico (300951/2015-9); Fundação de Amparo à Pesquisa do Estado de São Paulo (2014/11468-6); Fundação de Amparo à Pesquisa do Estado de São Paulo (2014/13367-2); Fundação de Amparo à Pesquisa do Estado de São Paulo (2015/14319-4); Fundação de Amparo à Pesquisa do Estado de São Paulo (2016/18436-8); Fundação de Amparo à Pesquisa do Estado de São Paulo (2017/11732-3); Fundação de Amparo à Pesquisa do Estado de São Paulo (2015/11406-3); Fundação de Amparo à Pesquisa do Estado de São Paulo (2014/11468-6),1,5,,Augusto César Ferreira de Moraes; Marcus Vinicius Nascimento-Ferreira; Cláudia Lúcia de Moraes Forjaz; Juan C. Aristizabal; Leticia Azzaretti; Walter Viana Nascimento Junior; Maria L. Miguel-Berges; Estela Skapino; Carlos Delgado; Luis A. Moreno; Heráclito Barbosa Carvalho,"Background; Multicenter studies from Europe and the United States have developed specifically standardized questionnaires for assessing and comparing sedentary behavior, but they cannot be directly applied for South American countries. The aim of this study was to assess the reliability and validity of the South American Youth Cardiovascular and Environmental (SAYCARE) sedentary behavior questionnaire.",20,,,https://link.springer.com/article/10.1186%2Fs12874-019-0893-7,http://dx.doi.org/10.1186/s12874-019-0893-7,0,31924168,10.1186/s12874-019-0893-7,2999783557,,002-828-084-991-465; 006-623-746-426-657; 007-731-929-737-743; 009-987-994-750-604; 014-144-228-210-911; 015-954-162-760-62X; 017-339-378-175-938; 020-201-432-310-261; 023-152-433-606-102; 023-755-700-271-734; 025-517-606-738-413; 026-255-404-292-416; 027-650-931-476-248; 029-408-645-563-030; 031-056-855-501-837; 031-376-865-240-24X; 032-434-903-527-209; 034-384-090-967-214; 034-820-275-341-857; 037-479-930-476-735; 038-901-652-380-203; 051-397-062-893-499; 051-964-145-638-694; 052-445-267-340-804; 060-602-189-190-164; 061-433-115-434-48X; 065-828-460-344-903; 075-204-316-984-583; 075-770-589-687-708; 081-048-365-773-278; 089-885-448-121-928; 091-888-982-607-616; 097-655-105-594-770; 100-524-224-454-355; 128-908-136-873-487; 170-284-439-533-009; 172-753-475-609-391,2
052-463-463-968-841,United Kingdom,00099104; 13652249,Wiley-Blackwell,Clinical and Experimental Immunology,High activation and skewed T‐cell differentiation are associated with low IL‐17A levels in a hu‐PBL‐NSG‐SGM3 mouse model of HIV infection,Virology; CD38; Immunology; T cell; HLA-DR; T cell differentiation; Biology,2020-01-17,2020,journal article,CD38; HIV; HLA-DR; IL-17A; NSG-SGM3; PD-1; T cell,IHV; Universidad de Antioquia; Corporacion Universitaria Remington; Fundacion Sapiencia in Medellin,,,,Federico Perdomo-Celis; Sandra Medina-Moreno; Harry Davis; Joseph Bryant; Natalia A. Taborda; María Teresa Rugeles; Shyamasundaran Kottilil; Juan C. Zapata,"The humanized NOD/SCID/IL-2 receptor γ-chain<sup>null</sup> (NSG) mouse model has been widely used for the study of HIV pathogenesis. Here, NSG mice with transgenic expression of human stem cell factor (SCF), granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin (IL)-3 (NSG-SGM3) were injected with peripheral blood leukocytes (PBL mice) from two HIV-infected (HIV<sup>+</sup> ) patients who were under anti-retroviral therapy (ART; referred as HIV<sup>+</sup> mice) or one HIV-seronegative healthy volunteer (HIV<sup>-</sup> ). Such mice are either hu-PBL-NSG-SGM3 HIV<sup>+</sup> or HIV<sup>-</sup> mice, depending on the source of PBL. The kinetics of HIV replication and T cell responses following engraftment were evaluated in peripheral blood and secondary lymphoid tissues. High HIV replication and low CD4 : CD8 ratios were observed in HIV<sup>+</sup> mice in the absence of anti-retroviral therapy (ART). Consistent with high activation and skewed differentiation of T cells from the HIV-infected donor, HIV<sup>+</sup> mice exhibited a higher T cell co-expression of human leukocyte antigen D-related (HLA-DR) and CD38 than HIV<sup>-</sup> mice, as well as a shifted differentiation to a CCR7<sup>-</sup> CD45RA<sup>+</sup> terminal effector profile, even in the presence of ART. In addition, HIV replication and the activation/differentiation disturbances of T cells were associated with decreased plasma levels of IL-17A. Thus, this hu-PBL-NSG-SGM3 mouse model recapitulates some immune disturbances occurring in HIV-infected patients, underlying its potential use for studying pathogenic events during this infection.",,,,https://www.onlinelibrary.wiley.com/doi/full/10.1111/cei.13416,http://dx.doi.org/10.1111/cei.13416,0,31951011,10.1111/cei.13416,2998877170,,000-460-395-044-064; 002-891-877-524-80X; 004-836-628-425-668; 006-608-058-804-372; 007-710-543-037-071; 008-923-419-215-518; 011-519-716-089-902; 012-124-930-391-475; 013-986-540-881-888; 014-045-721-195-264; 014-589-592-253-346; 014-854-273-406-442; 015-955-099-714-27X; 019-294-809-986-262; 022-115-295-630-606; 022-517-240-624-729; 023-523-383-472-23X; 024-313-046-637-225; 025-917-647-175-074; 028-147-534-487-523; 029-119-934-350-356; 031-811-072-006-131; 032-602-226-689-859; 032-724-035-516-651; 033-129-774-354-991; 038-002-306-769-946; 039-259-022-306-245; 039-316-696-357-151; 041-845-390-450-404; 042-440-935-602-895; 043-606-674-858-633; 045-831-945-211-22X; 045-877-245-021-98X; 049-925-955-978-750; 050-563-569-255-511; 057-111-760-600-165; 057-635-034-921-13X; 058-250-503-698-321; 061-043-758-353-997; 067-416-235-245-329; 068-532-332-227-936; 069-571-932-599-280; 069-959-903-933-033; 072-490-337-567-050; 073-295-883-233-691; 075-775-696-738-753; 076-450-059-346-125; 079-582-159-871-035; 080-062-045-676-414; 080-706-058-948-256; 085-352-482-242-70X; 087-615-186-922-561; 093-175-311-253-207; 095-396-126-142-064; 097-921-778-582-298; 098-875-749-407-943; 099-984-386-482-985; 113-561-425-821-240; 116-789-312-132-190; 118-686-649-131-696; 118-898-349-255-691; 120-684-837-294-33X; 127-011-649-147-859; 127-416-339-660-812; 138-147-429-713-056,0
052-502-680-855-631,,03042847; 22487026,Universidad Nacional de Colombia,Revista Facultad Nacional de Agronomía Medellín,"Biological control of symphylid pests in a commercial chrysanthemum (Dendranthema grandiflora) crop using the fungus Purpureocillium lilacinum, strain UdeA0106",Biological pest control; Crop; Horticulture; Fungus; Dendranthema grandiflora; Purpureocillium lilacinum; Entomopathogenic fungi; Biology,2020-01-01,2020,journal article,,,1,9057,9064,Diego A Salazar-Moncada; Julián Morales-Muñoz; Nadya L Cardona-Bustos,"Los sinfilidos, tambien conocidos como ciempies de jardin o pseudociempies, son artropodos habitantes del suelo de la clase Symphyla. Afectan diversos cultivos alrededor del mundo debido a que consumen raices jovenes y plantas de semillero. Este estudio presenta la efectividad del hongo Purpureocillium lilacinum UdeA0106 para reducir poblaciones de sinfilidos bajo condiciones de invernaderos comerciales. Los resultados muestran que esta cepa de hongo pudo reducir la densidad de sinfilidos en un 70.6%. Tambien se demostro que una alta concentracion de la cepa UdeA0106 ayuda a recuperar cultivos de crisantemo ( Dendranthema grandifIora ), cuando estos han sido infestados por sinfilidos. Los resultados mostrados son la primera evidencia de un control biologico efectivo de una plaga de sinfilidos en una plantacion comercial de fIores, representando el potencial de P. lilacinum UdeA0106 como agente de control biologico.",73,,,https://revistas.unal.edu.co/index.php/refame/article/view/76027/73614,http://dx.doi.org/10.15446/rfnam.v73n1.76027,0,,10.15446/rfnam.v73n1.76027,2999895843,,,0
054-383-832-909-664,Netherlands,17564646,Elsevier Limited,Journal of Functional Foods,Amaranth-hydrolyzate enriched cookies reduce the systolic blood pressure in spontaneously hypertensive rats,Bioavailability; Chemistry; Amaranth; Expansion factor; Food science; Biochemistry; Diabetes mellitus; Blood pressure,2020-01-01,2020,journal article,,Consejo Nacional de Ciencia y Tecnología,,103613,,Noé Ontiveros; Veronica Lopez-Teros; Marcela Vergara-Jimenez; Alma Rosa Islas-Rubio; Feliznando Isidro Cárdenas-Torres; E.O. Cuevas-Rodríguez; Cuauhtémoc Reyes-Moreno; Diana María Granda-Restrepo; Seneida Lopera-Cardona; Giovanni Isaí Ramírez-Torres; Francisco Cabrera-Chávez,"Abstract The effect of consuming baked foods enriched with antihypertensive compounds on blood pressure remains uncertain. In this study, an alcalase-generated amaranth hydrolyzate was used to prepare cookies and their technological characteristics (expansion factor, color, and texture) and antihypertensive properties evaluated. The bioavailability of the antihypertensive compounds were assessed in Balb/c mice and the antihypertensive effects in hypertensive rats. Enriched cookies developed a more intense yellow-brown color than the non-enriched ones (p",64,,,https://www.sciencedirect.com/science/article/pii/S1756464619305377,http://dx.doi.org/10.1016/j.jff.2019.103613,0,,10.1016/j.jff.2019.103613,2983582994,,008-352-396-541-356; 009-426-795-910-871; 010-891-219-801-027; 015-368-890-757-339; 022-781-378-675-089; 025-401-878-582-219; 028-057-054-530-618; 030-846-622-095-807; 035-363-116-530-672; 038-485-108-931-243; 047-592-687-264-27X; 050-895-101-094-290; 068-012-040-517-385; 073-024-951-420-065; 090-071-050-802-750; 110-906-960-901-498; 121-083-164-098-395; 128-364-563-425-328; 146-920-945-058-153; 170-746-603-643-060,0
054-951-698-993-801,United Kingdom,14772817; 1745039x,Taylor and Francis Ltd.,Archives of Animal Nutrition,A comparison of two methods to assess apparent total tract digestibility of nutrients in dogs,Animal science; Nutrient; CHROMIC OXIDE; Feces; Agronomy; Biology,2020-01-03,2020,journal article,Accuracy; Canis familiaris; chromic oxide; digestibility; faeces collection; markers; methodology,,,1,12,Juan C. Duque-Saldarriaga; Sandra Lucía Posada-Ochoa; Jorge H. Agudelo-Trujillo; Luis M. Gómez-Osorio,"ABSTRACTThe apparent total tract digestibility (ATTD) of nutrients can be assessed by total collection of faeces (TC), which is the reference method, or by the indicator method (IM). Little informa...",,,,https://www.tandfonline.com/doi/full/10.1080/1745039X.2019.1698899,http://dx.doi.org/10.1080/1745039x.2019.1698899,0,31899960,10.1080/1745039x.2019.1698899,2997034612,,000-558-336-525-568; 002-562-834-908-144; 004-778-346-552-973; 014-892-588-857-931; 019-505-546-243-922; 022-140-855-994-091; 028-471-600-657-450; 035-851-925-312-715; 039-878-864-115-712; 042-946-578-279-855; 044-310-862-267-519; 046-190-702-384-141; 071-925-887-884-193; 073-200-351-456-961; 077-979-844-484-378; 099-887-275-851-704; 105-345-013-072-267; 105-400-109-889-115; 119-020-990-741-311; 120-507-389-242-140; 127-401-108-770-617; 128-019-239-631-309; 129-537-045-956-304; 137-717-943-591-018; 151-478-718-024-369; 179-163-619-329-730,0
055-881-258-975-146,Germany,15571912; 15571920,Springer New York,Journal of Immigrant and Minority Health,Oral Health and Oral Health Service Utilization in Native and Immigrant Population: A Cross-Sectional Analysis from the PELFI Cohort in Spain,Psychiatry; Cross-sectional study; Odds; Demography; Logistic regression; Population; Oral health; Confidence interval; Immigration; Medicine; Cohort,2020-01-09,2020,journal article,Dental caries; Dental health surveys; Emigrants and immigrants; Oral health; Periodontal diseases,Healthcare Research Fund of the Spanish Ministry of Health (Ref. PI14/01146-PI14/02005),,1,10,Andrés A. Agudelo-Suárez; Natalia Muñoz-Pino; Annie M. Vivares-Builes; Elena Ronda-Pérez,"This study analyzes associated factors to self-perceived oral health and use of oral health services in native and immigrant adults from the PELFI cohort in Spain. A cross-sectional analysis was conducted (401 adults ≥ 18 years, from Spain, Ecuador, Colombia and Morocco). Frequencies for sociodemographic, self-perceived general and oral health variables were calculated. The association between oral health/oral health services use and origin country was estimated by logistic regression (adjusted odds ratio-aOR-; 95% confidence intervals -95%CI-). Ecuadorian men were more likely to report dental caries (aPR 2.75; 95%CI 1.30–5.80) and Moroccan women were more likely to report gingival bleeding (aPR 3.61; 95%CI 1.83–7.15) and the use of oral health services ≥ 1 year/never (aPR 1.69; 95%CI 1.06–2.69). Colombian women were less likely to report missing teeth (aPR 0.73; 95%CI 0.56–0.95). Poor self-perceived oral health indicators were observed in immigrants and were modified for sociodemographic and general health variables.",,,,https://link.springer.com/article/10.1007%2Fs10903-020-00972-0,http://dx.doi.org/10.1007/s10903-020-00972-0,0,31919785,10.1007/s10903-020-00972-0,3000535367,,005-428-121-791-945; 010-213-332-595-808; 011-375-826-641-059; 015-495-456-801-327; 016-056-920-343-852; 016-723-523-970-39X; 018-129-613-865-404; 020-638-981-625-292; 021-371-164-891-634; 021-746-902-279-008; 024-491-542-174-33X; 028-732-908-475-381; 032-102-646-733-675; 032-289-606-428-281; 038-054-739-067-629; 038-286-859-315-79X; 038-522-365-043-511; 043-741-267-728-390; 054-877-526-560-679; 062-739-317-348-561; 063-132-494-106-26X; 065-008-084-470-602; 069-894-835-270-383; 079-193-907-449-384; 082-776-841-465-973; 089-409-533-271-405; 089-600-000-860-165; 094-942-606-390-138; 102-234-418-118-082; 120-254-230-375-088; 121-301-103-214-703; 124-409-628-987-753; 126-691-621-308-580; 176-522-899-968-58X; 180-276-329-960-942,0
056-252-448-470-186,Netherlands,01672738,Elsevier,Solid State Ionics,Enhanced rate capability of lithium deficient spinel via controlling cooling rate,Analytical chemistry; Lattice (order); Chemistry; Spinel; Ethylene; Cooling rate; Lithium; Electrochemistry; Impurity,2020-02-01,2020,journal article,,Consejo Nacional de Investigaciones Científicas y Técnicas; Agencia Nacional de Promoción Científica y Tecnológica; Colombia Scientific Program,,115199,,F.A. Vásquez; J.E. Thomas; J.A. Calderón,"Abstract Lithium-deficient and Lithium-excess spinels LixMn1.6Ni0.4O4 (x = 1.05, 0.9) were synthesized by co-precipitation method assisted by ethylene glycol-oxalic acid. Control of cooling rates was performed in order to improve the crystallographic order, the lattice parameters and avoid the impurity precipitation. The samples were characterized physically and electrochemically. The best electrochemical performances were obtained for lithium-deficient spinels cooled at intermediate rates (2.2 °C min−1). For this optimized material, the discharge capacity was 122 mA h g−1 at 0.5C rate, retaining >83% of capacity at 10C rate and having good cycle life with >93.5% of initial capacity after 100 cycles at 0.5C rate.",345,,,https://www.sciencedirect.com/science/article/pii/S0167273819308434,http://dx.doi.org/10.1016/j.ssi.2019.115199,0,,10.1016/j.ssi.2019.115199,2997458704,,000-342-585-082-048; 001-548-690-087-289; 003-370-591-417-198; 011-535-321-181-19X; 021-531-486-524-423; 022-361-151-112-440; 022-976-624-382-83X; 023-074-394-257-745; 030-591-297-550-324; 031-194-095-015-304; 033-778-901-517-264; 039-948-827-633-044; 045-675-308-332-73X; 046-669-353-852-641; 051-839-993-676-308; 054-008-087-118-031; 057-441-435-230-182; 059-013-533-722-596; 059-977-084-723-222; 062-235-760-685-192; 072-169-289-993-475; 074-964-309-831-648; 076-002-241-432-776; 082-377-424-011-93X; 083-587-210-436-096; 087-812-210-337-702; 090-111-245-413-118; 092-245-169-226-308; 094-325-519-150-28X; 100-353-314-696-186; 100-842-229-892-518; 111-562-609-477-482; 111-683-416-811-035; 114-791-172-514-225; 117-329-874-275-037; 118-867-139-557-630; 122-471-227-939-114; 125-660-921-865-989; 129-315-636-459-672; 131-026-707-004-378; 153-001-342-534-057; 169-183-323-510-499; 174-419-496-284-652; 192-752-824-174-535,0
057-740-416-337-777,United States,10599630; 15441016,Springer New York,Journal of Thermal Spray Technology,Influence of Atmospheric Plasma Spraying Parameters on Porosity Formation in Coatings Manufactured from 45S5 Bioglass® powder,Glass transition; Composite material; Metallurgy; Materials science; Scanning electron microscope; Coating; Nozzle; Evaporation; Porosity; Plasma; Atmospheric-pressure plasma,2020-01-01,2020,journal article,,,1,185,198,Oscar Rojas; M. Prudent; M.E. Lopez; Fabio Vargas; Hélène Ageorges,"Atmospheric plasma spraying parameters were studied to understand their influence on the splat stacking and the porosity formation in coatings made from commercial Schott 45S5 Bioglass® powder onto AISI 304 L stainless steel substrate. The spraying parameters were established from numerical simulation carried out by the Jets&Poudres software. The plasma spraying was performed by using an Oerlikon Metco F4 MB gun with a 6-mm-internal-diameter nozzle. Three Ar/H2 mixtures were used as plasma-forming gas (95/5, 88/12 and 84/16 vol.%), and the current intensity was varied from 450 to 650 A and the spray distance from 60 to 100 mm. The cooling of the samples during spraying was controlled by air jet pressure. The x-ray diffraction and the scanning electron microscopy were used to determine phases and structural characteristics of coatings, respectively. The numerical simulation results for each set of spray parameters have shown suitable Sommerfeld number for proper splat stacking. However, Na2O and P2O5 evaporation occurred experimentally during spraying of 45S5 Bioglass® promoted the porosity formation into the coating structure. Low porosity was obtained for 45S5 Bioglass coatings manufactured under the appropriate relationship between plasma-forming gas mixture ratio, current intensity, spray distance and cooling air jet pressure to achieve thermal energy input enough to overcome the glass transition temperature and to avoid the evaporation of volatile oxides.",29,,,https://link.springer.com/article/10.1007/s11666-019-00952-3,https://link.springer.com/article/10.1007/s11666-019-00952-3,0,,,2985288849,,003-763-573-057-085; 004-936-611-503-437; 006-157-106-363-349; 006-287-835-785-635; 006-872-084-127-304; 009-481-676-340-425; 010-650-712-161-222; 012-999-306-493-20X; 016-293-786-059-293; 016-757-161-647-514; 016-907-116-240-759; 018-236-915-903-254; 019-362-482-200-943; 025-539-833-697-188; 027-887-492-404-837; 028-221-476-085-456; 031-357-529-888-959; 035-736-221-314-604; 037-275-275-672-531; 041-436-321-050-426; 043-536-226-259-900; 045-608-877-867-697; 046-001-557-127-257; 048-234-292-909-228; 048-476-747-552-125; 050-984-223-704-039; 055-698-218-547-176; 056-446-874-859-966; 058-483-091-531-61X; 063-208-500-505-426; 064-724-681-867-158; 067-162-252-008-213; 070-170-334-413-640; 070-859-344-294-243; 077-157-292-910-363; 078-644-053-798-348; 085-101-959-589-676; 094-542-832-730-759; 101-570-439-688-179; 105-025-355-075-238; 106-934-569-129-857; 114-293-125-329-332; 114-375-641-755-943; 122-219-987-831-849; 124-502-671-902-926; 134-173-244-128-495; 137-382-396-455-612; 154-151-686-813-930; 154-787-242-468-308; 155-713-915-704-50X; 172-143-716-383-138; 177-716-670-161-528; 179-126-544-685-489,0
058-100-037-608-144,Netherlands,03009440,Elsevier,Progress in Organic Coatings,Study of waterborne polyurethane materials under aging treatments. Effect of the soft segment length,Miscibility; Accelerated aging; Polyester; Composite material; Materials science; Paint adhesion testing; Adipic acid; Polyurethane; Polyol; Chemical engineering; Contact angle,2020-01-01,2020,journal article,,,,105357,,Anny C. Ospina; Víctor H. Orozco; Luis Fernando Garcés Giraldo; Mónica Fuensanta; José Miguel Martín-Martínez; Noemi Mateo-Oliveras,"Abstract Coatings made of waterborne polyurethane dispersions are a promising alternative to solvent-borne ones but their mechanical and thermal properties under harsh outdoor conditions such as high temperature and humidity are somewhat limited. In this work saturated polyesters (PBA) with different molecular weights (800–2600 g/mol) were synthesized by reacting adipic acid with 1,4 butanediol. These polyols, an internal emulsifier, and an aliphatic diisocyanate were used as raw materials to synthesize polyurethane (PU) aqueous dispersions with solids contents of 29–38 wt%. The increase of the molecular weight of the polyol decreased the mean particle size of the PU dispersions from 308 to 78 nm. Polyurethane (PU) films were obtained by water evaporation of the PU dispersions and they were annealed at 80 °C for 2 h. Accelerated aging studies were performed by submerging the PU films in the water at 80 °C for 2 h. The PU films synthesized with the polyols with lower molecular weight exhibited enhanced phase miscibility, giving place to storage and loss moduli of similar magnitudes in a wide temperature range and they were less susceptible to hydrolytic degradation. Microphase miscibility was favored when shorter polyols are used. Contact angle measurement and cross-hatch adhesion test on PU coatings placed on stainless steel plate, before and after annealing and water aging were carried out. All PU coatings retained the adhesion to the substrate after aging, the PU coatings synthesized with shorter polyols exhibited enhanced adhesion.",138,,,http://rua.ua.es/dspace/handle/10045/98092 https://www.sciencedirect.com/science/article/pii/S0300944019311671,http://dx.doi.org/10.1016/j.porgcoat.2019.105357,0,,10.1016/j.porgcoat.2019.105357,2981278828,,008-325-218-414-318; 011-283-720-904-49X; 031-993-057-865-253; 032-774-003-903-724; 035-724-805-175-494; 042-909-542-777-729; 053-491-276-889-878; 062-919-765-360-861; 064-901-990-190-94X; 082-274-151-923-156; 104-561-582-806-494; 106-953-423-686-793; 115-377-955-611-809; 122-637-084-764-501; 131-913-753-293-482; 138-334-742-290-508; 139-307-013-400-204; 143-528-007-605-725; 166-353-094-055-68X; 170-265-025-605-46X,0
059-193-511-860-219,Netherlands,09266690,Elsevier,Industrial Crops and Products,CosIng database analysis and experimental studies to promote Latin American plant biodiversity for cosmetic use,Biodiversity; Latin Americans; Chemistry; Cosmetic industry; Euterpe; Theobroma; Bixa; Eugenia stipitata; Database analysis; Traditional medicine; Botany,2020-02-01,2020,journal article,,"Departamento Administrativo de Ciencia, Tecnología e Innovación (COLCIENCIAS); Program of Postdoctoral Stays",,112007,,Karent Bravo; Camilo Quintero; Catalina Agudelo; Stiveen García; Adriana Bríñez; Edison Osorio,"Abstract Although Latin America is one of the regions with the greatest plant diversity on the planet and, its commercial exploitation has not impacted the economic growth of Latin American countries, with the exception of Brazil. The great plant biodiversity of Latin American countries is an opportunity for the development of sustainable and innovative cosmetic ingredients and products. Some studies have focused on identifying the potential cosmetic use of Latin American plants. However, their commercial use is not possible due to their limited availability as raw materials, their safety has not been proven, and their lack of inclusion in international lists. This study analyzed plant species in the CosIng database for UV-filtering, UV-absorbing, bleaching, skin-protecting, and antioxidant functions and assayed the properties of potential plants by in vitro assays to promote the cosmetic use of biodiverse Latin American plants. The results showed that the majority of cosmetic ingredients listed in CosIng are from Asiatic plants, while 9 % are from Latin American plants. Approximately half of the registered plants in CosIng are commercialized as cosmetic ingredients. In addition, 28 % of the plants registered in CosIng occur in Colombia, but of these, only 30 % are native. The experimental analysis showed that the Bixa orellana, Theobroma cacao, and Eugenia stipitata extracts had the highest skin protective activity due to their capacity to inhibit collagenase, elastase, and hyaluronidase enzymes. B. orellana and Euterpe oleracea extracts showed the highest antioxidant capacity, phenol contents, and spectrophotometric sun protection factor (SPFspectrophotometric) values. B. orellana, E. oleracea, and E. stipitata extracts showed photoprotective properties in human dermal fibroblasts due to the reduction of cell death, matrix metalloproteinase-1 (MMP-1) production, and reactive oxygen spices (ROS) production and an increase in pro-collagen production after ultraviolet (UV) exposure. Finally, a list of Latin American plants with possible cosmetic applications is presented proving the great potential of Latin American plant biodiversity and its low commercial exploitation in the cosmetic industry. This study evidences the antioxidant and skin protecting actions of Latin American plants and it is presented as a tool for the identification of vegetable species of Latin American biodiversity with potential cosmetic use to sustainable and short-term commercial exploitation.",144,,,https://www.sciencedirect.com/science/article/pii/S0926669019310179,http://dx.doi.org/10.1016/j.indcrop.2019.112007,0,,10.1016/j.indcrop.2019.112007,2994163336,,001-389-825-382-635; 001-446-939-374-703; 001-944-707-297-587; 002-896-084-862-959; 004-444-963-421-725; 008-928-418-752-330; 012-936-802-806-131; 013-604-779-999-064; 015-450-225-481-937; 015-453-542-114-19X; 016-317-894-337-629; 022-190-212-483-699; 027-302-580-363-143; 030-484-306-568-638; 034-413-209-440-445; 034-924-904-648-293; 035-430-592-850-973; 037-786-709-670-758; 040-033-387-505-814; 043-196-691-133-037; 046-455-835-110-057; 057-981-937-051-878; 058-044-483-719-094; 059-828-155-526-05X; 060-132-538-054-651; 062-905-637-565-371; 063-114-061-355-472; 067-466-589-116-802; 074-071-123-928-013; 074-800-403-924-348; 074-885-301-444-525; 077-442-173-079-186; 079-620-769-212-138; 081-987-592-368-761; 085-203-408-904-50X; 091-890-957-909-375; 097-131-456-048-555; 105-979-569-892-898; 106-658-700-127-411; 108-270-651-206-210; 108-989-269-691-064; 112-988-841-949-442; 113-338-082-151-668; 113-365-594-006-847; 115-631-329-225-725; 117-217-225-034-704; 121-326-824-266-344; 140-558-181-145-259; 150-026-445-007-593; 150-739-762-036-099; 156-248-250-294-82X,0
060-779-453-558-698,United Kingdom,15563650; 15569519,Informa Healthcare,Clinical Toxicology,A counterfeit multivitamin product inducing severe bleeding disorders in humans,Internal medicine; Warfarin; Multivitamin; Counterfeit; Counterfeit Drugs; Anesthesia; Diabetes mellitus; Medicine,2020-01-10,2020,journal article,Counterfeit drugs; bleeding disorders; dietary supplement; poison control centers; warfarin,,,1,3,Lina María Peña Acevedo; Andres F. Zuluaga; Alexander Aristizabal–Solis,"AbstractContext: During a period of 6 months, 36 people reported to health authorities in the Department of Antioquia, Colombia, presenting episodes of bleeding in varying magnitude and locations i...",,,,https://www.tandfonline.com/doi/full/10.1080/15563650.2019.1703999,http://dx.doi.org/10.1080/15563650.2019.1703999,0,31922430,10.1080/15563650.2019.1703999,2999168877,,027-036-996-806-21X; 028-294-537-324-850; 063-452-310-332-83X; 111-032-466-898-248,0
061-486-131-299-862,,01232576; 25007106,EDIMECO,Medicina y Laboratorio,La próstata desde una perspectiva inmunológica,Cancer; Internal medicine; Oncology; Prostate; Inflammation; Hyperplasia; Prostate cancer; Prostatitis; Fibrosis; Medicine; Immune system,2020-01-01,2020,journal article,,,1,13,35,Jenniffer Puerta-Suárez; Walter Cardona-Maya,"Inflammatory and infectious processes triggered in the prostate, the primary male reproductive gland, originate the three main diseases of this organ: prostatitis, benign prostatic hyperplasia and cancer. To understand the relationship between these three pathologies and inflammatory and infectious processes, a review of the scientific literature was carried out in PubMed database using the terms prostate, prostatitis, benign prostatic hyperplasia and prostate cancer. The revised articles highlight the importance of properly immune system functioning in the prostate tissue to remove the microorganisms that cause infections, a process which also triggers tissue inflammation. In addition, ascending urinary infections, which culminate in chronic prostatitis, favor the development of benign prostatic hyperplasia, enlargement and fibrosis of the prostate in adult men, and even its progression to cancer in genetically susceptible individuals. Furthermore, limitations in the diagnosis of prostatic disorders promote chronic inflammation, and the indiscriminate use of broad spectrum antibiotics for prostatitis treatment leads to sexual dissemination of multidrug-resistant microorganisms. Prostatic disorders, especially prostatitis, continue to be enigmatic pathologies of difficult diagnosis and treatment. The study of the prostate, its disorders and its relationship with the immune system will contribute to limit the indiscriminate use of antibiotics and to reduce health costs and the effects on the quality of life of affected individuals.",24,,,https://medicinaylaboratorio.com/index.php/myl/article/view/12,http://dx.doi.org/10.36384/01232576.12,0,,10.36384/01232576.12,2980660479,,000-250-543-012-000; 002-938-746-951-065; 007-345-399-092-398; 008-394-399-681-210; 012-480-704-979-087; 013-153-773-313-455; 014-405-799-642-825; 014-784-166-361-954; 015-574-100-323-315; 016-369-746-190-340; 017-218-794-913-273; 025-546-399-118-467; 027-457-839-229-08X; 028-026-262-983-986; 028-211-947-308-89X; 029-373-799-621-961; 031-195-807-225-647; 035-140-096-412-16X; 035-390-805-370-09X; 037-189-296-978-301; 037-999-104-359-35X; 038-166-219-023-784; 040-587-141-192-912; 044-459-366-677-063; 044-575-679-710-651; 048-433-100-330-054; 049-123-369-395-056; 050-065-296-494-557; 053-154-072-923-686; 054-114-068-086-90X; 054-573-879-238-578; 057-796-646-229-627; 060-883-227-365-265; 063-840-841-926-332; 064-632-618-403-897; 064-895-135-853-556; 066-396-842-765-033; 077-687-813-394-703; 078-471-501-095-791; 079-709-110-520-328; 079-822-416-341-677; 081-279-961-244-207; 082-138-473-172-176; 082-640-079-844-644; 085-142-487-473-309; 092-548-336-943-725; 110-305-716-295-525; 112-422-907-702-774; 117-496-145-493-622; 119-573-160-000-039; 131-680-240-280-198; 155-594-257-425-875,0
062-716-115-209-916,Netherlands,03010104,Elsevier,Chemical Physics,New stable phases of glycine crystals,Hydrogen bond; Potential energy surface; Computational chemistry; Density functional theory; Tetragonal crystal system; Chemistry; Glycine; Orthorhombic crystal system; Crystal; Monoclinic crystal system; Crystallography,2020-02-01,2020,journal article,,,,110645,,Doris Guerra; Luis A. Gómez; Albeiro Restrepo; Jorge David,"Abstract A Density Functional Theory (DFT) study of the electronic, energetic, dynamical, and mechanical properties of new glycine molecular crystals is presented here. Our search of the potential energy surface (PES) reproduces the previously reported structures for α –, β –, and γ –glycine with P 2 1 / n , P 2 1 , P 3 1 symmetries, respectively. In addition, we report three new orthorhombic (o), tetragonal (t), and monoclinic (m) crystals with P 2 1 2 1 2 1 , P 4 3 , and P 2 1 symmetries. The crystals have wide band gaps, classifying them in the range of insulators. All three new phases have low mechanical hardness ( ⋯ O, OH ⋯ O as well as secondary CH ⋯ O hydrogen bonds (HBs), act as the stabilizing factors resulting in large cohesive energies for the new phases of glycine crystals. Without exception, all types of HBs, for all new phases, perfectly fit the attractive region of a Lennard–Jones potential.",530,,,https://www.sciencedirect.com/science/article/pii/S0301010419311784,http://dx.doi.org/10.1016/j.chemphys.2019.110645,0,,10.1016/j.chemphys.2019.110645,2990646282,,002-820-120-047-484; 003-461-802-960-056; 004-403-227-145-661; 006-121-646-012-422; 007-141-379-158-21X; 008-729-800-530-50X; 010-522-048-028-880; 012-614-066-729-569; 013-426-188-615-242; 013-776-588-028-928; 015-721-481-671-360; 017-518-470-283-660; 018-241-729-027-592; 019-428-474-772-561; 019-805-475-754-489; 020-696-341-612-43X; 022-473-710-040-153; 022-842-494-999-490; 026-972-103-676-143; 027-366-006-904-809; 029-792-845-782-165; 031-132-673-791-775; 033-268-744-473-682; 034-639-915-391-11X; 034-668-246-136-05X; 036-006-330-056-60X; 036-301-629-577-153; 038-382-741-597-533; 038-727-869-881-817; 043-899-553-812-294; 045-523-802-829-116; 050-049-392-626-310; 050-949-879-398-35X; 051-809-150-606-822; 053-947-476-578-743; 054-821-197-237-316; 062-326-303-302-559; 070-612-682-037-640; 072-578-550-337-306; 075-709-138-327-591; 078-223-284-280-241; 081-270-422-728-64X; 082-639-221-536-207; 083-842-648-634-48X; 084-541-568-481-329; 086-061-536-358-553; 090-070-501-723-898; 094-282-862-890-35X; 100-936-062-383-11X; 102-160-650-040-145; 106-905-702-234-611; 113-091-777-965-148; 114-425-745-617-513; 119-471-056-490-675; 119-960-509-612-573; 121-142-783-235-309; 121-733-608-731-027; 122-912-777-520-044; 125-452-955-103-548; 125-964-666-972-05X; 127-839-649-954-167; 129-825-923-639-422; 141-506-672-444-458; 149-557-365-186-39X; 152-016-263-292-219; 165-823-360-749-21X; 173-674-066-691-137; 174-142-266-300-486; 176-964-739-325-305; 193-319-517-270-673; 194-655-807-125-211; 197-134-814-978-701,0
063-112-709-664-667,France,17732247,Editions de Sante,Journal of Drug Delivery Science and Technology,Role of a novel (−)-epigallocatechin-3-gallate delivery system on the prevention against oxidative stress damage in vitro and in vivo model of Parkinson's disease,Caspase 3; Chemistry; In vitro; In vivo; Oxidative stress; Paraquat; Antioxidant; Rotenone; Lipid peroxidation; Chromatography; Pharmacology,2020-02-01,2020,journal article,,"Departamento Administrativo de Ciencia, Tecnología e Innovación (COLCIENCIAS)",,101466,,Vanesa Sánchez-Giraldo; Yuliana Monsalve; Juliana Palacio; Miguel Mendivil-Perez; Ligia Sierra; Carlos Velez-Pardo; Betty L. López; Marlene Jimenez-Del-Rio,"Abstract Epigallocatechin-3-gallate (EGCG) is an antioxidant molecule that is studied, in this work, to evaluate its attenuating effect of the oxidative stress (OS) damage involved with the Parkinson disease (PD). To optimize the EGCG antioxidant effect, an appropriate deliver system is proposed that protects its stability and bioactivity and allows having a controlled delivery at the level of concentration required for obtaining such effect. The preparation of the novel core shell nanoparticles system for EGCG delivery starts from the formation of mixed micelles of the triblock copolymer Pluronic® F127 and sodium dodecyl sulfate surfactant followed by covering with chitosan and in situ EGCG encapsulation. The nanoparticles, after being purified by ultrafiltration, with average size around 35 nm, with encapsulation efficiency (%EE) of EGCG (~83%) and exhibiting colloidal stability and an in vitro EGCG sustained release, were chosen to evaluate the antioxidant effects of EGCG in vitro on nerve-like cells (NLCs) and in vivo in OS model of PD. They protected NLCs against OS generated by rotenone (ROT) by reducing levels of H2O2, and oxidation of DJ-1 protein. They also maintained the mitochondrial membrane potential (ΔΨm) and reduced the activation of cell death markers (CASPASE 3). In in vivo studies these nanoparticles prevented to the knockdown parkin Drosophila melanogaster, exposed to paraquat, against induced locomotor impairment, lipid peroxidation, and life span diminution. This study reaffirms the beneficial use of EGCG as an antioxidant agent and shows, through in vivo OS model of PD, the importance of its controlled delivery from an appropriate system to attain optimum results.",55,,,https://www.sciencedirect.com/science/article/pii/S1773224719315825,http://dx.doi.org/10.1016/j.jddst.2019.101466,0,,10.1016/j.jddst.2019.101466,2996280560,,001-577-349-823-88X; 003-136-399-553-151; 004-358-644-076-572; 007-993-482-561-242; 008-813-466-622-469; 009-162-316-497-930; 010-955-649-410-43X; 013-811-558-196-446; 013-924-115-657-03X; 014-917-244-429-413; 016-167-696-951-117; 016-246-816-717-997; 016-784-221-331-348; 016-792-652-053-933; 018-735-251-525-559; 021-000-746-583-153; 021-018-798-973-271; 021-880-389-912-913; 022-257-411-401-450; 024-843-460-438-326; 024-853-743-862-10X; 027-270-984-541-74X; 028-102-336-314-833; 029-009-994-472-091; 030-349-698-193-078; 031-094-695-070-990; 032-929-664-704-128; 034-741-800-649-548; 040-774-756-091-257; 042-500-616-792-822; 044-521-724-274-42X; 044-922-962-578-477; 046-100-941-365-835; 048-078-679-347-141; 048-246-132-332-878; 050-168-232-287-737; 052-645-706-496-592; 053-542-727-776-096; 058-946-821-871-615; 062-219-213-282-191; 063-850-334-236-280; 064-308-803-368-873; 064-417-051-543-546; 075-321-012-740-005; 078-415-671-629-374; 086-212-499-659-298; 088-648-900-209-657; 095-758-376-209-458; 096-617-542-916-957; 096-710-903-320-718; 100-057-758-282-316; 109-329-488-498-806; 110-775-733-334-836; 114-466-723-634-735; 114-848-612-176-595; 134-854-264-914-702; 136-318-977-105-335; 138-842-610-481-08X; 139-250-378-225-213; 145-331-757-617-219; 175-966-758-044-907; 195-823-588-724-690,0
063-918-517-636-912,United States,07403224,The Optical Society,Journal of The Optical Society of America B-optical Physics,Refractive index and group velocity of electromagnetic modes in a relativistic Fermi gas at finite temperatures,Metamaterial; Physics; Electromagnetic radiation; Transverse plane; Group velocity; Phase velocity; Quantum electrodynamics; Refractive index; Quantum mechanics; Negative refraction; Fermi gas,2020-01-06,2020,journal article,,CODI—University of Antioquia,2,211,217,J. D. Mazo-Vasquez; L. M. Hincapie-Zuluaga; E. Reyes-Gómez,"A theoretical study of the optical properties of a relativistic Fermi gas at a finite temperature is performed. The results are obtained from Maxwell’s equations, assuming bianisotropic constitutive relations for the relativistic gas. The longitudinal and transverse spatial directions are defined according to the properties of the electric permittivity tensor. The electromagnetic modes and the refractive index of the relativistic gas are calculated along such directions. The longitudinal and transverse group velocities corresponding to the respective propagation modes are also obtained. No typical characteristics of metamaterials are observed, neither in the refractive index nor in the group velocities corresponding to the transverse modes. However, in the case of longitudinal modes, negative values of the group velocity are observed in a region of the reciprocal space where particle–antiparticle excitations can occur.",37,,,https://www.osapublishing.org/josab/abstract.cfm?uri=josab-37-2-211,http://dx.doi.org/10.1364/josab.37.000211,0,,10.1364/josab.37.000211,2997579040,,005-833-986-286-525; 010-508-701-601-723; 011-821-174-177-680; 015-931-882-327-638; 028-577-894-576-554; 029-915-148-840-486; 037-646-532-036-190; 052-500-376-665-375; 061-205-651-620-660; 079-015-535-427-341; 081-827-247-577-367; 093-680-594-465-361,0
064-150-834-424-930,,,,,Un breve recorrido por la historia de la editorial Norma (1960-2016) y sus colecciones de ficción y literatura para adultos,Art; Publishing; Humanities; Breve,2020-01-01,2020,,,,46,159,176,Nancy Estella Vargas Castro,"In this text, we take a brief look at the history of Norma publishing house during the period 1960-2016 throughout its catalog of fiction or adult literature. With the collected information about the company's editorial fund, we show which were main publishing interests of Norma. Likewise, the description of the literary series allows us to size Norma's work within the editorial space and the establishment of specific literary values within the national literary field.",,,,https://aprendeenlinea.udea.edu.co/revistas/index.php/elc/article/view/339483/20795524,https://aprendeenlinea.udea.edu.co/revistas/index.php/elc/article/view/339483/20795524,0,,,3000034610,,,0
068-084-492-436-394,United Kingdom,14752875,BioMed Central,Malaria Journal,"IgG antibody response against Anopheles salivary gland proteins in asymptomatic Plasmodium infections in Narino, Colombia",Virology; Antibody; Anopheles gambiae; Asymptomatic; Malaria; Anopheles; Plasmodium Infections; Salivary Gland Proteins; Biology; Immune system,2020-01-23,2020,journal article,An. (Nys.) albimanus; An. (Nys.) darlingi; Antibodies; Asymptomatic malaria; Bite exposure,Colcom Foundation (US) (RC-766-2016); Colcom Foundation (US) (Code 111574455032); CDC-USAID (200-2018-M-00025),1,42,,Jehidys Montiel; Luisa F. Carbal; Alberto Tobón-Castaño; Gissella M. Vásquez; Michael L. Fisher; Berlin Londono-Renteria,"Background; The humoral immune response against Anopheles salivary glands proteins in the vertebrate host can reflect the intensity of exposure to Anopheles bites and the risk of Plasmodium infection. In Colombia, the identification of exposure biomarkers is necessary due to the several Anopheles species circulating. The purpose of this study was to evaluate risk of malaria infection by measuring antibody responses against salivary glands extracts from Anopheles (Nyssorhynchus) albimanus and Anopheles (Nys.) darlingi and also against the gSG6-P1 peptide of Anopheles gambiae in people residing in a malaria endemic area in the Colombian Pacific coast.",19,,,https://link.springer.com/article/10.1186%2Fs12936-020-3128-9,http://dx.doi.org/10.1186/s12936-020-3128-9,0,31973737,10.1186/s12936-020-3128-9,3003015933,,001-452-105-557-651; 002-150-735-767-007; 006-015-871-966-215; 008-554-512-782-030; 009-903-667-261-351; 011-164-452-118-633; 013-905-792-397-729; 015-049-058-071-154; 019-502-772-562-215; 022-226-070-948-105; 029-170-727-866-695; 030-520-550-737-398; 032-156-925-408-019; 035-185-396-637-343; 036-022-471-306-334; 039-495-130-023-319; 043-701-155-545-358; 043-975-376-856-81X; 046-013-645-360-735; 048-300-680-567-912; 048-754-069-289-942; 056-182-293-244-027; 057-335-267-281-482; 059-698-559-423-388; 060-149-664-183-113; 061-456-377-759-390; 061-507-121-495-27X; 064-106-700-456-71X; 068-398-217-550-610; 069-979-281-359-441; 074-805-052-971-988; 080-379-526-525-25X; 080-991-111-497-622; 089-423-705-818-755; 091-800-069-965-203; 095-981-227-889-770; 098-129-741-665-046; 123-925-222-157-017; 130-315-617-974-471; 145-914-106-875-446; 148-309-757-357-881; 171-384-295-171-540,0
068-505-294-673-463,,01237799; 22565337,Instituto Tecnologico Metropolitano (ITM),TecnoLógicas,Word-Embeddings and Grammar Features to Detect Language Disorders in Alzheimer’s Disease Patients,Artificial intelligence; Natural language processing; Grammar; Cross-validation; Small set; Language production; Disease; Low density; Brain functioning; Computer science; Text mining,2020-01-15,2020,journal article,,,47,63,75,Juan S. Guerrero-Cristancho; Juan Camilo Vásquez-Correa; Juan Rafael Orozco-Arroyave,"Alzheimer's Disease (AD) is a progressive neurodegenerative disorder that affects the language production and thinking capabilities of patients. The integrity of the brain is destroyed over time by interruptions in the interactions between neuron cells and associated cells required for normal brain functioning. AD comprises deterioration of the communicative skills, which is reflected in deficient speech that usually contains no coherent information, low density of ideas, and poor grammar. Additionally, patients exhibit difficulties to find appropriate words to structure sentences. Multiple ongoing studies aim to detect the disease considering the deterioration of language production in AD patients. Natural Language Processing techniques are employed to detect patterns that can be used to recognize the language impairments of patients. This paper covers advances in pattern recognition with the use of word-embedding and word-frequency features and a new approach with grammar features. We processed transcripts of 98 AD patients and 98 healthy controls in the Pitt Corpus of the Dementia-Bank database. A total of 1200 word-embedding features, 1408 Term Frequency—Inverse Document Frequency features, and 8 grammar features were extracted from the selected transcripts. Three models are proposed based on the separate extraction of such feature sets, and a fourth model is based on an early fusion strategy of the proposed feature sets. All the models were optimized following a Leave-One-Out cross validation strategy. Accuracies of up to 81.7 % were achieved using the early fusion of the three feature sets. Furthermore, we found that, with a small set of grammar features, accuracy values of up to 72.8 % were obtained. The results show that such features are suitable to effectively classify AD patients and healthy controls.",23,,,https://revistas.itm.edu.co/index.php/tecnologicas/article/view/1387,http://dx.doi.org/10.22430/22565337.1387,0,,10.22430/22565337.1387,2997535983,,,0
068-988-760-901-881,United States,00219983; 1530793x,SAGE Publications Ltd,Journal of Composite Materials,"Cantilever creep method for testing ceramic composites and a case study for chemically bonded phosphate ceramic composites reinforced with glass, carbon and basalt fibers, including both experiments and simulations:",Composite number; Ceramic; Cantilever; Creep; Composite material; Basalt; Materials science; Basalt fiber; Phosphate; Carbon,2020-01-23,2020,journal article,,,,002199832090222,,Henry A. Colorado; Elkin I Gutiérrez-Velásquez; Clem Hiel,"This paper presented the cantilever beam experiments and the method for creep in chemically bonded ceramics reinforced with glass, carbon, and basalt unidirectional fibers. The ceramic composite sa...",,,,https://journals.sagepub.com/doi/full/10.1177/0021998320902221,http://dx.doi.org/10.1177/0021998320902221,0,,10.1177/0021998320902221,3003093465,,000-817-052-025-936; 017-990-157-697-911; 026-521-166-339-061; 038-943-482-278-438; 045-438-424-109-480; 050-664-878-045-377; 051-654-554-849-245; 057-249-973-588-093; 059-148-050-362-504; 068-914-009-643-757; 069-114-243-595-600; 070-430-149-080-408; 071-943-603-645-158; 086-922-970-694-498; 092-414-888-711-080; 097-306-748-503-427; 098-243-160-596-045; 098-420-858-054-912; 117-942-633-533-07X; 119-935-957-871-849; 129-149-122-941-567; 131-437-602-385-799; 132-533-443-165-399; 135-531-492-760-434; 139-131-416-361-83X; 152-648-116-328-934; 154-783-617-790-742; 157-589-277-665-194,0
072-194-835-645-027,Netherlands,02578972,Elsevier,Surface & Coatings Technology,"Development and characterization of TiAlN (Ag, Cu) nanocomposite coatings deposited by DC magnetron sputtering for tribological applications",Tribology; Lubrication; Metallurgy; Materials science; Hardenability; Coating; Nanoindentation; Sputter deposition; Microstructure; Nanocomposite,2020-01-01,2020,journal article,,,,125095,,D V Hernán Mejía; D. Perea; Gilberto Bejarano,"Abstract AISI 420 stainless steel is currently used in the manufacture of surgical and dental instrumentation due to its hardenability, acceptable biocompatibility and resistance to corrosion. However its resistance to wear is relatively low and therefore multiple strategies of surface modification are used to reduce the wear volume and to confer other specific properties on this steel. In this work, TiAlN coatings doped with five different content proportions of Ag and Cu nanoparticles (11 at.% to 20 at.%) were deposited onto 420 steel by means of DC magnetron sputtering, using two targets of Ti/Al and Ag/Cu (both 50/50 at.%), which were placed facing each other at 180° and spaced 42 cm apart. The microstructure, and chemical and phase composition, were analyzed by X-ray diffraction, scanning and transmission electron microscopy and energy dispersive X-ray spectroscopy, while roughness was determined using atomic force microscopy. Hardness and Young's modulus were evaluated by nanoindentation measurements. Finally, the tribological properties were assessed using the ball on disc test method. The composite coatings initially showed a continuous decrease in hardness and a significant reduction in the coefficient of friction and wear volume with the increase in Ag–Cu content, due to the solid lubrication effect of the metallic nanoparticles. However, above 17 at.% of Ag–Cu, the coefficient of friction and wear volume of the coating increased, due to the low hardness of the coating, which lead to the wear process being mainly cohesive type between coating and substrate, and adhesive type between coating and ball. The lowest wear volume, of 7.7 × 10−5 mm3, was exhibited by the coating deposited with 17 at.% Ag–Cu. This was much lower than that of uncoated steel which was 5.4 × 10−4 mm3. This new nanostructured coating could be considered for potential application in manufacturing processes where protection of tools against wear is required, due to its adequate balance between hardness and wear resistance.",381,,,https://www.sciencedirect.com/science/article/pii/S0257897219310862,http://dx.doi.org/10.1016/j.surfcoat.2019.125095,0,,10.1016/j.surfcoat.2019.125095,2987936083,,001-779-768-853-616; 015-308-582-465-17X; 015-674-020-180-201; 015-884-742-295-460; 023-701-424-751-737; 024-852-468-263-852; 034-892-507-143-87X; 036-548-592-842-906; 040-706-021-748-17X; 051-590-010-172-15X; 053-821-105-029-995; 056-846-401-601-976; 064-844-639-566-358; 065-704-107-876-912; 069-464-182-871-500; 069-799-565-246-934; 073-533-332-573-199; 082-578-904-073-444; 082-999-350-629-409; 092-785-200-515-309; 093-680-866-190-34X; 097-190-766-743-705; 105-566-990-883-527; 107-060-253-784-160; 112-122-666-770-965; 115-233-644-525-994; 116-269-719-506-079; 118-419-479-095-808; 120-494-120-907-920; 120-749-021-949-609; 129-127-332-039-54X; 142-175-123-115-208; 176-060-056-199-440; 176-230-706-846-363; 185-638-130-535-268; 197-316-031-688-318,0
078-642-001-350-438,Germany,14346044; 14346052,Springer New York,European Physical Journal C,"Measurement of electroweak production of a $$\mathrm{W} $$W boson in association with two jets in proton–proton collisions at $$\sqrt{s}=13\,\text {Te}\text {V} $$s=13Te",Particle physics; Physics; Invariant mass; Electroweak interaction; Hadron; Muon; Standard Model; Proton; Boson; W and Z bosons,2020-01-18,2020,journal article,,,1,43,,A. M. Sirunyan; Armen Tumasyan; Wolfgang Adam; Federico Ambrogi; Ece Aşılar; Thomas Bergauer; Johannes Brandstetter; Marko Dragicevic; Janos Erö; A. Escalante Del Valle; Martin Flechl; R. Frühwirth; V. M. Ghete; Josef Hrubec; Manfred Jeitler; Natascha Krammer; Ilse Krätschmer; Dietrich Liko; Thomas Madlener; Ivan Mikulec; Navid Rad; Herbert Rohringer; Jochen Schieck; Robert Schöfbeck; Markus Spanring; Daniel Spitzbart; Wolfgang Waltenberger; Johannes Wittmann; C.-E. Wulz; Mateusz Zarucki; Vladimir Chekhovsky; V. Mossolov; J. Suarez Gonzalez; E. A. De Wolf; D. Di Croce; Xavier Janssen; Jasper Lauwers; Aleksandra Lelek; Maxim Pieters; H. Van Haevermaet; P. Van Mechelen; N. Van Remortel; Freya Blekman; Jorgen D'Hondt; J. De Clercq; Kevin Deroover; Giannis Flouris; Denys Lontkovskyi; Steven Lowette; Ivan Marchesini; Seth Moortgat; Lieselotte Moreels; Quentin Python; K. Skovpen; Stefaan Tavernier; W. Van Doninck; P. Van Mulders; I. Van Parijs; Diego Beghin; Bugra Bilin; Hugues Brun; Barbara Clerbaux; G. De Lentdecker; Hugo Delannoy; Brian Dorney; Laurent Favart; Anastasia Grebenyuk; Amandeep Kaur Kalsi; Jelena Luetic; Andrey Popov; Nicolas Postiau; Elizabeth Starling; Laurent Thomas; C. Vander Velde; Pascal Vanlaer; David Vannerom; Qun Wang; Tom Cornelis; Didar Dobur; Alexis Fagot; Muhammad Gul; Illia Khvastunov; Christos Roskas; Daniele Trocino; Michael Tytgat; Willem Verbeke; Basile Vermassen; Martina Vit; N. Zaganidis; O. Bondu; Giacomo Bruno; Claudio Caputo; Pieter David; Christophe Delaere; Martin Delcourt; Andrea Giammanco; Georgios Krintiras; Vincent Lemaitre; Alessio Magitteri; Krzysztof Piotrzkowski; Alessia Saggio; M. Vidal Marono; Pietro Vischia; Joze Zobec; Fábio Lúcio Alves; G. A. Alves; G. Correia Silva; C. Hensel; Arthur Moraes; M. E. Pol; P. Rebello Teles; E. Belchior Batista Das Chagas; W. Carvalho; Jose Chinellato; Eduardo Coelho; E. M. Da Costa; G. G. Da Silveira; D. De Jesus Damiao; C. De Oliveira Martins; S. Fonseca De Souza; L. M. Huertas Guativa; Helena Malbouisson; D. Matos Figueiredo; M. Melo De Almeida; C. Mora Herrera; Luiz Mundim; Helio Nogima; W. L. Prado Da Silva; L. J. Sanchez Rosas; A. Santoro; A. Sznajder; Mauricio Thiel; E. J. Tonelli Manganote; F. Torres Da Silva De Araujo; A. Vilela Pereira; Sudha Ahuja; Cesar Augusto Bernardes; Luigi Calligaris; T. R. Fernandez Perez Tomei; Eduardo De Moraes Gregores; P. G. Mercadante; Sergio F Novaes; SandraS. Padula; Aleksandar Aleksandrov; R. Hadjiiska; P. Iaydjiev; Andrey Marinov; Milena Misheva; M. Rodozov; Mariana Shopova; G. Sultanov; A. Dimitrov; Leander Litov; B. Pavlov; P. Petkov; Wenxing Fang; Xinlei Gao; Li Yuan; M. Ahmad; J. G. Bian; G. M. Chen; H. S. Chen; M. Chen; Y. C. Chen; C. H. Jiang; Duncan Leggat; H. Liao; Z. K. Liu; S. M. Shaheen; Aniello Spiezia; J. Tao; E. Yazgan; H. Zhang; S. Zhang; J. Zhao; Y. Ban; G. Chen; Andrew Levin; Jing Li; Liang Li; Q. Li; Y. J. Mao; S. J. Qian; Dong Wang; Y. Wang; C. Avila; A. Cabrera; C. A. Carrillo Montoya; L. F. Chaparro Sierra; C. Florez; C. F. González Hernández; M. A. Segura Delgado; J. D. Ruiz Alvarez; Nikola Godinovic; Damir Lelas; Ivica Puljak; Toni Sculac; Z. Antunovic; Marko Kovac; V. Brigljevic; D. Ferencek; K. Kadija; Benjamin Mesic; Matej Roguljic; A. Starodumov; Tatjana Susa; Mohsan Waseem Ather; Alexandros Attikis; Marina Kolosova; Sotiroulla Konstantinou; Georgios Mavromanolakis; Jehad Mousa; C. Nicolaou; Fotios Ptochos; P. A. Razis; Hans Rykaczewski; M. Finger; Edy Ayala; E. Carrera Jarrin; A. A. Abdelalim; A. Ellithi Kamel; Elsayed Salama; Sandeep Bhowmik; A. Carvalho Antunes De Oliveira; Ram Krishna Dewanjee; Karl Ehataht; M. Kadastik; M. Raidal; Christian Veelken; Paula Eerola; Henning Kirschenmann; Juha Pekkanen; M. Voutilainen; Joona Havukainen; Jaana Kristiina Heikkilä; Terhi Jarvinen; Veikko Karimäki; Ritva Kinnunen; Tapio Lampén; Kati Lassila-Perini; Santeri Laurila; Sami Lehti; Tomas Lindén; Panja-Riina Luukka; Teppo Mäenpää; Hannu Siikonen; Eija Tuominen; Jorma Tuominiemi; Tuure Tuuva; Marc Besancon; Fabrice Couderc; M. Dejardin; D. Denegri; Jérôme Faure; F. Ferri; S. Ganjour; A. Givernaud; P. Gras; G. Hamel de Monchenault; P. Jarry; Clément Leloup; E. Locci; J. Malcles; J. Rander; A. Rosowsky; M. Ö. Sahin; A. Savoy-Navarro; M. Titov; Chiara Amendola; F. Beaudette; P. Busson; C. Charlot; Batoul Diab; R. Granier de Cassagnac; Inna Kucher; Artur Lobanov; J. Martin Blanco; C. Martin Perez; Matthew Nguyen; C. Ochando; Giacomo Ortona; P. Paganini; Jonas Rembser; R. Salerno; J. B. Sauvan; Y. Sirois; A. Zabi; Amina Zghiche; J. L. Agram; J. Andrea; D. Bloch; Guillaume Bourgatte; J. M. Brom; E. C. Chabert; Caroline Collard; E. Conte; J. C. Fontaine; D. Gelé; U. Goerlach; Markéta Jansová; A. C. Le Bihan; Nicolas Tonon; P. Van Hove; Sébastien Gadrat; Stephanie Beauceron; Colin Bernet; G. Boudoul; N. Chanon; R. Chierici; D. Contardo; P. Depasse; H. El Mamouni; J. Fay; S. Gascon; Maxime Gouzevitch; G. J. Grenier; B. Ille; Francois Lagarde; I. B. Laktineh; Hugues Lattaud; M. Lethuillier; L. Mirabito; S. Perries; V. Sordini; Gaël Touquet; M. Vander Donckt; Sébastien Viret; Tengizi Toriashvili; Iuri Bagaturia; C. Autermann; L. Feld; M. K. Kiesel; K. Klein; Martin Lipinski; Danilo Meuser; Alexander Pauls; Marius Preuten; Max Philip Rauch; Christian Schomakers; Johannes Schulz; Marius Teroerde; B. Wittmer; Andreas Albert; M. Erdmann; Sören Erdweg; Thomas Esch; R. Fischer; Saranya Ghosh; T. Hebbeker; Carsten Heidemann; K. Hoepfner; Henning Keller; Luca Mastrolorenzo; Markus Merschmeyer; Andreas Bernhard Meyer; Philipp Millet; Swagata Mukherjee; Andrzej Novak; Tobias Pook; Andrey Pozdnyakov; Markus Radziej; H. Reithler; Marcel Rieger; Alexander Schmidt; Archana Sharma; D. Teyssier; Sebastian Thüer; G. Flügge; Olena Hlushchenko; T. Kress; Thomas Müller; Alexander Nehrkorn; A. Nowack; Claudia Pistone; O. Pooth; Dennis Roy; Hale Sert; A. Stahl; M. Aldaya Martin; Till Arndt; C. Asawatangtrakuldee; Illia Babounikau; H. Bakhshiansohi; Kelly Beernaert; Olaf Behnke; U. Behrens; A. Bermúdez Martínez; David Bertsche; A. A. Bin Anuar; Kerstin Borras; Valeria Botta; A. J. Campbell; Patrick Connor; Christian Contreras-Campana; Vladyslav Danilov; A. De Wit; Matteo Maria Defranchis; C. Diez Pardos; D. Domínguez Damiani; G. Eckerlin; Thomas Eichhorn; Adam Elwood; Engin Eren; Elisabetta Gallo; A. Geiser; J. M. Grados Luyando; Alexander Grohsjean; Moritz Guthoff; Mykyta Haranko; Ali Harb; Nur Zulaiha Jomhari; H. Jung; M. Kasemann; James Keaveney; C. Kleinwort; Joscha Knolle; D. Krücker; W. Lange; Teresa Lenz; J. Leonard; K. Lipka; W. Lohmann; R. Mankel; Isabell-Alissandra Melzer-Pellmann; A. B. Meyer; M. Meyer; Marino Missiroli; Gregor Mittag; J. Mnich; Volodymyr Myronenko; Svenja Karen Pflitsch; D. Pitzl; Alexei Raspereza; Andrej Saibel; Mykola Savitskyi; Pooja Saxena; Valerie Scheurer; Paul Schütze; C. Schwanenberger; Rostyslav Shevchenko; A. P. Singh; Heiner Tholen; Oleksii Turkot; Antonio Vagnerini; M. Van De Klundert; G. P. Van Onsem; R. Walsh; Y. Wen; Katarzyna Wichmann; Christoph Wissing; O. Zenaiev; Robin Aggleton; Samuel Bein; Lisa Benato; Anna Benecke; Volker Blobel; Torben Dreyer; Aliakbar Ebrahimi; Erika Garutti; D. Gonzalez; P. Gunnellini; Johannes Haller; Andreas Hinzmann; Anastasia Karavdina; Gregor Kasieczka; R. Klanner; Roman Kogler; Nataliia Kovalchuk; Simon Kurz; Viktor Kutzner; J. C. Lange; Daniele Marconi; Jens Multhaup; Marek Niedziela; C. E. N. Niemeyer; Dominik Nowatschin; Adrian Perieanu; Arne Reimers; Oliver Rieger; Christian Scharf; P. Schleper; Svenja Schumann; J. Schwandt; Jory Sonneveld; Hartmut Stadie; G. Steinbrück; F. M. Stober; Marc Stöver; Benedikt Vormwald; Irene Zoi; Melike Akbiyik; C. Barth; Marta Baselga; Sebastian Baur; Thomas Berger; Erik Butz; René Caspart; Thorsten Chwalek; W. De Boer; A. Dierlamm; K. El Morabit; Nils Faltermann; M. Giffels; Marco Alexander Harrendorf; F. Hartmann; U. Husemann; I. Katkov; Simon Kudella; Soureek Mitra; M. U. Mozer; Th. Müller; M. Musich; G. Quast; Klaus Rabbertz; M. Schröder; Ivan Shvetsov; H. J. Simonis; Ralf Ulrich; M. Weber; Clemens Wöhrmann; Roger Wolf; G. Anagnostou; G. Daskalakis; T. Geralis; A. Kyriakis; D. Loukas; Garyfallia Paspalaki; Antonis Agapitos; George Karathanasis; Pantelis Kontaxakis; A. D. Panagiotou; Ioanna Papavergou; Niki Saoulidou; Konstantinos Vellidis; Georgios Bakas; Konstantinos Kousouris; Ioannis Papakrivopoulos; Georgios Tsipolitis; I. Evangelou; C. Foudas; Paraskevas Gianneios; Panagiotis Katsoulis; P. Kokkas; Stavros Mallios; Kalliopi Manitara; N. Manthos; I. Papadopoulos; Evangelos Paradas; John Strologas; Frixos A Triantis; Dimitrios Tsitsonis; Márton Bartók; Mate Csanad; Nicolas Filipovic; Péter Major; Koushik Mandal; Ankita Mehta; Marton Imre Nagy; Gabriella Pasztor; Olivér Surányi; Gabor Istvan Veres; G. Bencze; C. Hajdu; D. Horvath; null Hunyadi; F. Sikler; Tamás Álmos Vámi; Viktor Veszpremi; G. Vesztergombi; N. Beni; S. Czellar; János Karancsi; Alajos Makovec; J. Molnar; Z. Szillasi; P. Raics; Z. L. Trocsanyi; Balazs Ujvari; Samrat Choudhury; Jyothsna Rani Komaragiri; Praveen Chandra Tiwari; Seema Bahinipati; Chandiprasad Kar; Prolay Mal; A. Nayak; S. Roy Chowdhury; D. K. Sahoo; S. K. Swain; Sunil Bansal; S. B. Beri; V. Bhatnagar; Shubhanshu Chauhan; Ridhi Chawla; Nitish Dhingra; Ruchi Gupta; A. Kaur; M. Kaur; Sandeep Kaur; Priyanka Kumari; Manisha Lohan; Meena Meena; Kaur Sandeep; Samandeep Sharma; J. B. Singh; A. K. Virdi; Genius Walia; A. Bhardwaj; B. C. Choudhary; R. B. Garg; Mohit Gola; Sumit Keshri; Ashok Kumar; Shivali Malhotra; M. Naimuddin; Priyanka Priyanka; K. Ranjan; Aashaq Shah; R. Sharma; Rishika Bhardwaj; Monika Bharti; Rajarshi Bhattacharya; S. Bhattacharya; U. Bhawandeep; Debabrata Bhowmik; Sourav Dey; Suneel Dutt; Suchandra Dutta; Manas Maity; Kuntal Mondal; Saswati Nandan; Arnab Purohit; Prasant Kumar Rout; A. Roy; Gourab Saha; S. Sarkar; Tanmay Sarkar; Manoj Sharan; Bipen Singh; Shalini Thakur; Prafulla Kumar Behera; Alibordi Muhammad; Ruchi Chudasama; D. Dutta; Vishwajeet Jha; V. Kumar; Dipak Kumar Mishra; Pawan Kumar Netrakanti; L. M. Pant; P. Shukla; Praveenkumar Suggisetti; T. Aziz; Muzamil Ahmad Bhat; S. R. Dugad; G. B. Mohanty; Nairit Sur; RavindraKumar Verma; Sunanda Banerjee; S. Chatterjee; Pallabi Das; M. Guchait;  Jain; Saikat Karmakar; Sanjeev Kumar; G. Majumder; K. Mazumdar; Niladribihari Sahoo; Siddhesh Sawant; Sourabh Dube; Vinay Hegde; A. Kapoor; Kunal Kothekar; Shubham Pandey; Aditee Rane; Angira Rastogi; Shirin Chenarani; E. Eskandari Tadavani; S. M. Etesami; Mohsen Khakzad; M. Mohammadi Najafabadi; M. Naseri; F. Rezaei Hosseinabadi; Batool Safarzadeh; Maryam Zeinali; M. Felcini; M. W. Grünewald; M. Abbrescia; C. Calabria; Anna Colaleo; D. Creanza; Leonardo Cristella; N. De Filippis; M. De Palma; A. Di Florio; Filippo Errico; L. Fiore; Andrea Gelmi; Giuseppe Iaselli; Merve Ince; Samet Lezki; Giorgio Maggi; M. Maggi; Giorgia Miniello; S. My; S. Nuzzo; Alexis Pompili; Gabriella Pugliese; R. Radogna; A. Ranieri; G. Selvaggi; L. Silvestris; R. Venditti; P. Verwilligen; Giovanni Abbiendi; Carlo Battilana; D. Bonacorsi; Lisa Borgonovi; S. Braibant-Giacomelli; Renato Campanini; P. Capiluppi; A. Castro; F. R. Cavallo; Simranjit Singh Chhibra; G. Codispoti; M. Cuffiani; G. M. Dallavalle; F.L. Fabbri; A. Fanfani; Elisa Fontanesi; Paolo Giacomelli; C. Grandi; L. Guiducci; Fabio Iemmi; S. Lo Meo; S. Marcellini; Gianni Masetti; A. Montanari; F. L. Navarria; Andrea Perrotta; Federica Primavera; A. M. Rossi; T. Rovelli; G. P. Siroli; Nicolò Tosi; Sebastiano Albergo; A. Di Mattia; Renato Potenza; A. Tricomi; C. Tuve; Giuseppe Barbagli; Kalyanmoy Chatterjee; V. Ciulli; C. Civinini; R. D'Alessandro; E. Focardi; Giuseppe Latino; P. Lenzi; M. Meschini; S. Paoletti; Lorenzo Russo; G. Sguazzoni; D. Strom; Lorenzo Viliani; L. Benussi; Stefano Bianco; D. Piccolo; Fabrizio Ferro; Roberto Mulargia; Enrico Robutti; S. Tosi; Andrea Benaglia; Andrea Beschi; Francesco Brivio; Vincenzo Ciriolo; S. Di Guida; Mauro Emanuele Dinardo; Sara Fiorendi; S. Gennai; A. Ghezzi; P. Govoni; Martina Malberti; S. Malvezzi; D. Menasce; Fabio Monti; L. Moroni; M. Paganoni; D. Pedrini; S. Ragazzi; T. Tabarelli de Fatis; Davide Zuolo; S. Buontempo; N. Cavallo; A. De Iorio; A. Di Crescenzo; Francesco Fabozzi; Francesco Fienga; Giuliana Galati; Alberto Orso Maria Iorio; L. Lista; Sabino Meola; P. Paolucci; C. Sciacca; Elena Voevodina; Patrizia Azzi; Nicola Bacchetta; D. Bisello; Alessio Boletti; Alberto Bragagnolo; Roberto Carlin; P. Checchia; Martino Dall'Osso; P. De Castro Manzano; T. Dorigo; Umberto Dosselli; F. Gasparini; Ugo Gasparini; Andrea Gozzelino; Siew Yan Hoh; S. Lacaprara; Paul Lujan; Martino Margoni; A. T. Meneguzzo; Jacopo Pazzini; Matteo Presilla; P. Ronchese; Roberto Rossin; Franco Simonetto; Andres Tiko; E. Torassa; Mia Tosi; Marco Zanetti; P. Zotto; Gianni Zumerle; Alessandro Braghieri; Alice Magnani; Paolo Montagna; S. P. Ratti; Valerio Re; Martina Ressegotti; C. Riccardi; Paola Salvini; I. Vai; P. Vitulo; M. Biasini; G. M. Bilei; Claudia Cecchi; Diego Ciangottini; L. Fanò; Paolo Lariccia; Roberto Leonardi; Elisa Manoni; G. Mantovani; Valentina Mariani; Mauro Menichelli; Antonio Rossi; Attilio Santocchia; Daniele Spiga; Konstantin Androsov; P. Azzurri; G. Bagliesi; Lorenzo Bianchini; T. Boccali; Laura Borrello; R. Castaldi; Ma Ciocci; R. Dell'Orso; Giacomo Fedi; Francesco Fiori; Leonardo Giannini; A. Giassi; Maria Teresa Grippo; F. Ligabue; Elisabetta Manca; Giulio Mandorli; Alberto Messineo; Fabrizio Palla; A. Rizzi; G. Rolandi; A. Scribano; P. Spagnolo; R. Tenchini; Guido Tonelli; A. Venturi; P. G. Verdini; L. Barone; F. Cavallari; Marco Cipriani; D. Del Re; E. Di Marco; M. Diemoz; Simone Gelli; Egidio Longo; Badder Marzocchi; P. Meridiani; G. Organtini; F. Pandolfi; R. Paramatti; Federico Preiato; Claudio Quaranta; S. Rahatlou; Carlo Rovelli; Francesco Santanastasio; N. Amapane; Roberta Arcidiacono; S. Argiro; M. Arneodo; Nazar Bartosik; R. Bellan; C. Biino; Alessandra Cappati; Nicolo Cartiglia; F. Cenna; Simona Cometti; M. Costa; R. Covarelli; Natale Demaria; Bilal Kiani; Chiara Mariotti; S. Maselli; E. Migliore; V. Monaco; Ennio Monteil; M. Monteno; M. M. Obertino; Luca Pacher; N. Pastrone; Mario Pelliccioni; G. L. Pinna Angioni; A. Romero; M. Ruspa; R. Sacchi; Riccardo Salvatico; Ksenia Shchelina; Valentina Sola; Ada Solano; Dario Soldi; A. Staiano; S. Belforte; V. Candelise; M. Casarsa; F. Cossutti; A. Da Rold; G. Della Ricca; Federico Vazzoler; A. Zanetti; Dh Kim; G. N. Kim; Min Suk Kim; Jsh Lee; S. W. Lee; C. S. Moon; Y. D. Oh; S. I. Pak; Sezen Sekmen; D. C. Son; Y. C. Yang; Hyunyong Kim; Dong Ho Moon; Geonhee Oh; Brieuc Francois; Junghwan Goh; Tae Jeong Kim; Sungwoong Cho; S. Choi; Yeonju Go; Dooyeon Gyun; Seungkyu Ha; B. Hong; Youngkwon Jo; K. S. Lee; Kisung Lee; Soon-Gul Lee; J. K. Lim; S. K. Park; Youn Roh; H. S. Kim; John Almond; J. S. Kim; Jongjeong Kim; H. S. Lee; Kyungwook Nam; S. B. Oh; Benjamin Charles Radburn-Smith; S. h. Seo; U. K. Yang; H. D. Yoo; Geum Bong Yu; D. Jeon; J. H. Kim; J. S. H. Lee; I. C. Park; Y. Choi; Chanwook Hwang; I. Yu; Viesturs Veckalns; Vytautas Dudenas; Andrius Juodagalvis; J. Vaitkus; Z. A. Ibrahim; Mabm Ali; F. Mohamad Idris; W. A. T. Wan Abdullah; Mohd Nizam Yusli; Zukhaimira Zolkapli; Jose F Benitez; A. M. Castaneda Hernandez; J. A. Murillo Quijada; Heriberto Castilla-Valdez; E. De La Cruz-Burelo; M. C. Duran-Osuna; I. Heredia-De La Cruz; Ricardo Lopez-Fernandez; Raúl Iraq Rabadán-Trejo; Gabriel Ramirez-Sanchez; Rogelio Reyes-Almanza; A. Sanchez-Hernandez; S. Carrillo Moreno; C. Oropeza Barrera; M. Ramirez-Garcia; F. Vazquez Valencia; Jan Eysermans; Isabel Pedraza; H. A. Salazar Ibarguen; C. Uribe Estrada; A. Morelos Pineda; Natasa Raicevic; D. Krofcheck; Srinidhi Bheesette; P. H. Butler; Ashfaq Ahmad; M. I. Asghar; Qamar Hassan; H. R. Hoorani; W. A. Khan; Mehar Ali Shah; Muhammad Shoaib; Muhammad Waqas; Helena Bialkowska; M. Bluj; Bozena Boimska; Tomasz Frueboes; M. Górski; Malgorzata Kazana; Michal Szleper; P. Traczyk; P. Zalewski; K. Bunkowski; Adrian Byszuk; K. Doroba; A. Kalinowski; M. Konecki; J. Krolikowski; Maciej Misiura; M. Olszewski; Andrzej Pyskir; Marek Walczak; Mariana Araujo; Pedrame Bargassa; Diogo Bastos; C. Beirão Da Cruz E Silva; A. Di Francesco; P. Faccioli; Bruno Galinhas; M. Gallinaro; Jj Hollar; Nuno Leonardo; J. Seixas; Giles Strong; Oleksii Toldaiev; Joao Varela; Serguei Afanasiev; Pavel Bunin; Mikhail Gavrilenko; I. Golutvin; Ilya Gorbunov; A. Kamenev; Vladimir Karjavine; A. Lanev; Alexander Malakhov; V. A. Matveev; P. Moisenz; V. Palichik; V. Perelygin; S. Shmatov; Siarhei Shulha; Nikolai Skatchkov; V. Smirnov; Nikolay Voytishin; A. Zarubin; V. Golovtsov; Y. Ivanov; V. Kim; Ekaterina Kuznetsova; P. Levchenko; Victor Murzin; Vadim Oreshkin; I. Smirnov; Dmitry Sosnov; V. Sulimov; L. Uvarov; Sergey Vavilov; A. Vorobyev; Yu. Andreev; Alexander Dermenev; S. Gninenko; N. Golubev; Anton Karneyeu; M. Kirsanov; N. Krasnikov; A. Pashenkov; Arseniy Shabanov; D. Tlisov; A. Toropin; Vladimir Epshteyn; Vladimir Gavrilov; Natalia Lychkovskaya; Vladimir Popov; Ivan Pozdnyakov; Grigory Safronov; Alexander Spiridonov; Anton Stepennov; V. Stolin; Maria Toms; Evgueni Vlasov; Alexander Zhokin; T. Aushev; Marina Chadeeva; Dmitry Philippov; E. Popova; Vladimir Rusinov; Valeri Andreev; Maksim Azarkin; Igor Dremin; Martin Kirakosyan; Adel Terkulov; Alexander Belyaev; E. E. Boos; Mikhail Dubinin; L. V. Dudko; A. Ershov; A. Gribushin; Vyacheslav Klyukhin; O. Kodolova; I. Lokhtin; Stepan Obraztsov; S. Petrushanko; V. Savrin; Alexander Snigirev; Alexander Barnyakov; V. E. Blinov; Tatyana Dimova; L. V. Kardapoltsev; Yuri Skovpen; Igor Azhgirey; Igor Bayshev; Sergei Bitioukov; Vassili Kachanov; Alexey Kalinin; Dmitri Konstantinov; Petr Mandrik; V. Petrov; Roman Ryutin; Sergei Slabospitskii; Andrei Sobol; Sergey Troshin; Nikolay Tyurin; Andrey Uzunian; A.E. Volkov; Anton Babaev; Sergei Baidali; Aleksandr Iuzhakov; Vitalii Okhotnikov; P. Adzic; Predrag Cirkovic; Damir Devetak; Milos Dordevic; Predrag Milenovic; Jovan Milosevic; J. Alcaraz Maestre; A. lvarez Fernández; Irene Bachiller; M. Barrio Luna; J. A. Brochero Cifuentes; Marcos Cerrada; N. Colino; B. De La Cruz; A. Delgado Peris; C. Fernandez Bedoya; J. P. Fernández Ramos; Jose Flix; M. C. Fouz; O. Gonzalez Lopez; S. Goy Lopez; J. M. Hernandez; M. I. Josa; Dermot Moran; A. Pérez-Calero Yzquierdo; J. Puerta Pelayo; I. Redondo; L. Romero; S. Sánchez Navas; Mara Senghi Soares; Andrea Triossi; C. Albajar; J. F. de Trocóniz; J. Cuevas; Carlos Erice; J. Fernandez Menendez; Santiago Folgueras; I. Gonzalez Caballero; J. R. González Fernández; E. Palencia Cortezon; V. Rodríguez Bouza; S. Sanchez Cruz; J. M. Vizan Garcia; Iban Jose Cabrillo; A. Calderon; B. Chazin Quero; J. Duarte Campderros; M. Fernandez; P. J. Fernández Manteca; A. García Alonso; G. Gomez; A. Lopez Virto; C. Martinez Rivero; P. Martinez Ruiz del Arbol; F. Matorras; J. Piedra Gomez; Cédric Prieels; T. Rodrigo; Alberto Ruiz-Jimeno; L. Scodellaro; Nicolò Trevisani; Ivan Vila; Nadeesha Wickramage; D. Abbaneo; Bora Akgun; Etiennette Auffray; Georg Auzinger; Paul Baillon; A. H. Ball; David Barney; Joshua Bendavid; Michele Bianco; Andrea Bocci; C. Botta; Erica Brondolin; Tiziano Camporesi; M. Cepeda; Gianluca Cerminara; Emilien Chapon; Giacomo Cucciati; D. d’Enterria; A. Dabrowski; Nadir Daci; Vincenzo Daponte; A. David; A. De Roeck; Nikkie Deelen; Marc Dobson; Marc Dünser; Niels Dupont; A. Elliott-Peisert; Francesco Fallavollita; Daniele Fasanella; G. Franzoni; J. Fulcher; W. Funk; D. Gigi; Andrew Gilbert; K. Gill; F. Glege; Marek Gruchala; Maxime Guilbaud; Doga Gulhan; Jeroen Hegeman; Constantin Heidegger; Yutaro Iiyama; V. Innocente; Gian Michele Innocenti; Abideh Jafari; P. Janot; Olena Karacheban; Jan Kieseler; Andreas Kornmayer; Manfred Krammer; Clemens Lange; P. Lecoq; Carlos Lourenco; L. Malgeri; M. Mannelli; A. Massironi; F. Meijers; J. A. Merlin; S. Mersi; E. Meschi; F. Moortgat; M. Mulders; Jennifer Ngadiuba; Shervin Nourbakhsh; Styliani Orfanelli; L. Orsini; Felice Pantaleo; L. Pape; Emmanuelle Perez; M. Peruzzi; A. Petrilli; G. Petrucciani; Andreas Pfeiffer; M. Pierini; Florian Michael Pitters; Dinyar Rabady; A. Racz; M. Rovere; H. Sakulin; C. Schäfer; C. Schwick; Michele Selvaggi; Pedro Silva; P. Sphicas; Anna Stakia; Jan Steggemann; Vittorio Raoul Tavolaro; D. Treille; A. Tsirou; Adish Vartak; Mauro Verzetti; Wolfram Dietrich Zeuner; Lea Caminada; K. Deiters; W. Erdmann; R. Horisberger; Q. Ingram; H. C. Kaestli; D. Kotlinski; U. Langenegger; T. Rohe; Stephan Albert Wiederkehr; Malte Backhaus; Pirmin Berger; Nadezda Chernyavskaya; G. Dissertori; M. Dittmar; M. Donegà; Christian Dorfer; T. A. Gómez Espinosa; Christoph Grab; D. Hits; Thomas Klijnsma; W. Lustermann; Riccardo Andrea Manzoni; M. Marionneau; Maren Tabea Meinhard; F. Micheli; P. Musella; F. Nessi-Tedaldi; F. Pauss; Gaël Perrin; L. Perrozzi; Simone Pigazzini; Michael Reichmann; Christina Reissel; Thomas Reitenspiess; Daniele Ruini; D. A. Sanz Becerra; Myriam Schönenberger; Lesya Shchutska; K. Theofilatos; M. L. Vesterbacka Olsson; R. Wallny; D. H. Zhu; T. K. Aarrestad; C. Amsler; Danyyl Brzhechko; M. F. Canelli; A. De Cosa; R. Del Burgo; Silvio Donato; Camilla Galloni; Tomas Hreus; B. Kilminster; Stefanos Leontsinis; Vinicius Massami Mikuni; Izaak Neutelings; Giorgia Rauco; P. Robmann; Daniel Salerno; Korbinian Schweiger; Claudia Seitz; Yuta Takahashi; Sébastien Wertz; Alberto Zucchetta; Thi Hien Doan; C. M. Kuo; W.T. Lin; S. S. Yu; P. Chang; Y. Chao; K. F. Chen; Po-Hsun Chen; W. S. Hou; Y. F. Liu; R.-S. Lu; Efstathios Paganis; Andreas Psallidas; Arnaud Steen; Burin Asavapibhop; Norraphat Srimanobhas; Narumon Suwonjandee; A. Bat; Fatma Boran; S. Cerci; Serdal Damarseckin; Zuhal Seyma Demiroglu; Furkan Dolek; Candan Dozen; Isa Dumanoglu; Gul Gokbulut; EmineGurpinar Guler; Yalcin Guler; Ilknur Hos; Candan Isik; E. E. Kangal; Ozgun Kara; A. Kayis Topaksu; Ugur Kiminsu; Mehmet Oglakci; Gulsen Onengut; Kadri Ozdemir; Sertac Ozturk; D. Sunar Cerci; Bayram Tali; Ufuk Guney Tok; Semra Turkcapar; Ibrahim Soner Zorbakir; Caglar Zorbilmez; B. Isildak; Guler Karapinar; Metin Yalvac; M. Zeyrek; Ismail Okan Atakisi; E. Gülmez; M. Kaya; O. Kaya; Berkan Kaynak; Özlem Özçelik; Suat Ozkorucuklu; Sevgi Tekten; Elif Asli Yetkin; Altan Cakir; Kerem Cankocak; Yildiray Komurcu; S. Sen; Boris Grynyov; L. Levchuk; Fionn Ball; J. J. Brooke; Dustin Burns; Emyr Clement; D. Cussans; Olivier Davignon; Henning Flacher; J. Goldstein; G. P. Heath; H. F. Heath; L. Kreczko; D. M. Newbold; Sudarshan Paramesvaran; Bjoern Penning; T. Sakuma; David J. Smith; V. J. Smith; Joseph Taylor; Alexander Titterton; K. W. Bell; C. Brew; R. M. Brown; Davide Cieri; David Ja Cockerill; J. A. Coughlan; Kristian Harder; S. Harper; Jacob Linacre; Konstantinos Manolopoulos; E. O. Olaiya; David Petyt; Thomas Reis; Thomas Schuh; C. H. Shepherd-Themistocleous; Alessandro Thea; I. R. Tomalin; Thomas Williams; William John Womersley; R. Bainbridge; Philippe Bloch; Johan Borg; Shane Breeze; O. Buchmuller; Aaron Bundock; GurpreetSingh Chahal; D. Colling; P. D. Dauncey; G. Davies; M. Della Negra; R. Di Maria; Pieter Everaerts; G. Hall; G. Iles; Thomas James; Matthias Komm; Christian Laner; L. Lyons; Anne-Marie Magnan; S. Malik; Arabella Martelli; Vukasin Milosevic; J. A. Nash; A. Nikitenko; Vito Palladino; M. Pesaresi; D. M. Raymond; Alexander Richards; A. Rose; Edward Scott; C. Seez; Antoni Shtipliyski; M. Stoye; Thomas Strebler; Sioni Summers; A. Tapper; Kirika Uchida; T. Virdee; N. Wardle; Daniel Winterbottom; Jack Wright; Seth Conrad Zenz; J. E. Cole; Peter R Hobson; A. Khan; Paul Kyberd; C. K. Mackay; Alexander Morton; I. D. Reid; L. Teodorescu; Sema Zahid; Kenneth Call; J. R. Dittmann; K. Hatakeyama; Christopher Madrid; Brooks McMaster; Nathaniel Pastika; Caleb Smith; Rachel Bartek; A. Dominguez; Andrew Buccilli; Otman Charaf; Seth Cooper; C. Henderson; P. Rumerio; C. West; Daniel Arcaro; T. Bose; Zeynep Demiragli; Daniel Gastler; Semiray Girgis; Deborah Pinna; Clint Richardson; J. Rohlf; D. Sperka; Indara Suarez; L. R. Sulak; David Zou; Gabriele Benelli; Bjorn Burkle; Xavier Coubez; D. Cutts; Mary Hadley; John Hakala; U. Heintz; Julie Managan Hogan; K. H. M. Kwok; E. Laird; G. Landsberg; Z. Mao; M. Narain; Sinan Sagir; Rizki Syarif; Emanuele Usai; David Yu; Reyer Band; Christopher Brainerd; R. Breedon; M. Calderon De La Barca Sanchez; M. Chertok; J. Conway; Rylan Conway; P. T. Cox; R. Erbacher; Chad Flores; Garrett Funk; W. Ko; Ota Kukral; R. L. Lander; Michael Mulhearn; D. E. Pellett; J. Pilot; M. Shi; Dustin Stolp; Devin Taylor; Kyle Tos; M. Tripathi; Zhixing Wang; Fengwangdong Zhang; Michail Bachtis; Cameron Bravo; R. Cousins; Abhigyan Dasgupta; Alice Florent; J. Hauser; M. Ignatenko; Nickolas Mccoll; Simon Regnard; D. Saltzberg; Christian Schnaible; V. Valuev; Kira Burt; R. Clare; J. W. Gary; S. M. A. Ghiasi Shirazi; Gail Hanson; Georgia Karapostoli; Elizabeth Kennedy; O. R. Long; M. Olmedo Negrete; Mirena Ivova Paneva; W. Si; Long Wang; H. Wei; S. J. Wimpenny; Brent Yates; J. G. Branson; S. Cittolin; Mark Derdzinski; Raffaele Gerosa; Dylan Gilbert; Bobak Hashemi; A. Holzner; Daniel Klein; Gouranga Kole; V. Krutelyov; J. Letts; Mario Masciovecchio; S. May; Dominick Olivito; Sanjay Padhi; M. Pieri; V. Sharma; Matevz Tadel; John Wood; F. Würthwein; A. Yagil; G. Zevi Della Porta; Nick Amin; Rohan Bhandari; C. Campagnari; Matthew Citron; Valentina Dutta; M. Franco Sevilla; Loukas Gouskos; J. Incandela; Bennett Marsh; Hualin Mei; Ana Ovcharova; H. Qu; J. D. Richman; Ulascan Sarica; D. Stuart; Sicheng Wang; J. Yoo; Dana Z. Anderson; A. Bornheim; Jay Mathew Lawhorn; Nan Lu; H. B. Newman; Thong Nguyen; Joosep Pata; Maria Spiropulu; J. R. Vlimant; R. Wilkinson; Si Xie; Zhicai Zhang; R. Y. Zhu; Michael Benjamin Andrews; T. Ferguson; Tanmay Mudholkar; Manfred Paulini; M. Sun; I. Vorobiev; M. Weinberg; J. P. Cumalat; W. T. Ford; Frank Jensen; Andrew Johnson; Emily MacDonald; Troy Mulholland; Rishi Patel; Alexx Perloff; K. Stenson; K. A. Ulmer; S. R. Wagner; J. P. Alexander; Jorge Chaves; Yangyang Cheng; J. Chu; Abhisek Datta; Andre Frankenthal; Kevin Mcdermott; Nathan Mirman; Jose Monroy; J. R. Patterson; D. Quach; Aurelijus Rinkevicius; A. Ryd; Louise Skinnari; Livia Soffi; S. M. Tan; Z. Tao; J. Thom; J. Tucker; P. Wittich; Margaret Zientek; S. Abdullin; Michael Albrow; Maral Alyari; Giorgio Apollinari; Artur Apresyan; A. Apyan; L. A. T. Bauerdick; A. Beretvas; Jeffrey Berryhill; P. C. Bhat; K. Burkett; J. N. Butler; A. Canepa; Giuseppe Benedetto Cerati; H. W. K. Cheung; Frank Chlebana; Matteo Cremonesi; Javier Duarte; V. D. Elvira; J. C. Freeman; Zoltan Gecse; Erik Gottschalk; L. Gray; D. R. Green; Stefan Grünendahl; O. Gutsche; J. Hanlon; R. M. Harris; S. Hasegawa; Ryan Heller; James Hirschauer; Z. Hu; Bodhitha Jayatilaka; S. Jindariani; M. Johnson; U. Joshi; B. Klima; Matti J. Kortelainen; Benjamin Kreis; S. Lammel; Don Lincoln; R. Lipton; Miaoyuan Liu; T. Liu; J. Lykken; Kaori Maeshima; John Michael Marraffino; D. Mason; P. McBride; P. Merkel; S. Mrenna; S. Nahn; V. O'Dell; Kevin Pedro; Cristian Pena; O. Prokofyev; G. Rakness; Fabio Ravera; Allison Reinsvold; L. Ristori; Basil Schneider; E. Sexton-Kennedy; Nicholas Smith; Aron Soha; W. J. Spalding; L. Spiegel; S. Stoynev; James Strait; Nadja Strobbe; L. Taylor; S. Tkaczyk; N. V. Tran; Lorenzo Uplegger; E. W. Vaandering; Caterina Vernieri; Marco Verzocchi; R. Vidal; M. H. L. S. Wang; Hannsjoerg Artur Weber; D. Acosta; P. Avery; Pierluigi Bortignon; D. Bourilkov; Andrew Brinkerhoff; Luca Cadamuro; A. Carnes; Vladimir Cherepanov; D. Curry; R. D. Field; Sergei Gleyzer; Bhargav Madhusudan Joshi; M. Kim; J. Konigsberg; A. Korytov; Kin Ho Lo; P. Ma; K. Matchev; Nicholas Menendez; G. Mitselmakher; Daniel Rosenzweig; K. Shi; Jing Wang; X. Zuo; Yagya Raj Joshi; S. Linn; Todd Adams; Andrew Askew; S. Hagopian; V. Hagopian; K. F. Johnson; Raman Khurana; Ted Kolberg; German Martinez; T. Perry; H. B. Prosper; Anirban Saha; Catherine Schiber; Rachel Yohay; M. M. Baarmand; Vallary Bhopatkar; Stefano Colafranceschi; Marcus Hohlmann; D. Noonan; Mehdi Rahmani; Titas Roy; Mark Saunders; F. Yumiceva; M. R. Adams; Leonard Apanasevich; Douglas Berry; R. R. Betts; R. Cavanaugh; Xuan Chen; Susan Dittmer; O. Evdokimov; C. E. Gerber; Dhanush Anil Hangal; D. J. Hofman; Kurt Jung; Corrinne Mills; Marguerite Tonjes; N. Varelas; Hui Wang; Xiao Wang; Z. Wu; Jian Zhang; Mohammad Alhusseini; Burak Bilki; Warren Clarida; Kamuran Dilsiz; Süleyman Durgut; R. P. Gandrajula; Maksat Haytmyradov; Viktor Khristenko; Ohannes Kamer Köseyan; Jean-Pierre Merlo; A. Mestvirishvili; Anthony Moeller; J. Nachtman; Hasan Ogul; Y. Onel; Ferhat Ozok; A. Penzo; Christina Snyder; E. Tiras; James Wetzel; B. Blumenfeld; Alice Cocoros; Nicholas Eminizer; David Fehling; Lei Feng; A. V. Gritsan; W. T. Hung; P. Maksimovic; Jeffrey Roskes; Melody A. Swartz; Meng Xiao; Ayman Al-bataineh; Philip Baringer; A. Bean; Samuel Boren; James Bowen; Alexander Bylinkin; James Castle; S. Khalil; Anna Kropivnitskaya; Devdatta Majumder; William Mcbrayer; M. Murray; Christopher Rogan; S. Sanders; Erich Schmitz; J. D. Tapia Takaki; Senka Duric; Andrew Ivanov; Ketino Kaadze; Doyeong Kim; Yurii Maravin; Dalath Rachitha Mendis; Tyler Mitchell; Atanu Modak; Abdollah Mohammadi; Finn Rebassoo; D. M. Wright; A. Baden; Owen Baron; Alberto Belloni; S. C. Eno; Y. Feng; Charles Ferraioli; N. J. Hadley; Shabnam Jabeen; Geng-Yuan Jeng; R. G. Kellogg; Joshua Kunkle; A. C. Mignerey; Sara Nabili; Francesca Ricci-Tam; Markus Seidel; Y. H. Shin; Andris Skuja; Suresh C Tonwar; Kak Wong; Daniel Abercrombie; Brandon Allen; Virginia Azzolini; Austin Baty; Ran Bi; Stephanie Brandt; Wit Busza; I. A. Cali; Mariarosaria D'Alfonso; G. Gomez Ceballos; Maxim Goncharov; Philip Harris; Dylan Hsu; Miao Hu; Markus Klute; Dmytro Kovalskyi; Yen-Jie Lee; P. D. Luckey; Benedikt Maier; Andrea Carlo Marini; Christopher Mcginn; Camelia Mironov; Siddharth Narayanan; Xinmei Niu; C. Paus; Dylan Rankin; C. Roland; G. Roland; Z. Shi; George Stephans; Konstanty Sumorok; Kaya Tatar; Dragos Velicanu; T. W. Wang; Bolek Wyslouch; A. C. Benvenuti; Rajdeep Mohan Chatterjee; Andrew Evans; Peter Hansen; Joshua Hiltbrand; Sh. Jain; Sean Kalafut; Michael Krohn; Y. Kubota; Zachary Lesko; J. Mans; R. Rusack; Mohammad Abrar Wadud; John Gabriel Acosta; Sandra Oliveros; Ekaterina Avdeeva; Kenneth Bloom; D. R. Claes; Caleb Fangmeier; Linda Finco; Frank Golf; R. Gonzalez Suarez; Rami Kamalieddin; I. Kravchenko; Joaquin Emilo Siado; G. R. Snow; Benjamin Stieger; Andrew Godshalk; Charles Harrington; I. Iashvili; Avto Kharchilava; Christine Mclean; Duong Nguyen; A. Parker; S. Rappoccio; Bahareh Roozbahani; G. Alverson; E. Barberis; Chad Freer; Yacine Haddad; Apichart Hortiangtham; Gabriel Madigan; D. M. Morse; T. Orimoto; Abraham Tishelman-Charny; Tanvi Wamorkar; Baokai Wang; Andrew Wisecarver; D. R. Wood; James Bueghly; Thoth Gunter; Kristan Allan Hahn; Nathaniel Odell; Michael Henry Schmitt; Kevin Sung; Marco Trovato; M. Velasco; Rachael Bucci; Nabarun Dev; Reza Goldouzian; M. D. Hildreth; K. Hurtado Anampa; Colin Jessop; D. J. Karmgard; K. Lannon; Wei Li; Nikitas Loukas; N. Marinelli; F. Meng; Charles Mueller; Y. Musienko; Michael Planer; R. Ruchti; Prasanna Siddireddy; Graeme Smith; Silvia Taroni; M. Wayne; Andrew Wightman; M. Wolf; Anna Woodard; Juliette Alimena; Louis Antonelli; Ben Bylsma; L. S. Durkin; Sean Flowers; B. Francis; C. Hill; Weifeng Ji; Anthony Lefeld; T. Y. Ling; Wuming Luo; Brian L Winer; Stephane Cooperstein; Gage Dezoort; P. Elmer; Joshua Hardenbrook; Nicholas Haubrich; Samuel Higginbotham; Alexis Kalogeropoulos; Stephanie Kwan; D. Lange; Marco Toliman Lucchini; J. Luo; Daniel Marlow; Kelvin Mei; Isabel Ojalvo; James Olsen; C. Palmer; P.A. Piroué; Jakob Salfeld-Nebgen; D.P. Stickland; C. Tully; Scarlet Norberg; Anthony Barker; V. E. Barnes; Souvik Das; L.J. Gutay; M. Jones; Aw Jung; Ajeeta Khatiwada; Bibhuprasad Mahakud; D. H. Miller; Giulia Negro; N. Neumeister; Cheng-Chieh Peng; Stefan Piperov; H. Qiu; Jan-Frederik Schulte; J. Sun; Fuqiang Wang; Rui Xiao; W. Xie; Tongguang Cheng; James Dolen; N. Parashar; Zhenyu Chen; K. M. Ecklund; Sarah Freed; F. J. M. Geurts; Matthew Kilpatrick; Arun Kumar; B. P. Padley; Jay Roberts; Jamal Rorie; W. Shi; A. G. Stahl Leiton; Z. Tu; A. Zhang; A. Bodek; P. de Barbaro; Regina Demina; Y. t. Duh; Joseph Lynn Dulemba; Colin Fallon; T. Ferbel; M. Galanti; Aran Garcia-Bellido; J. Y. Han; Otto Hindrichs; Aleko Khukhunaishvili; Evan Ranken; P. Tan; Rhys Taus; Brandon Chiarito; John Paul Chou; Yuri Gershtein; Eva Halkiadakis; Andrew Hart; Maximilian Heindl; Elliot Hughes et al.,"A measurement is presented of electroweak (EW) production of a $$\mathrm{W} $$ boson in association with two jets in proton–proton collisions at $$\sqrt{s}=13\,\text {Te}\text {V} $$. The data sample was recorded by the CMS Collaboration at the LHC and corresponds to an integrated luminosity of 35.9$$\,\text {fb}^{-1}$$. The measurement is performed for the $$\ell \nu $$jj final state (with $$\ell \nu $$ indicating a lepton–neutrino pair, and j representing the quarks produced in the hard interaction) in a kinematic region defined by invariant mass $$m_\mathrm {jj} >120\,\text {Ge}\text {V} $$ and transverse momenta $$p_\mathrm {T j} > 25\,\text {Ge}\text {V} $$. The cross section of the process is measured in the electron and muon channels yielding $$\sigma _\mathrm {EW}(\mathrm{W} \mathrm {jj})= 6.23 \pm 0.12 \,\text {(stat)} \pm 0.61 \,\text {(syst)} \,\text {pb} $$ per channel, in agreement with leading-order standard model predictions. The additional hadronic activity of events in a signal-enriched region is studied, and the measurements are compared with predictions. The final state is also used to perform a search for anomalous trilinear gauge couplings. Limits on anomalous trilinear gauge couplings associated with dimension-six operators are given in the framework of an effective field theory. The corresponding 95% confidence level intervals are $$-2.3< c_{{\mathrm{W} \mathrm{W} \mathrm{W}}}/\varLambda ^2 < 2.5\,\text {Te}\text {V} ^{-2}$$, $$-8.8< c_{\mathrm{W}}/\varLambda ^2 < 16\,\text {Te}\text {V} ^{-2}$$, and $$-45< c_{\mathrm{B}}/\varLambda ^2 < 46\,\text {Te}\text {V} ^{-2}$$. These results are combined with the CMS EW $$\mathrm{Zjj} $$ analysis, yielding the constraint on the $$c_{{\mathrm{W} \mathrm{W} \mathrm{W}}}$$ coupling: $$-1.8< c_{{\mathrm{W} \mathrm{W} \mathrm{W}}}/\varLambda ^2 < 2.0\,\text {Te}\text {V} ^{-2}$$.",80,,,https://link.springer.com/content/pdf/10.1140/epjc/s10052-019-7585-7.pdf https://publikationen.bibliothek.kit.edu/1000105317,http://dx.doi.org/10.1140/epjc/s10052-019-7585-7,0,32026888,10.1140/epjc/s10052-019-7585-7,3001114151,,001-717-766-573-633; 007-995-633-591-617; 008-542-017-460-466; 012-956-424-349-428; 013-410-861-022-337; 015-018-020-803-389; 017-193-576-454-314; 021-396-956-475-496; 021-429-797-622-054; 024-491-646-673-723; 026-250-856-400-286; 026-845-226-315-688; 028-887-938-590-280; 029-675-157-442-391; 029-992-588-626-925; 032-773-974-508-191; 035-222-701-055-674; 035-362-109-906-796; 036-248-911-236-352; 037-084-919-517-907; 037-823-190-461-30X; 040-193-796-441-690; 042-076-717-221-316; 042-385-382-835-699; 042-540-330-025-333; 045-017-584-677-588; 046-592-043-774-411; 047-348-632-092-63X; 049-815-520-720-788; 052-033-590-781-625; 053-038-778-199-353; 055-898-555-590-876; 057-951-133-699-022; 060-178-084-193-561; 061-234-155-311-757; 064-566-675-280-499; 067-210-249-420-77X; 068-621-886-259-045; 073-175-694-630-034; 079-817-033-015-675; 088-150-939-459-516; 096-579-974-168-417; 098-244-526-145-164; 098-760-887-695-883; 102-196-801-947-401; 105-028-736-235-657; 108-406-250-691-403; 116-513-756-142-413; 116-966-766-685-122; 119-419-648-208-284; 119-559-419-072-971; 120-936-507-985-590; 125-580-914-666-201; 125-990-757-984-012; 130-916-550-881-740; 131-669-264-644-585; 132-457-807-647-451; 135-973-600-029-840; 140-088-654-343-228; 142-142-334-508-553; 147-398-702-033-901; 160-813-316-281-938; 166-782-833-552-109; 170-131-373-584-948; 182-124-863-260-356; 183-088-376-803-393; 186-699-916-242-163; 187-903-305-703-073,0
078-755-397-602-291,,,,,El catálogo de Pijao Editores (1972-2000): una editorial “alternativa”,Latin American literature; Art; Humanities; Hasta,2020-01-01,2020,,,,46,177,194,Paula Andrea Marín Colorado,"desde el enfoque de los estudios editoriales, aqui se reconstruye parte de la historia de Pijao Editores (1972-actual), una de las editoriales literarias colombianas de mas larga trayectoria en el pais, reconocida por su robusto catalogo literario y por haber funcionado como casa de difusion de las primeras obras de muchos autores colombianos, en un momento en el que no encontraban facilmente apoyo para la publicacion de sus obras. Los objetivos del texto son presentar una parte de la historia —hasta hoy inexistente— de la editorial y reconstruir y analizar su catalogo (1972-2000).",,,,https://aprendeenlinea.udea.edu.co/revistas/index.php/elc/article/view/339520/20795525,https://aprendeenlinea.udea.edu.co/revistas/index.php/elc/article/view/339520/20795525,0,,,3000105533,,,0
080-048-892-667-462,Netherlands,1877959x; 18779603,Elsevier GmbH,Ticks and Tick-borne Diseases,Ehrlichia canis TRP36 diversity in naturally infected-dogs from an urban area of Colombia,Genotype; Virology; Antibody; Coinfection; Canis; Ehrlichia canis; 16S ribosomal RNA; Serology; Polymerase chain reaction; Biology,2020-01-07,2020,journal article,Canine monocytic ehrlichiosis; Colombia; ELISA; Ehrlichia canis; Genotype; Tandem repeat protein,"Departamento Administrativo de Ciencia, Tecnología e Innovación (COLCIENCIAS); Universidad de Antioquia",,101367,,Esteban Arroyave; Juan David Rodas-González; Xiaofeng Zhang; Marcelo B. Labruna; María S. González; Jorge A Fernández-Silva; Jere W. McBride,"Abstract Ehrlichia canis is the etiologic agent of a highly prevalent tick-borne disease, canine monocytic ehrlichiosis (CME). Four defined E. canis genotypes based on the trp36 gene sequences have been reported, three of them identified in North or South America. The diversity of E. canis has been investigated using genetic and serologic approaches based on distinct 36 kDa tandem repeat protein (trp36) gene sequences that have been reported. The main objectives of this study were to determine the prevalence of E. canis infection in dogs from Medellin, Colombia by PCR and determine the E. canis diversity using molecular and serologic approaches. Blood was collected from dogs (n = 300) with clinical signs of CME for PCR detection of E. canis 16S rRNA, dsb and trp36 DNA. Phylogenetic analysis of trp36 gene sequences was performed using MEGA. A serological evaluation was performed using immunofluorescence microscopy and ELISA with species-specific peptides from E. canis TRP19 and TRP36 (3 genotypes) and E. chaffeensis (TRP32). E. canis DNA (16S rRNA and/or dsb) was detected in 18% (53/300) of dogs by PCR amplification. The trp36 gene was amplified and sequenced from 35/53 16S rRNA/dsb PCR positive samples revealing three genotypes: United States (US; n = 21), Costa Rica (CR; n = 11), and Brazil (BR; n = 3). All dogs with detectable trp36 DNA (n = 35) had anti-E. canis TRP19 and TRP36 peptide antibodies that corresponded to the genotype detected by PCR. Dogs that had antibodies to the TRP19 peptide (82/300; 38%), also had antibodies to one or more genotype-specific TRP36 peptides. Based on TRP36 serology, the dogs exhibited highest frequency of infection with the US genogroup (US = 26), followed by the CR genogroup (CR = 19) and the BR genogroup (BR = 11). Notably, 26/53 trp36 PCR positive dogs had detectable antibodies to multiple E. canis genotypes (US/BR/CR = 8, BR/CR = 7, US/CR = 6 and US/BR = 5) suggesting coinfection or multiple sequential infections with different genotypes. Colombian dogs did not have antibodies to E. chaffeensis as determined by a TRP32 species-specific ELISA. Our results demonstrate the presence of three previously defined genotypes in North and South America in Colombian dogs (US, BR, CR). These results also demonstrate that TRP19 and TRP36 serology can provide valuable information regarding E. canis exposure and the potential genotype(s) involved in infection.",,,,https://www.sciencedirect.com/science/article/abs/pii/S1877959X19303103,http://dx.doi.org/10.1016/j.ttbdis.2019.101367,0,31987818,10.1016/j.ttbdis.2019.101367,2998843175,,001-958-819-921-636; 002-989-656-823-297; 007-800-716-327-202; 008-919-243-323-096; 010-506-044-976-883; 011-572-531-559-317; 011-947-769-539-277; 013-235-509-381-159; 013-587-601-087-293; 016-321-365-114-966; 021-017-457-758-675; 028-904-909-870-437; 031-207-588-863-096; 033-211-621-365-748; 036-186-374-343-732; 038-987-412-493-292; 041-851-801-416-317; 042-860-219-178-051; 052-751-193-825-897; 052-852-268-594-599; 057-136-973-875-972; 058-320-993-486-911; 061-924-596-737-444; 066-960-698-904-434; 067-935-215-154-598; 069-225-455-255-394; 074-940-241-703-343; 080-558-280-363-898; 086-643-325-662-715; 087-922-012-136-333; 092-749-130-315-37X; 114-285-412-034-238; 132-620-545-324-966; 140-584-011-679-070; 144-861-861-694-611; 159-704-182-828-898; 163-607-267-356-498; 168-021-228-115-126; 169-296-047-916-652; 178-343-433-498-976,0
083-370-477-248-193,United States,10507256; 15579077,Mary Ann Liebert Inc.,Thyroid,Experience with active surveillance of thyroid microcarcinomalow-risk carcinoma in a developing country,Internal medicine; Endocrinology; Oncology; Carcinoma; Papillary carcinomas; Thyroid carcinoma; Thyroid; Diabetes mellitus; Medicine; Developing country,2020-01-17,2020,journal article,,,,,,Álvaro Sanabria,Background: The incidence of thyroid carcinoma is growing worldwide. More than 50% of new malignant tumors are classified as classical papillary carcinomas in low-risk category with a low rate of r...,,,,https://www.liebertpub.com/doi/abs/10.1089/thy.2019.0522,http://dx.doi.org/10.1089/thy.2019.0522,0,31950887,10.1089/thy.2019.0522,3000004247,,000-653-439-012-920; 004-370-545-482-50X; 004-518-134-732-912; 005-894-370-102-483; 006-171-178-918-543; 007-203-462-149-649; 009-580-119-721-704; 013-605-958-873-779; 020-469-549-643-358; 021-237-755-157-370; 021-518-634-997-585; 025-712-445-770-458; 029-107-680-080-115; 037-255-574-407-289; 037-676-894-963-87X; 047-140-476-042-485; 047-391-291-893-159; 061-753-713-177-295; 061-823-779-559-123; 069-932-775-758-604; 075-445-127-849-793; 097-954-819-548-899; 101-128-063-267-576; 103-419-331-046-714; 114-914-606-041-689; 121-025-991-131-122; 122-766-423-199-406; 154-055-277-940-453; 154-459-044-078-98X; 162-068-724-010-892,0
086-321-560-585-009,Netherlands,00243795,Elsevier Inc.,Linear Algebra and its Applications,On the characterization of digraphs with given rank,Combinatorics; Vertex (geometry); Adjacency matrix; Bipartite graph; Digraph; Mathematics,2020-02-01,2020,journal article,,"Departamento Administrativo de Ciencia, Tecnología e Innovación (COLCIENCIAS); Universidad de Antioquia; Becas COLCIENCIAS",,215,227,Natalia A. Agudelo; Juan Monsalve; Juan Rada,"Abstract The rank of a digraph is defined as the rank of its adjacency matrix. In this paper we show how to find all digraphs of rank k from the reduced bipartite graphs of rank 2k. In particular, since the bipartite graphs of rank 2 , 4 and 6 are known, then we characterize digraphs of rank 1 , 2 and 3. The results are based on rank-preserving operations on digraphs such as splitting and fusion of vertices or twin-deletion and vertex-multiplication.",587,,,https://www.sciencedirect.com/science/article/pii/S0024379519304781,http://dx.doi.org/10.1016/j.laa.2019.11.008,0,,10.1016/j.laa.2019.11.008,2988516549,,002-853-537-581-755; 011-220-360-049-435; 015-021-145-832-420; 019-487-147-715-826; 028-738-046-619-27X; 033-836-585-990-81X; 039-470-397-175-177; 041-754-964-323-153; 057-235-089-302-448; 057-885-129-119-74X; 067-117-223-920-155; 109-539-532-155-161; 122-962-483-703-289; 130-166-775-778-592; 133-701-479-993-504; 162-331-041-833-932; 164-789-988-438-270,0
087-868-252-222-113,Australia,10313613,CSIRO,"Reproduction, Fertility and Development",68 Anti-Mullerian hormone levels in different bovine species and the relationship with in vitro embryo production,Internal medicine; Endocrinology; Theriogenology; Oogenesis; Andrology; Embryo; Anti-Müllerian hormone; Embryo culture; Reproductive technology; Reproductive biology; Folliculogenesis; Biology,2020-01-01,2020,journal article,,,2,159,160,J. Berdugo; Ariel Marcel Tarazona-Morales; J. Echeverry-Zuluaga; W. Cardona Maya; Albeiro López-Herrera; G. A. Crudeli; J. L. Konrad; G. Espasandin,"The development of markers for reproductive function has been a goal for the embryo production industry and reproductive biology as a method to improve success and increase the ability to explain reproductive phenomena. Cattle and buffalo are bovines that show different reproductive parameters raised in the same conditions. The aim of this work was to compare the results of the in vitro production of cows (Bos indicus) and buffalo (Bubalus bubalis) from animals kept under the same conditions of feeding and handling. This study was conducted in an Argentinian commercial herd of buffalo and cattle located in the province of Corrientes (−27.742859 latitude, −57.773611 longitude) during the breeding season of 2018 (March-May). Twenty animals of each species were used. Anti-Mullerian hormone (AMH) levels of each animal were determined using ELISA. Standardized protocols were used for oocyte aspiration, maturation, fertilisation, and culture of the embryos, and frozen semen of a single proven bull was used in each species. The numbers of follicles, oocytes, and embryos were recorded and analysed individually and grouped by species (Table 1). The normality of the data was evaluated with the D’Agostino and Shapiro-Wilk tests and the comparisons between species using the Mann-Whitney and ANOVA tests, and correlation analysis was performed using the Spearman test. Values are shown as median and range. A P-value  0.05). There were no significant differences in the number of follicles and the quality of the oocytes. Significant differences were found in the number of oocytes cleaved of 4 (0-17) vs. 0.5 (0-4) and blastocysts per animal of 1.5 (0-15) vs. 0.1 (0-2) for cows and buffalo, respectively. The number of blastocysts in relation to the number of oocytes cleaved did not show statistical significance. In spite of the difference in the AMH levels and the embryo production parameters, which were lower in buffalo, no correlation was found between AMH and the parameters studied in both species. The results obtained here are confirmed by others in the literature. Levels of AMH as a marker for embryo production are not useful in cattle and buffalo and do not explain the differences observed, certainly AMH is a marker for quantity as the preserver of the ovarian reserve. Table 1.Comparison of individual values of AMH levels, oocyte quality, and embryo production between cattle and buffalo Parameter Median (range) P-value Cattle Buffalo AMH (pg mL−1) 688.5 (45.3-2394) 73.8 (14.8-262.5) <0.001 Follicles Follicles RO 3 (0-9) 4 (0-6) Follicles LO 5 (0-10) 4 (1-8) Total follicles 7 (2-18) 7 (2-12) Oocyte quality GI 2 (1-3) 1.5 (1-3) 0.22 GII 2 (1-9) 2 (1-6) 0.67 GIII 2.5 (0-18) 2 (1-4) 0.91 GIV 1 (1-5) 2 (1-4) 0.10 Total oocytes 9 (0-23) 4.5 (1-11) 0.02 Total viable 5.5 (0-21) 5 (0-11) 0.36 Cleavage 4 (0-17) 0.5 (0-4) 0.01 Blastocyst 1.5 (0-15) 0.1 (0-2) 0.02",32,,,https://www.publish.csiro.au/RD/RDv32n2Ab68,http://dx.doi.org/10.1071/rdv32n2ab68,0,,10.1071/rdv32n2ab68,2991643323,,,0
089-400-591-300-736,United Kingdom,20452322,Nature Publishing Group,Scientific Reports,Sampling and processing blood samples within the South American Youth/Child cARdiovascular and Environmental (SAYCARE) Study,Concordance; Insulin resistance; Hyperlipidemia; Overweight; Frozen storage; Scarce data; Obesity; Medicine; Biomarker (medicine); Environmental health,2020-01-20,2020,journal article,,Universidad de Buenos Aires (University of Buenos Aires) (20020250100042BA); Universidad de Buenos Aires (University of Buenos Aires) (20020250100042BA); Universidad de Buenos Aires (University of Buenos Aires) (20020250100042BA); Universidad de Buenos Aires (University of Buenos Aires) (20020250100042BA); Universidad de Buenos Aires (University of Buenos Aires) (20020250100042BA),1,1,7,Graciela López; Raphael Assali Serruya; Magalí Barchuk; Diego Gaitán-Charry; Francisco Leonardo Torres-Leal; Luis A. Moreno; Carlos Delgado; Heráclito Barbosa Carvalho; Augusto César Ferreira de Moraes; Gabriela Berg,"Obesity and overweight in children and adolescents is increasing rapidly worldwide; however, scarce data have been reported from South America countries. With the purpose of assessing hyperlipidemia, insulin resistance and chronic inflammation, the evaluation of blood biomarkers such as glucose, lipoproteins and chronic inflammation proteins is required. In the context of the SAYCARE study, in children and adolescents (3 to 18 years) from seven South American cities, our aim was to assess the impact of pre analytical conditions on different biomarkers evaluated in 474 fresh serum samples, in different country centers. We also evaluated the stability according to time and frozen storage within this study across the concordance of the results obtained from the 49 blood samples measured in three different centers. Significant correlations as well as concordance were observed in TG, Total-C, HDL-C and glucose between Buenos Aires and Sao Paulo. The samples evaluated in Teresina and Sao Paulo presented similar results, with exception of total cholesterol. We observed acceptable concordance between Buenos Aires vs Sao Paulo and Teresina vs Sao Paulo, suggesting that samples could be processed in each of these centers. This concordance is a consequence of the strict pre analytical conditions previously established in the SAYCARE study.",10,,,https://www.nature.com/articles/s41598-020-57457-1 https://www.nature.com/articles/s41598-020-57457-1.pdf,http://dx.doi.org/10.1038/s41598-020-57457-1,0,31959781,10.1038/s41598-020-57457-1,2998809738,,006-623-746-426-657; 012-881-194-229-346; 017-652-821-851-883; 019-932-969-930-683; 026-231-957-067-183; 027-521-531-516-684; 028-437-505-003-177; 031-030-452-299-085; 031-056-855-501-837; 039-243-437-075-024; 039-359-265-487-798; 044-357-848-910-203; 045-201-107-411-584; 047-132-690-746-993; 049-179-718-376-842; 056-449-720-055-029; 057-977-032-339-699; 058-791-359-627-992; 076-440-744-589-134; 086-843-163-160-152; 100-524-224-454-355; 195-462-993-180-024,0
090-377-772-560-222,,,,,EFECTO PLACEBO Y ESTIMULACIÓN SONORA BINAURAL DE ONDAS BETA Y THETA EN EL RENDIMIENTO DE UNA TAREA DE MEMORIA DE TRABAJO (Placebo Effect and Binaural Sound Stimulation of Beta Wave and Theta Wave in a Working Memory Task Performance),Beta wave; Humanities; Psychology; Binaural recording; Working memory; Placebo; Memoria; SOUND STIMULATION; Immediate memory; Theta rhythm,2020-01-01,2020,,,,1,32,51,Sebastian Alonso Rojas-Álvarez; Ancizar Valencia; Mauricio Alberto Barrera-Valencia,"En el presente trabajo se realizo un estudio cuasi experimental de medidas repetidas con grupos caso y control, cuyo objetivo fue medir el efecto de los sonidos binaurales de onda beta y theta, y de la informacion placebo relacionada a ellos, sobre el rendimiento de una tarea de memoria de trabajo computarizada, version libre del Automated Operation Span Task -AOSPAN- de Unsworth, Heitz, Schrock y Engle (2005). Dicha tarea se repitio en dos sesiones separadas por un lapso minimo de dos semanas, una de las cuales se resolvia mientras se escuchaba una estimulacion sonora binaural de onda beta o theta que, dependiendo del grupo, se acompanaba o no de informacion placebo. Se evaluaron 98 personas con distinto nivel de escolaridad divididas en seis grupos experimentales y uno de control. Se encontraron diferencias significativas en el tiempo de presentacion de la tarea experimental asociada a informacion placebo, mostrando una mejoria en la segunda aplicacion de la tarea. Debido a ambiguedades en los resultados, a pesar de encontrar diferencias significativas asociadas a la estimulacion binaural de onda beta, no pudieron establecerse relaciones concretas entre la mejoria en el recuerdo de conjuntos de hasta cuatro elementos con la presencia de dicha variable. No se encontraron diferencias significativas en las variables de recuerdo global, lo cual puede explicarse por el tipo de tarea de memoria utilizado. Palabras Clave : Memoria de trabajo, Sonidos binaurales, AOSPAN, Evaluacion computarizada, Psychopy, Procesamiento de la informacion, recuerdo inmediato, Psicologia Experimental, Estimulacion sonora, Memoria a corto plazo, Pruebas de interferencia. Abstract In this work, a quasi-experimental study of repeated measures with case and control groups was carried out, whose objective was to measure the effect of binaural sounds of beta and theta waves, and the placebo information related to them, on the performance of a computerized working memory task, Automated Operation Span Task -AOSPAN- free version of Unsworth, Heitz, Schrock and Engle (2005). This task was repeated in two sessions separated by an interval of two weeks, one of which was resolved while listening to a binaural sound stimulation of beta wave or theta that, depending on the group, was supported or not by placebo information. 98 people with different levels of schooling were tested twice, divided into six experimental groups and one control group. Significant differences were found related to time duration in performing the experimental task associated with placebo information; it was showed an improvement the second time the task was administered. Due to ambiguities in the results, despite finding significant differences associated with binaural stimulation of beta wave, it was not possible to establish concrete relations between the improvement in the memory of sets up four elements with the presence of this variable. No significant differences were found in the global recall variables, which can be explained by the type of memory task performed. Keywords: Working Memory, Binaural Sounds, AOSPAN, Computerized Assessment, Psychopy, Information Processing, Immediate Memory, Psychology, Experimental Psychology, Sound Stimulation, Short-Term Memory, Interference Tests.",13,,,http://revistas.ces.edu.co/index.php/psicologia/article/view/4883,http://revistas.ces.edu.co/index.php/psicologia/article/view/4883,0,,,2990051885,,,0
094-735-427-700-223,United States,19352727; 19352735,Public Library of Science,PLOS Neglected Tropical Diseases,Test accuracy of polymerase chain reaction methods against conventional diagnostic techniques for Cutaneous Leishmaniasis (CL) in patients with clinical or epidemiological suspicion of CL: Systematic review and meta-analysis,Internal medicine; Recombinase Polymerase Amplification; Immunology; Biopsy; Leishmaniasis; Cutaneous leishmaniasis; Leishmania infantum; Population; Polymerase chain reaction; Loop-mediated isothermal amplification; Biology; Gastroenterology,2020-01-21,2020,journal article,,"Departamento Administrativo de Ciencia, Tecnología e Innovación (COLCIENCIAS)",1,e0007981,,Luz Estella Mesa; Rubén Manrique; Carlos Muskus; Sara M. Robledo,"Background ; Molecular diagnostic tests, notably polymerase chain reaction (PCR), are highly sensitive test for Leishmania detection, which is especially relevant in chronic cutaneous lesion with lower parasite load. An accurate diagnosis is essential because of the high toxicity of the medications for the disease. Nevertheless, diagnosis of cutaneous leishmaniasis (CL) is hampered by the absence of a reference standard. Assuming that the PCR-based molecular tools are the most accurate diagnostic method, the objective of this systematic review was to assess the diagnostic accuracy of PCR-based molecular tools in a meta-analysis of the published literature.; ; ; Methodology/Principal findings ; A search of the published literature found 142 papers of which only 13 studies met the selection criteria, including conventional PCR, real-time PCR, Loop-mediated isothermal amplification (LAMP), recombinase polymerase amplification (RPA), polymorphism-specific PCR (PS-PCR). The sensitivities of the individual studies ranged from 61% to 100%, and specificities ranged from 11% to 100%. The pooled sensitivities of PCR in smears were 0.95 (95% CI, 0.90 to 0.98), and the specificity was 0.91(95% CI, 0.70 to 0.98). In general population, estimates were lower in aspirates, skin biopsies and swab samples with 0.90 (95% CI, 0.80 to 0.95) and 0.87 (95% CI, 0.76 to 0.94) for sensitivity and specificity, respectively. The specificity was lower in consecutive studies, at 0.88 (95% CI, 0.59 to 0.98) and its CI were wider.; ; ; Conclusions/Significance ; No statistically significant differences between the accuracy in smears, aspirate, skin biopsies or swabs samples were observed. Therefore, a simple smear sample run by PCR, instead more invasive samples, may be enough to obtain a positive diagnosis of CL. The results for PCR in all samples type confirm previous reports that consider PCR as the most accurate method for the diagnosis of CL.",14,,,https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0007981,http://dx.doi.org/10.1371/journal.pntd.0007981,0,31961871,10.1371/journal.pntd.0007981,3002449752,,001-337-304-101-856; 008-522-439-894-530; 008-900-970-749-085; 018-841-953-910-549; 023-040-771-043-430; 025-000-812-547-085; 033-408-743-669-263; 039-011-209-100-758; 040-767-899-483-973; 041-634-245-629-934; 054-618-164-136-937; 056-091-598-218-934; 056-290-016-331-657; 057-075-056-237-870; 057-807-417-390-282; 072-082-641-659-897; 077-331-595-258-318; 079-673-667-617-563; 096-410-305-571-096; 103-450-062-114-138; 134-440-680-112-290; 163-222-072-721-718; 172-701-997-244-794,0
096-148-714-847-216,United States,20470525,Springer Science + Business Media,"Perioperative medicine (London, England)",Technical and clinical evaluation of a closed loop TIVA system with SEDLine TM spectral density monitoring: Multicentric prospective cohort study,Spectral density; Hemodynamics; Prospective cohort study; Propofol; Anesthetic; Remifentanil; Elective surgery; Anesthesia; Medicine; Control theory,2020-01-09,2020,journal article,Closed loop; Propofol; Remifentanil; SEDline; Spectral density; Total intravenous anesthesia,,1,1,,Claudia Castellanos Peñaranda; Fabian David Casas Arroyave; Francisco Javier Gómez; Paola A. Pinzón Corredor; Juan Manuel Fernández; Marcela Velez Botero; Juan D. Bohórquez Bedoya; Carlos Marulanda Toro,"Closed loop total intravenous anesthesia is a technique in which the patient’s hemodynamic and anesthetic depth variables are monitored, and based on this information, a computer controls the infusion rate of drugs to keep them within pre-established clinical parameters. To describe the technical and clinical performance of a closed loop system for total intravenous anesthesia with propofol and remifentanil, using the SEDLineTM monitor Multicentric prospective cohort study Surgery room ASA I-II undergoing elective surgery The authors designed a closed loop system that implements a control algorithm based on anesthetic depth monitoring and the Patient State Index (PSITM) of the SEDLine monitor for propofol, and on hemodynamic variables for remifentanil. The measurement of clinical performance was made based on the percentage of PSITM maintenance time in the range 20–50. Precision analysis was evaluated by measuring median performance error (MDPE) can be defined as the median difference between actual and desired values, which refers to the degree of precision in which the controller is able to maintain the control variable within the objective set by the anesthesiologist; it represents the direction (over-prediction or under-prediction) of performance error (PE) rather than size of errors, which is represented by MDAPE, median absolute percentage error, Wobble index, which is used for measuring the intrasubject variability in performance error. Data were obtained from 93 patients in three healthcare centers. The percentage of PSITM maintenance time in the 20–50 range was 92% (80.7–97.0). MDPE was 10.7 (− 11.0–18.0), MDAPE 21.0 (14.2–26.8) and wobble 10.7 (7.0–16.9). No adverse surgical or anesthetic events were found. The closed loop total intravenous anesthesia system with SEDLine developed by the authors was used without major complication and appear to be feasible its use in clinical performance.",9,,,https://link.springer.com/article/10.1186%2Fs13741-019-0130-2 https://www.ncbi.nlm.nih.gov/pubmed/31921411,http://dx.doi.org/10.1186/s13741-019-0130-2,0,31921411,10.1186/s13741-019-0130-2,3000123002,,005-044-328-466-901; 007-011-055-465-699; 010-584-801-081-985; 012-912-417-103-046; 014-935-659-761-353; 020-902-117-451-904; 022-887-017-140-826; 023-903-317-479-243; 029-744-240-491-449; 032-445-083-289-834; 034-485-343-384-782; 039-571-033-519-680; 040-332-556-353-031; 042-262-896-984-202; 043-408-460-592-211; 053-321-794-224-911; 053-463-825-981-557; 057-603-956-847-646; 062-852-850-549-622; 065-501-643-218-120; 071-387-177-847-595; 073-329-328-008-340; 073-940-262-378-272; 082-755-884-925-201; 090-349-381-805-773; 095-918-993-399-103; 096-477-078-945-962; 099-599-413-375-560; 110-729-523-979-129; 118-890-240-481-699; 138-807-568-944-904; 161-187-259-194-977,0
097-325-151-893-614,United States,13616137; 1469493x; 14651858,John Wiley and Sons Ltd,Cochrane Database of Systematic Reviews,Interventions for chronic pruritus of unknown origin,Intensive care medicine; Psychological intervention; Chronic pruritus; Medicine,2020-01-25,2020,journal article,,,1,CD013128,,Andrea Andrade; Chii Yang Kuah; Juliana Esther Martin-Lopez; Shunjie Chua; Volha Shpadaruk; Gloria Sanclemente; Juan Va Franco,"<AbstractText Label=""BACKGROUND"">Pruritus is a sensation that leads to the desire to scratch; its origin is unknown in 8% to 15% of affected patients. The prevalence of chronic pruritus of unknown origin (CPUO) in individuals with generalised pruritus ranges from 3.6% to 44.5%, with highest prevalence among the elderly. When the origin of pruritus is known, its management may be straightforward if an effective treatment for the causal disease is available. Treatment of CPUO is particularly difficult due to its unknown pathophysiology.</AbstractText>;           <AbstractText Label=""OBJECTIVES"">To assess the effects of interventions for CPUO in adults and children.</AbstractText>;           <AbstractText Label=""SEARCH METHODS"">We searched the following up to July 2019: Cochrane Skin Group Specialised Register, CENTRAL, MEDLINE, Embase, and trials registries. We checked the reference lists of included studies for additional references to relevant trials.</AbstractText>;           <AbstractText Label=""SELECTION CRITERIA"">We sought to include randomised controlled trials and quasi-randomised controlled trials that assessed interventions for CPUO, as defined in category VI ('Other pruritus of undetermined origin, or chronic pruritus of unknown origin') of the International Forum for the Study of Itch (IFSI) classification, in children and adults. Eligible interventions were non-pharmacological or topical or systemic pharmacological interventions, and eligible comparators were another active treatment, placebo, sham procedures, or no treatment or equivalent (e.g. waiting list).</AbstractText>;           <AbstractText Label=""DATA COLLECTION AND ANALYSIS"">We used standard methodological procedures expected by Cochrane. Our primary outcomes were 'Patient- or parent-reported pruritus intensity' and 'Adverse events'. Our secondary outcomes were 'Health-related quality of life', 'Sleep disturbances', 'Depression', and 'Patient satisfaction'. We used GRADE to assess the certainty of evidence.</AbstractText>;           <AbstractText Label=""MAIN RESULTS"">We found there was an absence of evidence for the main interventions of interest: emollient creams, cooling lotions, topical corticosteroids, topical antidepressants, systemic antihistamines, systemic antidepressants, systemic anticonvulsants, and phototherapy. We included one study with 257 randomised (253 analysed) participants, aged 18 to 65 years; 60.6% were female. This study investigated the safety and efficacy of three different doses of oral serlopitant (5 mg, 1 mg, and 0.25 mg, once daily for six weeks) compared to placebo for severe chronic pruritus; 25 US centres participated (clinical research centres and universities). All outcomes were measured at the end of treatment (six weeks from baseline), except adverse events, which were monitored throughout. A pharmaceutical company funded this study. Fifty-five per cent of participants suffered from CPUO, and approximately 45% presented a dermatological diagnosis (atopic dermatitis/eczema 37.3%, psoriasis 6.7%, acne 3.6%, among other diagnoses). We unsuccessfully attempted to retrieve outcome data from study authors for the subgroup of participants with CPUO. Participants had pruritus for six weeks or longer. Total study duration was 10 weeks. Participants who received serlopitant 5 mg may have a greater rate of relief of patient-reported pruritus intensity as measured by the visual analogue scale (VAS; a reduction in VAS score indicates improvement) compared to placebo (126 participants, risk ratio (RR) 2.06, 95% confidence interval (CI) 1.27 to 3.35; low-certainty evidence). We are uncertain of the effects of serlopitant 5 mg compared to placebo on the following outcomes due to very low-certainty evidence: adverse events (127 participants; RR 1.48, 95% CI 0.87 to 2.50); health-related quality of life (as measured by the Dermatology Life Quality Index (DLQI); a higher score indicates greater impairment; 127 participants; mean difference (MD) -4.20, 95% CI -11.68 to 3.28); and sleep disturbances (people with insomnia measured by the Pittsburgh Sleep Symptom Questionnaire-Insomnia (PSSQ-I), a dichotomous measure; 128 participants; RR 0.49, 95% CI 0.24 to 1.01). Participants who received serlopitant 1 mg may have a greater rate of relief of patient-reported pruritus intensity as measured by VAS compared to placebo; however, the 95% CI indicates that there may also be little to no difference between groups (126 participants; RR 1.50, 95% CI 0.89 to 2.54; low-certainty evidence). We are uncertain of the effects of serlopitant 1 mg compared to placebo on the following outcomes due to very low-certainty evidence: adverse events (128 participants; RR 1.45, 95% CI 0.86 to 2.47); health-related quality of life (DLQI; 128 participants; MD -6.90, 95% CI -14.38 to 0.58); and sleep disturbances (PSSQ-I; 128 participants; RR 0.38, 95% CI 0.17 to 0.84). Participants who received serlopitant 0.25 mg may have a greater rate of relief of patient-reported pruritus intensity as measured by VAS compared to placebo; however, the 95% CI indicates that there may also be little to no difference between groups (127 participants; RR 1.66, 95% CI 1.00 to 2.77; low-certainty evidence). We are uncertain of the effects of serlopitant 0.25 mg compared to placebo on the following outcomes due to very low-certainty evidence: adverse events (127 participants; RR 1.29, 95% CI 0.75 to 2.24); health-related quality of life (DLQI; 127 participants; MD -5.70, 95% CI -13.18 to 1.78); and sleep disturbances (PSSQ-I; 127 participants; RR 0.60, 95% CI 0.31 to 1.17). The most commonly reported adverse events were somnolence, diarrhoea, headache, and nasopharyngitis, among others. Our included study did not measure depression or patient satisfaction. We downgraded the certainty of evidence for all outcomes due to indirectness (only 55% of study participants had CPUO) and imprecision. We downgraded outcomes other than patient-reported pruritus intensity a further level due to concerns regarding risk of bias in selection of the reported result and some concerns with risk of bias due to missing outcome data (sleep disturbances only). We deemed risk of bias to be generally low.</AbstractText>;           <AbstractText Label=""AUTHORS' CONCLUSIONS"">We found lack of evidence to address our review question: for most of our interventions of interest, we found no eligible studies. The neurokinin 1 receptor (NK1R) antagonist serlopitant was the only intervention that we could assess. One study provided low-certainty evidence suggesting that serlopitant may reduce pruritus intensity when compared with placebo. We are uncertain of the effects of serlopitant on other outcomes, as certainty of the evidence is very low. More studies with larger sample sizes, focused on patients with CPUO, are needed. Healthcare professionals, patients, and other stakeholders may have to rely on indirect evidence related to other forms of chronic pruritus when deciding between the main interventions currently used for this condition.</AbstractText>;           <CopyrightInformation>Copyright © 2020 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd.</CopyrightInformation>",1,,,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013128.pub2/abstract,http://dx.doi.org/10.1002/14651858.cd013128.pub2,0,31981369,10.1002/14651858.cd013128.pub2,3001544271,,000-720-805-749-20X; 001-096-618-054-314; 001-512-495-667-435; 001-618-374-381-858; 001-897-864-335-648; 001-960-476-679-384; 001-979-764-991-890; 002-480-780-443-732; 002-761-747-302-488; 002-868-836-264-479; 003-956-742-486-712; 004-787-657-801-265; 004-926-924-534-614; 005-663-818-775-064; 006-961-439-829-685; 007-169-491-648-707; 007-397-271-288-679; 008-888-782-855-148; 009-659-686-885-176; 010-168-180-090-551; 010-275-232-687-362; 010-330-638-453-717; 010-404-665-509-092; 010-986-300-154-332; 011-830-188-107-215; 012-494-468-979-778; 012-535-603-925-800; 012-817-542-496-154; 013-780-696-077-542; 013-946-736-872-784; 014-867-005-028-396; 015-930-150-272-884; 016-221-355-748-182; 016-344-484-891-022; 016-601-745-253-198; 016-718-354-115-715; 017-164-048-681-633; 017-212-633-422-353; 017-318-291-647-338; 018-075-080-973-697; 018-172-221-915-779; 018-845-369-201-629; 019-167-835-996-972; 019-272-761-025-368; 020-373-738-841-795; 020-867-263-042-470; 021-842-429-934-504; 021-944-720-672-500; 022-167-331-666-679; 023-953-374-657-523; 023-954-057-266-670; 024-428-381-179-778; 025-798-332-596-676; 025-859-911-386-805; 025-999-308-359-006; 026-459-665-793-192; 026-702-837-981-980; 027-046-769-229-247; 027-169-738-960-723; 027-313-968-238-430; 027-799-271-878-094; 028-407-386-896-373; 029-655-600-118-097; 029-800-144-894-989; 029-967-580-717-73X; 029-998-532-086-12X; 030-336-679-561-426; 030-518-609-189-03X; 030-879-261-513-292; 031-081-481-738-77X; 031-409-298-090-190; 031-717-048-945-55X; 031-877-069-806-092; 032-410-152-541-088; 033-806-598-901-241; 034-392-927-146-806; 034-815-106-895-246; 035-557-074-272-673; 037-693-080-934-177; 037-799-786-316-093; 037-929-672-211-886; 040-085-956-229-667; 040-656-187-288-422; 042-379-029-356-338; 043-723-841-386-323; 043-774-407-986-30X; 044-036-465-464-448; 044-233-897-262-615; 044-425-087-167-807; 044-856-095-242-461; 046-142-161-646-316; 046-728-120-745-594; 046-737-243-414-36X; 047-101-459-380-894; 047-621-758-783-780; 047-989-945-120-603; 048-820-306-655-946; 048-834-190-271-330; 049-480-696-398-751; 050-000-535-682-903; 050-580-874-289-501; 051-612-876-936-688; 053-394-773-720-227; 053-725-050-422-086; 053-893-246-227-306; 054-197-521-403-990; 054-481-620-917-653; 054-786-449-893-010; 055-603-736-856-492; 057-393-900-411-488; 057-583-959-582-537; 057-810-669-154-734; 058-044-971-877-710; 058-249-072-147-115; 058-343-166-712-534; 058-511-842-184-301; 058-793-130-607-95X; 059-970-933-269-166; 060-394-644-583-936; 060-430-264-551-452; 062-577-452-675-232; 063-136-496-343-865; 063-147-274-971-536; 063-536-507-070-659; 064-580-409-608-499; 064-732-720-487-802; 065-029-971-162-123; 065-276-866-388-727; 065-511-274-289-212; 065-809-821-651-404; 065-911-563-333-972; 068-633-443-954-346; 069-474-106-299-724; 070-447-957-206-276; 071-152-448-563-37X; 071-728-862-040-725; 072-464-112-318-599; 072-920-720-480-254; 073-155-211-080-835; 074-825-175-841-890; 075-320-261-946-288; 075-375-483-022-046; 076-870-237-628-362; 077-148-338-665-662; 078-825-455-461-396; 080-729-512-647-720; 086-409-586-432-63X; 087-907-054-977-522; 089-992-204-102-257; 090-842-014-429-875; 092-754-251-528-829; 094-307-287-341-642; 096-107-862-497-499; 096-162-281-636-309; 098-091-658-712-330; 101-797-761-675-890; 102-630-856-862-703; 102-889-472-535-140; 104-095-614-309-025; 108-389-959-253-265; 108-728-681-323-110; 110-416-053-986-158; 112-640-433-281-941; 116-545-673-782-550; 117-333-792-714-587; 117-540-493-521-808; 119-627-398-099-308; 120-352-443-293-325; 122-287-275-830-519; 124-379-916-869-175; 125-330-173-682-666; 125-423-259-035-809; 128-779-869-122-279; 129-556-849-963-941; 133-881-583-060-350; 137-031-473-827-367; 137-627-635-256-024; 138-838-285-469-447; 143-359-084-268-000; 147-204-957-174-484; 158-365-360-654-836; 171-985-821-171-043; 176-096-861-406-400; 179-886-741-503-850; 197-138-862-413-842,0
101-529-285-472-580,Venezuela,01215612; 19006004,Universidad de los Andes,Colombia Internacional,"La dimensión ideológica de los discursos anticorrupción en Colombia y Ecuador, 2002-2017",Sociology; Humanities; Public administration,2020-01-01,2020,journal article,,,101,187,218,Blendi Kajsiu; Ana Maria Restrepo Ossa,,,,,http://dx.doi.org/10.7440/colombiaint101.2020.07,http://dx.doi.org/10.7440/colombiaint101.2020.07,0,,10.7440/colombiaint101.2020.07,2998922063,,002-741-290-023-025; 004-672-744-377-909; 008-642-672-279-450; 043-553-965-095-705; 098-578-100-133-510; 111-994-850-039-541; 140-632-437-859-769; 163-763-745-980-549; 176-185-414-118-110; 176-499-453-082-378,0
105-176-720-992-324,,01200976,,Revista Interamericana de BibliotecologÃ­a,Las joyas del archivo Santa Laura Montoya Upegui (Jericó 1874-Medellín 1949): historia de la recuperación de su acervo documental,Sociology; Library science; Mysticism; Printing press; Documentary collection; Missiology; SAINT; Art history,2020-01-01,2020,journal article,,,1,1,,María Eugenia Osorio; Carmen Sofía Camacho; Luis Carlos Toro Tamayo,"The aim of this article is to investigate the process of recovery, restoration and classification of the documentary collection of Laura Montoya Upegui, better known as Madre Laura. She founded the Comunidad Misionera de Maria Inmaculada y Santa Catalina de Sena and she was canonized in 2013. The archive houses approximately 28,000 pages written by the author, among which there are all her original works. The history of the recovery of the Archive begins in 1949, when the writer dies, and since then it has been enriching and modernizing. The organization of documents are divided into the areas that involve the intellectual profile of this saint: theology, mysticism, anthropology, missiology, literature, among others. On the other hand, the archive conserves the books of her personal library, a photographic archive and the collection of books and magazines that the missionary edited and published in her own printing press, called Santa Teresita.",43,,,https://aprendeenlinea.udea.edu.co/revistas/index.php/RIB/article/view/340516/20795488,https://aprendeenlinea.udea.edu.co/revistas/index.php/RIB/article/view/340516/20795488,0,,,2996806988,,,0
114-697-336-621-270,Netherlands,09204105,Elsevier,Journal of Petroleum Science and Engineering,A microfluidic study to investigate the effect of magnetic iron core-carbon shell nanoparticles on displacement mechanisms of crude oil for chemical enhanced oil recovery,Porous medium; Wetting; Chemistry; Particle size; Viscous fingering; Enhanced oil recovery; Polydimethylsiloxane; Capillary number; Chemical engineering; Pulmonary surfactant; Petroleum engineering,2020-01-01,2020,journal article,,"Departamento Administrativo de Ciencia, Tecnología e Innovación (COLCIENCIAS); Consejo Nacional de Investigaciones Científicas y Técnicas; Agencia Nacional de Promoción Científica y Tecnológica; Agencia Nacional de Promoción Científica y Tecnológica; Universidad Nacional de Colombia, Sede Manizales; Universidad de Granada; Ankara Numune Egitim ve Arastirma Hastanesi; Ministerio de Ciencia, Innovación y Universidades; Federación Española de Enfermedades Raras",,106589,,Stefanía Betancur; Carol M. Olmos; Maximiliano S. Pérez; Betiana Lerner; Camilo A. Franco; Masoud Riazi; Jaime Gallego; Francisco Carrasco-Marín; Farid B. Cortés,"Abstract The main objective of this work is to evaluate the effect of the simultaneous use of a surfactant mixture and magnetic iron core-carbon shell nanoparticles on oil recovery via a microfluidic study based on the rock-on-a-chip technology. The surfactant solution used for all experiments was prepared based on a field formulation and consisted of a mixture of a hydrophilic and a lipophilic surfactant. Magnetic iron core-carbon shell nanoparticles with a mean particle size of 60 nm and a surface area of 123 m2 g−1 were employed. The displacement experiments consisted of waterflooding, surfactant flooding and nanoparticle-surfactant flooding and were performed using PDMS (polydimethylsiloxane)-glass microdevices type random network. The characteristics and design of the microfluidic device allowed to emulate a mixed wettability of a porous medium. Then, the oil was displaced by injecting the solution at a constant injection rate, until steady-state conditions were obtained. Furthermore, the effect of three injection rates corresponding to 0.1 ft day−1, 1 ft day−1, and 10 ft day−1 was investigated. The increase in the injection rate favored the oil recovery percentage. In addition, for all injection rates, the oil recovery decreased in the following order: nanoparticle-surfactant flooding > surfactant flooding > waterflooding. The nanoparticle-surfactant system at the injection rate of 1.9 μL min−1 presented the highest oil recovery (i.e., 84%). Likewise, nanoparticle-surfactant flooding showed a more stable displacement front and consequently, the highest capillary number among the injection fluids. Oil recovery by waterflooding was the lowest among the evaluated systems due to the viscous fingering phenomena under different injection rates. In addition, it can be observed that for all injection rates, the presence of the surfactant mixture and nanoparticles reduce the viscous fingering effect. The results can be used to visually and quantitatively analyze the role of the simultaneous use of nanoparticles with surfactants in enhanced oil recovery processes.",184,,,https://www.sciencedirect.com/science/article/pii/S0920410519310101,http://dx.doi.org/10.1016/j.petrol.2019.106589,0,,10.1016/j.petrol.2019.106589,2981203655,,000-674-181-429-253; 005-940-152-907-341; 011-250-311-175-387; 012-883-919-740-408; 014-702-065-176-985; 018-560-759-235-745; 019-282-826-961-069; 023-702-918-335-148; 024-561-468-209-370; 025-952-972-387-875; 027-531-784-272-509; 027-786-198-196-720; 029-536-512-179-47X; 032-126-779-414-324; 034-811-609-310-176; 036-527-369-047-165; 039-092-223-262-590; 041-021-095-489-38X; 045-091-205-023-935; 046-094-428-754-698; 048-017-954-521-564; 051-214-306-762-31X; 054-578-830-230-471; 054-663-817-470-039; 057-666-973-991-357; 058-506-077-944-257; 059-271-798-912-987; 059-503-638-320-421; 061-542-227-495-837; 062-409-894-844-811; 069-330-885-288-553; 069-520-292-544-723; 070-725-260-854-086; 074-545-802-300-094; 076-962-327-520-29X; 077-937-789-035-75X; 085-110-234-609-267; 085-936-254-558-103; 087-352-819-185-871; 090-899-239-127-840; 095-055-981-479-527; 095-713-007-742-821; 114-629-408-923-645; 119-545-904-725-174; 120-286-906-709-268; 133-651-475-598-782; 134-940-888-965-285; 144-990-618-309-761; 172-036-827-767-210; 180-476-559-974-756,2
117-925-537-830-360,,24056650,Elsevier BV,Emerging Contaminants,Use of simulated sunlight radiation and hydrogen peroxide in azithromycin removal from aqueous solutions: Optimization & mineralization analysis,Environmental chemistry; Effluent; Aqueous solution; Chemistry; Peroxide; Bacteria; Hydrogen peroxide; Sewage treatment; Mineralization (biology); Pollutant,2020-01-01,2020,journal article,,Universidad de Antioquia,,53,61,Pablo Andrés Cano; Marcela Jaramillo-Baquero; Henry Zúñiga-Benítez; Yudy A. Londoño; Gustavo A. Peñuela,"Abstract Azithromycin (AZT) is a broad-spectrum antibiotic from the group of macrolides that acts against several Gram-positive and Gram-negative bacteria, which has promoted its use in the treatment of different respiratory and sexually transmitted diseases. However, its presence in environmental matrices and in the effluents of conventional wastewater treatment plants has been evidenced in recent years, which reflects the need to develop new treatment alternatives that allow its total removal and minimize the eventual adverse effects, selection of resistant bacterial strains, associated with its presence in water bodies. Simulated sunlight radiation and H2O2 were used to remove AZT from water assessing the effects of operational parameters like the solution initial pH and the peroxide concentration. Results indicate that hydroxyl free radical is the main responsible for pollutant removal but acidic solution conditions and larger H2O2 doses negatively affect OH• generation under the evaluated experimental conditions. Pollutant removal was almost complete after 120 min of photo-treatment. In addition, reduction of the organic carbon content in the treated samples was ∼50.0%; and a significant increase of nitrates concentration in solution was evidenced.",6,,,https://www.sciencedirect.com/science/article/pii/S2405665019300332,http://dx.doi.org/10.1016/j.emcon.2019.12.004,0,,10.1016/j.emcon.2019.12.004,2996784871,,002-584-757-786-581; 002-605-723-846-769; 002-799-091-961-74X; 003-961-289-206-511; 010-938-000-626-813; 011-837-073-982-978; 011-897-266-884-527; 015-007-688-186-786; 018-262-174-839-863; 020-787-720-597-456; 021-470-754-025-211; 025-295-844-405-322; 027-836-559-256-227; 030-382-754-856-185; 031-104-425-416-900; 035-593-099-544-055; 037-231-293-819-395; 038-595-044-702-923; 038-812-936-109-330; 047-195-962-589-919; 048-439-914-386-556; 050-584-575-275-925; 057-857-767-425-399; 059-836-300-304-227; 060-931-239-470-920; 061-618-692-360-151; 063-120-757-961-56X; 063-278-310-451-74X; 064-792-294-588-305; 069-446-810-992-612; 069-561-549-228-12X; 080-479-773-926-147; 088-563-134-412-230; 091-633-815-476-415; 091-731-869-579-128; 111-589-724-208-835; 112-806-925-636-742; 117-288-820-138-442; 121-322-508-295-700; 123-460-954-777-740; 123-771-434-589-656; 131-656-828-085-991; 155-619-336-144-009; 156-166-943-977-042; 164-060-255-985-836; 165-162-508-622-915; 190-952-818-437-478; 191-647-973-836-204,0
119-392-200-070-953,United Kingdom,07423071; 14645491,Wiley-Blackwell,Diabetic Medicine,Management of type 2 diabetes using non‐insulin glucose‐lowering therapies: a critical appraisal of clinical practice guidelines with the AGREE II instrument,Internal medicine; Endocrinology; Critical appraisal; Intensive care medicine; Type 2 diabetes; Insulin; Clinical Practice; Diabetes mellitus; Medicine,2020-01-14,2020,journal article,,University of Toronto; CIHR; Diabetes Canada and the Heart and Stroke Richard Lewar Centre of Excellence,,,,W.M.J. Lam; Reem Al-Khalifah; Ivan D. Florez; L. Cruz‐Lopes; M.F. Sekercioglu; R. Couban; R. Fu; D.Z.I. Cherney; Nigar Sekercioglu,"<AbstractText Label=""AIM"" NlmCategory=""OBJECTIVE"">Type 2 diabetes is a major global epidemic affecting over 400 million people worldwide. The objective of this systematic review was to provide an overview of recommendations from clinical practice guidelines (guidelines) addressing non-insulin based pharmacological management of among non-pregnant adults in an outpatient setting, and critically appraise their methodological development.</AbstractText>;           <AbstractText Label=""METHODS"" NlmCategory=""METHODS"">We systematically searched MEDLINE and Embase databases, for relevant guidelines using the Ovid interface. We scanned the bibliographies of all eligible guidelines for additional relevant citations. Teams of two reviewers, independently and in duplicate, screened titles and abstracts and potentially eligible full text reports to determine eligibility and appraised the reporting quality of guidelines using the Advancing Guideline Development, Reporting and Evaluation in Health Care instrument II (AGREE II) instrument.</AbstractText>;           <AbstractText Label=""RESULTS"" NlmCategory=""RESULTS"">Our search yielded 11264 unique citations, of which 124 were retrieved for full-text review; 17 guidelines proved eligible. The highest scoring AGREE domain was 'clarity of presentation' (66%; range 7-92%), followed by 'scope and purpose' (58%; range 25-92%), 'editorial independence' (55%; range 0-91%), 'stakeholder involvement' (45%; range 11-90%) and 'rigour of development' (43%; range 4-92%). The poorest domain was 'applicability' (37%; range 6-84%). The guidelines authored by the World Health Organization group achieved the highest AGREE overall score.</AbstractText>;           <AbstractText Label=""CONCLUSIONS"" NlmCategory=""CONCLUSIONS"">Most of the guidelines provided recommendations with a local jurisdictional focus and showed significant variation in the quality. Nevertheless, only a small number of those scored well overall.</AbstractText>;           <CopyrightInformation>© 2020 Diabetes UK.</CopyrightInformation>",,,,https://onlinelibrary.wiley.com/doi/abs/10.1111/dme.14231?af=R,http://dx.doi.org/10.1111/dme.14231,0,31943344,10.1111/dme.14231,2999432167,,003-038-143-744-57X; 003-681-838-602-335; 003-985-062-053-561; 004-533-649-103-600; 004-745-062-336-100; 005-946-305-843-172; 007-498-079-447-601; 016-142-391-049-631; 020-518-376-803-808; 025-515-788-633-700; 032-896-581-159-621; 038-910-189-974-425; 048-381-537-077-635; 058-432-780-495-52X; 059-249-524-819-389; 059-387-921-733-533; 060-901-340-848-791; 062-996-446-802-06X; 077-557-058-901-058; 079-684-021-182-162; 092-063-145-100-658; 109-538-124-463-793; 135-454-723-762-503; 155-794-623-474-05X; 185-545-776-245-312,0
119-607-608-032-008,Netherlands,00759511; 18735851,Urban und Fischer Verlag Jena,Limnologica,"Root-associated biofilms of Eichhornia heterosperma Alexander, 1939 contribute to the remediation of the tropical reservoir Porce II, Colombia",Environmental chemistry; Macrophyte; Nutrient; Ecology; Eichhornia; Sediment; Sedimentation; Environmental remediation; Phytoremediation; Microbial population biology; Biology,2020-01-01,2020,journal article,,"Universidad de Antioquia; Empresas Públicas de Medellin (EPM), Universidad Nacional de Colombia",,125745,,Heazel Grajales; Néstor Aguirre; Francisco Mauricio Toro; Jürgen Marxsen; Elisabeth Pohlon,"Abstract Two key factors were identified that enhance remediation of a hypereutrophic reservoir colonised by Eichhornia heterosperma Alexander, 1939. These factors are the high abundance of the microbial community in root-associated biofilms and their high extracellular enzyme activity (EEA). The capacity of macrophytes for nutrients removal has been widely acknowledged. However, there has been little discussion on the role of root-associated biofilms in enhancing phytoremediation. We determined nutrient levels across the reservoir quarterly during two years. We assessed the structure of the microbial community in water, root-associated biofilms, and sediments along with their phosphatase and β-glucosidase activities. We hypothesised that reservoir remediation is enhanced by increased nutrient remineralisation and bioavailability, arising from EEA in root-associated biofilms attached to E. heterosperma. Sedimentation removed 51 % of the total nitrogen (TN) and 85 % of the total phosphorus (TP) external load. E. heterosperma and its root-associated biofilms removed extra 8 % TN and 7 % TP. The abundance of the microbial community in root-associated biofilms was generally higher than in water and sediment, being dominated by Alphaproteobacteria and Betaproteobacteria. The EEA in root-associated biofilms ranged 117-1760 µmol g-1 wet weight h-1 for phosphatase and 107-676 µmol g-1 wet weight h-1 for β-glucosidase, indicating high mineralisation rates. These results showed that the microbial community in root-associated biofilms favours reservoir remediation by supplying mineralised nutrients to algae and macrophytes, but the permanent introduction of high nutrient loads exceeds the reservoir capacity for remediation. Improving the trophic state of the reservoir requires thus long-term strategies at basin scale for reducing the nutrient loads.",80,,,https://www.sciencedirect.com/science/article/abs/pii/S0075951118302317,http://dx.doi.org/10.1016/j.limno.2019.125745,0,,10.1016/j.limno.2019.125745,2994782694,,002-344-379-025-562; 004-294-496-319-578; 006-957-125-658-391; 015-751-025-865-53X; 017-975-204-302-56X; 021-450-923-192-531; 023-228-591-112-907; 023-724-009-066-478; 028-022-110-838-458; 033-354-100-517-927; 035-230-135-430-491; 040-779-968-131-33X; 049-860-044-981-25X; 055-200-850-179-53X; 055-474-972-605-363; 056-121-889-760-461; 060-475-392-801-259; 064-764-561-367-470; 071-131-129-890-426; 072-026-916-453-833; 074-335-432-057-406; 074-889-907-952-856; 076-287-019-038-665; 082-982-423-025-374; 088-868-393-757-265; 091-663-549-469-251; 091-824-381-269-946; 099-098-831-523-786; 101-614-715-619-818; 108-073-179-826-762; 108-516-754-439-890; 121-202-324-806-936; 122-698-987-948-132; 133-891-132-328-417; 135-526-303-709-706; 163-882-041-075-219; 169-607-559-923-667,0
119-656-789-962-036,,01200976,,Revista Interamericana de BibliotecologÃ­a,El quehacer de la memoria en tiempos de cambio social,Sociology; Humanities; Library science; Memoria,2020-01-01,2020,journal article,,,1,,,Yhoban Camilo Hernandez,,43,,,https://aprendeenlinea.udea.edu.co/revistas/index.php/RIB/article/view/340787/20795329,https://aprendeenlinea.udea.edu.co/revistas/index.php/RIB/article/view/340787/20795329,0,,,2998680500,,,0
122-962-271-521-926,,,,,"La economía antioqueña antes de la Independencia, 1760-1821",Economy; Economic sector; Economics; Gold mining; Population; Historiography; Domestic market,2020-01-01,2020,,,,1,,,Juan Carlos Jurado Jurado; Rodrigo de J. García Estrada,"Based on the most important historiography, this article reviews the economic history of the region of Antioquia during the period 1760-1810, showing the most significant changes in the structures and, particularly, in the dynamic relations between different economic sectors. Bearing in mind the differentiation and specialization of the different Neogranadine regions, the particularities of the Antioquia case are evident, characterized by the sustained growth of the population, an accelerated process of miscegenation, the decomposition of slavery, and the predominance of a free and multiethnic population. It was precisely this economic agent which allowed to understand the development of gold mining in the hands of the so-called “mazamorreros”, whose consumption capacity explains the proliferation of people engaged in trade and, in turn, the creation of an internal market.",7,,,https://revistas.utadeo.edu.co/index.php/TyE/article/view/1561,https://revistas.utadeo.edu.co/index.php/TyE/article/view/1561,0,,,2997025761,,,0
127-060-331-301-589,,01200976,,Revista Interamericana de BibliotecologÃ­a,Consideraciones interdisciplinares sobre el estado de la terminología archivística en Colombia,Sociology; Library science; Constitution; Panorama; Portuguese; Terminology; Information science,2020-01-01,2020,journal article,,,1,1,,María Teresa Múnera Torres; María Cristina Betancur Roldán; John Jairo Giraldo Ortiz,"The experience of an interdisciplinary work between terminologists, archivists and librarians is presented here. In the first place, an introduction to the subject of archival terminology is made. Its status, reflected in an inventory of reference terminological resources, is shown in the three working languages of greatest use by archival experts in Colombia: Spanish, English and Portuguese. Secondly, the working methodology is applied for the constitution of terminology databases. Thirdly, the main results are shown: A monolingual terminology database with English and Portuguese equivalences; a system of archival concepts, and the main features of the terms of this area from a brief qualitative and quantitative analysis. Finally, the reflections arising from the collaborative work process among experts of different disciplines are presented as a conclusion. Likewise, some considerations on the panorama of archival terminology and its projection in the country are presented",43,,,http://aprendeenlinea.udea.edu.co/revistas/index.php/RIB/article/view/339271/20795002,http://dx.doi.org/10.17533/udea.rib.v43n1ei1,0,,10.17533/udea.rib.v43n1ei1,2995891093,,,0
128-573-432-657-365,South Africa,00068241,National Botanical Institute,Bothalia,"Energía calórica, biomasa y estructura de los macroinvertebrados acuáticos en la reserva La Nitrera, Concordia, Antioquia, Colombia",River ecosystem; Invertebrate; Aquatic ecosystem; Ecology; Biomass; Wet season; Trophic level; Biology; Dry season,2020-01-01,2020,journal article,,,1,29,36,Julián Andrés Ruiz Toro; Néstor Jaime Aguirre Ramírez; Juan Pablo Serna Lopez; Esnedy Hernández Atilano; Fabio de Jesús Vélez Macías,"The reservoir La Nitrera is located at 2140 m.a.s.l. in Concordia´s town, in the Antioquia´s department (Colombia) and is the only source of water supply in the municipality. The operation of a reservoir on a lotic system generates affectations in the structure and assembly of aquatic ecosystems. The purpose of this research was to analyze the distribution of biomass of aquatic macroinvertebrates before and after of the reservoir to determine the impact of it on the hydrobiological communities. For this purpose, the hydrobiological variables were analyzed in dry season, rain season and in different periods of transition between 2016 and 2017 in four monitoring stations, making the determination, counting and defining the trophic role of aquatic macroinvertebrates, in addition to a thermogravimetric analysis (TGA) of the biomass. With the obtained information, a trophic model and an analysis of the loss of the available caloric energy of the biomass (TGA) was made. The results showed that the communities of aquatic macroinvertebrates had a similar modularity between them in the stations before the reservoir and different modularity in the station after the reservoir. Through the modularity index (Ghepi model) and the TGA analysis, it could be established that the reservoir generates an alteration in the trophic chain of aquatic macroinvertebrate communities.",25,,,https://revistas.unal.edu.co/index.php/actabiol/article/view/76435/pdf,http://dx.doi.org/10.15446/abc.v25n1.76435,0,,10.15446/abc.v25n1.76435,2994662060,,,0
135-935-025-006-062,Brazil,22387854,Elsevier Editora Ltda,Journal of materials research and technology,Formation mechanisms of chitosan-silica hybrid materials and its performance as solid support for KR-12 peptide adsorption: Impact on KR-12 antimicrobial activity and proteolytic stability,Adsorption; Catalysis; Chemistry; Hybrid material; Peptide; Chitosan; Molecule; Chemical engineering; Antimicrobial; Hydrophobic effect,2020-01-01,2020,journal article,,"Departamento Administrativo de Ciencia, Tecnología e Innovación (COLCIENCIAS); Código; Código",1,890,901,Johnatan Diosa; Fanny Guzmán; Claudia Bernal; Monica Mesa,"Abstract Chitosan-silica materials offer a specific environment for the adsorption of biofunctional molecules, such as the antimicrobial peptide KR-12. The objective here is to rationalize the changes in the physicochemical properties of these chitosan-silica materials in function of the synthesis pH, using 0.02 w/v % chitosan as catalyst and aggregation agent and, to correlate these characteristics with the loading/delivery and activity/stability of KR-12 antimicrobial peptide. The CS-6 material, prepared at pH 6, exhibits higher surface area (745 m2/g) and total pore volume (0.58 cm3/g) due to the lower incorporation of chitosan swollen chains (9.36 wt %). Higher pHs produced denser materials (CS-7 and CS-8) with higher entangled chitosan incorporated (> 17 wt%). Adsorption of KR-12 peptide was found to take two different mechanisms depending on the chitosan-silica support, Langmuir-type for CS-6 material and Freundlich-type for CS-7 and CS-8 materials. According to the KR-12 release profiles, more hydrophobic interactions were observed in the CS-6 material exposing Lys and Arg residues from the peptide towards the material surface. This was correlated with the higher antimicrobial activity of this material against S. aureus strain (MIC = 128 μg/mL). Additionally, the KR-12 peptide adsorbed in the CS-6 hybrid support is 34 % more protected from the proteolytic action of α-chymotrypsin than the free one. In conclusion, the proposed models of different porous environments in the studied chitosan-silica materials supports the KR-12 peptide loading/delivery mechanisms, leading to biofunctionalized solid antimicrobial materials exhibiting proteolytic stability. This knowledge is useful for designing new antibacterial materials for biomedical applications.",9,,,https://www.sciencedirect.com/science/article/pii/S2238785419310907,http://dx.doi.org/10.1016/j.jmrt.2019.11.029,0,,10.1016/j.jmrt.2019.11.029,2991625814,,001-391-145-248-849; 001-430-371-751-118; 003-941-492-969-604; 004-759-689-560-541; 006-754-603-846-46X; 008-010-393-329-384; 008-643-710-555-810; 009-764-717-072-288; 011-100-811-555-673; 011-269-522-509-690; 011-582-325-437-887; 011-937-880-219-475; 012-230-972-907-678; 016-273-639-851-557; 016-332-017-881-230; 019-679-478-470-225; 021-164-505-605-834; 021-772-620-436-641; 023-715-834-817-636; 025-495-106-759-723; 027-132-504-180-469; 029-196-437-783-221; 029-292-217-753-119; 029-764-962-992-585; 030-139-635-061-216; 030-410-543-085-54X; 034-507-265-028-057; 038-012-131-538-60X; 038-407-988-407-381; 039-824-548-234-513; 046-661-393-440-506; 047-323-876-004-826; 052-995-739-697-948; 053-085-018-526-093; 054-029-942-976-997; 055-050-763-148-988; 058-872-107-417-037; 063-773-298-921-742; 069-077-489-977-000; 071-216-743-447-11X; 073-848-222-008-179; 073-929-326-260-445; 078-822-774-954-258; 079-432-916-090-241; 082-299-660-237-235; 083-067-879-437-673; 089-584-631-943-509; 089-834-124-256-754; 105-341-476-657-669; 105-453-569-288-416; 106-061-386-767-178; 108-877-943-366-962; 114-426-579-390-935; 116-082-556-283-391; 116-790-440-358-926; 117-160-641-090-225; 118-489-931-088-369; 143-958-803-016-470; 152-024-786-790-356; 152-629-771-819-015; 159-932-220-840-607; 186-355-569-356-748,0
135-945-845-764-95X,,01202596,,Lecturas de EconomÃ­a,Sobre los determinantes de la sostenibilidad fiscal de los municipios en Colombia. El caso de Antioquia 2008-2017,Labour economics; Humanities; Economics,2020-01-24,2020,journal article,,,92,173,200,Jorge Barrientos Marín; Juan Felipe Quintero; Manuela Mendoza,"En este trabajo estamos interesados en establecer los determinantes de la sostenibilidad fiscal, entre ellas si las reglas de gasto, la denominada Ley 617 de 2000 coadyuvo a la promocion de la sostenibilidad de las finanzas publicas en los 125 municipios del departamento de Antioquia (Colombia) en el periodo 2008-2017. Para esto explotamos las heterogeneidades observables entre los 125 municipios de Antioquia en el periodo 2008-2017, debido a la endogeneidad de variables como deuda y el numero de empresas usamos un estimador Hausman y Taylor. Nuestros resultados indican que la ley es efectiva en el aumento del ingreso tributario y el gasto de inversion, pero no es efectiva en cuanto disminuir el gasto en funcionamiento; otras variables de caracteristicas de municipio como el numero de empresas y el endeudamiento preexistente son explicativas y predictores del comportamiento de los ingresos tributarios, el gasto en funcionamiento y el gasto de inversion.",,,,https://aprendeenlinea.udea.edu.co/revistas/index.php/lecturasdeeconomia/article/view/340570,https://aprendeenlinea.udea.edu.co/revistas/index.php/lecturasdeeconomia/article/view/340570,0,,,3003064753,,,0
137-274-291-293-17X,,,,,Ediciones Espiral y Editorial Iqueima (1944-1975): una apues-ta por la literatura,Art; Publishing; Humanities; Poetry,2020-01-01,2020,,,,46,117,138,Ana María Agudelo Ochoa,"This article studies the cultural project led by the Spanish exiled based in Bogota Clemente Airo, a project consisting of two publishing houses and a magazine. Both publishing houses, Ediciones Espiral and Editorial Iqueima, play a key role in the revitalization of Colombian literary and publishing fields in the mid-twentieth century. The review of the respective catalogs allows us to verify a determined bet on literature, and more specifically on novel and poetry.",,,,https://aprendeenlinea.udea.edu.co/revistas/index.php/elc/article/view/339480/20795522,https://aprendeenlinea.udea.edu.co/revistas/index.php/elc/article/view/339480/20795522,0,,,3000172875,,,0
141-237-246-175-723,Colombia,01205633,Sociedad Colombiana de Cardiologia y Cirugia Cardiovascular,Revista Colombiana de CardiologÃ­a,Consenso colombiano de fibrinólisis selectiva con catéter en enfermedad vascular tromboembólica,Gynecology; Medicine,2020-01-01,2020,journal article,,,,,,César Hernández; Juan Mauricio Lozano; Juan Fernando Muñoz; Diego Velásquez; Álvaro Escobar; Jorge Villegas; Luis A. Cruz; Luis Gerardo Cadavid,"Resumen En los pacientes con trombosis arterial o venosa, in situ o por embolia, el uso de fibrinoliticos (como el rtPA) administrados directamente en el trombo a traves de un cateter selectivo en el sitio de la oclusion, permite una resolucion mas rapida de la oclusion trombotica o embolica con menos dosis total del agente fibrinolitico y por ende con menos complicaciones hemorragicas que con el uso sistemico. Las indicaciones en las cuales se puede considerar la fibrinolisis selectiva con cateter son basicamente la isquemia aguda de una extremidad por oclusion arterial, la tromboembolia pulmonar, la trombosis venosa profunda iliofemoral (proximal), la trombosis venosa profunda proximal axilo-subclavia, la trombosis de los accesos venosos para dialisis y en los pacientes pediatricos en los casos de trombosis o embolia arterial con extremidad isquemica y en casos seleccionados de trombosis venosa profunda proximal de extremidades. En este consenso describira cada una de las indicaciones a traves de un protocolo para el manejo con rtPA en cada situacion, como monitorizar su uso y como tartar las complicaciones hemorragicas.",,,,https://www.sciencedirect.com/science/article/pii/S0120563319301810,http://dx.doi.org/10.1016/j.rccar.2019.03.007,0,,10.1016/j.rccar.2019.03.007,3001336194,,000-601-446-064-767; 002-071-907-785-530; 007-626-631-138-292; 007-655-075-909-369; 011-488-064-376-885; 017-477-400-498-676; 019-862-080-403-781; 020-042-824-041-990; 025-784-078-309-91X; 028-996-028-954-252; 031-790-843-832-088; 031-824-979-900-783; 033-567-953-987-647; 033-810-239-123-03X; 034-776-636-557-560; 034-827-496-133-500; 038-226-296-879-107; 045-392-846-682-526; 045-408-822-508-025; 046-441-423-944-453; 047-500-538-868-394; 049-246-658-582-149; 052-688-696-938-026; 053-567-578-995-033; 054-408-103-519-330; 055-190-234-186-852; 082-171-476-004-164; 086-446-472-129-221; 099-401-142-940-794; 102-052-819-894-00X; 110-582-877-193-947; 115-345-251-213-558; 121-415-357-044-519; 139-829-924-214-62X,0
141-427-050-434-188,,,,,"El Áncora Editores (Bogotá, 1980): un acercamiento a la editorial y su catálogo",Publishing; Humanities; Political science; Sociology of literature,2020-01-01,2020,,,,46,215,230,Almary Cristina Gutierrez Diaz,"The Bogota company El Ancora Editores was founded by Patricia Hoher and Felipe Escobar in 1980 and is still in operation. The purpose of this text is to present an approach to the history of El Ancora publishing house, analyze its editorial line based on study of the reconstructed catalog and show how the company was inserted into the publishing market of the last decades of the twentieth century and throughout the 21st century; all of this having as a theoretical-methodological framework the sociology of literature and the publishing studies.",,,,https://aprendeenlinea.udea.edu.co/revistas/index.php/elc/article/view/339496/20795527,https://aprendeenlinea.udea.edu.co/revistas/index.php/elc/article/view/339496/20795527,0,,,2999403785,,,0
145-162-592-916-258,Egypt,20901844; 20901836,Hindawi Publishing Corporation,Pulmonary Medicine,Nasal Provocation Test with Cat and Dog Extracts: Results according to Molecular Components,Provocation test; Physical therapy; Immunology; Allergy; Sensitization; Nasal provocation test; Fel d 1; Atopy; Allergen; Medicine; Dander,2020-01-24,2020,journal article,,Universidad de Antioquia,,1,10,Andres Sánchez; Ricardo Cardona; Marlon Munera; Víctor Calvo; Manuela Tejada-Giraldo; Jorge Sánchez,"Background. IgE sensitization (atopy) to pets is commonly evaluated using pet dander extracts. However, the diagnosis by components seems to be more adequate to evaluate the clinical relevance (allergy) of sIgE sensitization. Objective. To study the association between IgE sensitization to pet allergen components and clinical symptoms. Methodology. Dander extracts and sIgE levels to pet components (Can f 1, Can f 2, Can f 3, Can f 5, Fel d 1, Fel 2, and Fel 4) were measured in a rhinitis group ( ) and a control group ( ). Nasal provocation tests with pet extract were done in patients with atopy to pets. Results. Dog (34.6% vs. 23.5%) and cat dander (26.7% vs. 8.8%, ) IgE sensitization was frequent among rhinitis and no-rhinitis subjects, and it was similar to dog (29.7% vs. 20.5%) and cat (18.8% vs. 8.8%) components. Polysensitization for dog (3.1, 95% CI: 1.5 to 6.1, ) or cat (2.5, 95% CI: 0.8 to 8.0, ) components was the principal risk factor for a positive nasal provocation test. Additionally, positive nasal provocation test with one animal increased the risk of atopy and positive nasal provocation test to others animals. Pet ownership or asthma was not associated with increased risk of atopy or positive nasal provocation test. Conclusions. Sensitization to pet dander extract identifies atopic patients, but its utility to predict clinical relevance is poor. Allergenic components could help to define the clinical relevance of sensitization to furry animals and could reduce the need for provocation test.",2020,,,https://www.hindawi.com/journals/pm/2020/6365314/ http://downloads.hindawi.com/journals/pm/2020/6365314.pdf,http://dx.doi.org/10.1155/2020/6365314,0,,10.1155/2020/6365314,3001007791,,000-187-096-464-005; 002-328-387-150-718; 002-858-184-506-997; 004-384-578-492-920; 004-871-665-545-451; 005-257-187-067-390; 007-935-328-698-501; 010-127-324-646-512; 010-248-177-581-499; 015-394-103-123-206; 019-903-317-312-713; 020-235-803-469-438; 021-014-449-031-958; 026-346-144-148-701; 031-469-049-140-163; 032-826-103-470-18X; 033-235-549-719-64X; 042-152-943-376-596; 044-322-923-308-942; 046-556-204-212-172; 049-731-719-186-684; 055-146-078-530-253; 056-070-888-070-162; 059-101-627-045-207; 060-435-708-391-318; 061-820-126-958-57X; 067-158-323-007-276; 071-353-725-086-841; 080-462-414-938-524; 081-507-540-300-559; 082-422-305-013-211; 085-264-571-693-772; 091-033-322-893-991; 094-182-169-175-552; 103-568-612-434-886; 106-197-237-322-039; 117-671-947-323-559; 124-179-977-272-288; 139-329-126-938-163; 183-165-557-542-678,0
151-925-400-867-528,Switzerland,22971769,Frontiers Media SA,Frontiers in Veterinary Science,"Concomitant Presence of Ovarian Tumors (Teratoma and Granulosa Cell Tumor), and Pyometra in an English Bulldog Female Dog: A Case Report",Pathology; Immunology; Teratoma; Granulosa cell; Ovary; Uterus; Concomitant; Malignancy; Pyometra; Ovarian Teratoma; Biology,2020-01-14,2020,journal article,dog; neoplasia; ovary; tumor; uterus,,,500,,Carlos A. Oviedo-Peñata; Luis Alberto Hincapié; Carlos Riaño-Benavides; Juan G Maldonado-Estrada,"The diagnosis of ovarian tumors in dogs is usually complicated because the clinical signs can be very discrete and can be easily confused with other diseases. There are few reports of ovarian tumors with different cellular characteristics in the same dog. Our objective was to describe an unusual case of the concomitant presence of ovarian teratoma and granulosa cell tumors in a female dog presenting symptoms compatible with pyometra at clinical consultation. Clinical history: A non-spayed six-years-old female English Bulldog was attended at the consultation, with no history of previous steroid hormonal treatment. The dog had presented regular estrus every six months; three months elapsed between the last estrus and consultation. The dog had presented vulvar discharge for more than two weeks. Clinical and laboratory findings: the patient presented a slightly pale oral mucosa, decay, vulvar edema, and mucous-purulent uterine discharge. The ultrasound examination revealed the presence of neoformations in the ovaries, and evidence of cystic endometrial hyperplasia-pyometra in the uterus. Treatment: We performed a ventral ovariohysterectomy. During the surgical procedure, it was found several masses in the left and right ovaries, exhibiting characteristics of other tissues different from ovarian tissue. All samples were sent for histopathological examination. The diagnosis was a granulosa cell tumor in the left ovary and a well-differentiated teratoma in the right ovary. Conclusion: Practitioners must improve the use of diagnostic tools when attending non-spayed dogs at advanced ages (more than six years old), which would probably be at high risk of suffering from undetected ovarian tumors, some of them with malignancy behavior.",6,,,https://www.frontiersin.org/articles/10.3389/fvets.2019.00500/full,http://dx.doi.org/10.3389/fvets.2019.00500,0,31993447,10.3389/fvets.2019.00500,2998986753,,005-342-375-837-264; 007-792-238-168-157; 008-608-847-057-931; 018-057-410-347-260; 018-089-090-218-924; 028-800-149-240-777; 033-621-831-089-528; 035-565-973-397-904; 050-840-663-164-694; 055-487-933-460-192; 057-785-371-779-588; 062-103-889-984-711; 064-046-909-072-811; 069-611-557-745-55X; 075-042-149-419-253; 082-412-949-577-988; 087-679-027-984-952; 095-708-196-716-879; 096-535-112-851-314; 099-427-447-288-704; 113-799-347-591-119; 121-689-345-269-559; 125-778-086-127-459; 130-189-059-373-844; 179-239-035-698-645,0
153-092-205-843-335,United Kingdom,00092509,Elsevier BV,Chemical Engineering Science,Applicability of a modified breakage and coalescence model based on the complete turbulence spectrum concept for CFD simulation of gas-liquid mass transfer in a stirred tank reactor,Coalescence (physics); Turbulence kinetic energy; Bubble; Chemistry; Turbulence; Rushton turbine; Multiphase flow; Sauter mean diameter; Mass transfer; Mechanics; Thermodynamics,2020-01-01,2020,journal article,,,,115272,,Lilibeth Nino; Ricardo Gelves; Haider Ali; Jannike Solsvik; Hugo A. Jakobsen,"Abstract A generalized model for bubble breakage and coalescence is proposed using Computational Fluid Dynamics – CFD for considering the complete energy spectrum. An eulerian model and balance equations are simultaneously used to simulate the multiphase flow and bubble size distribution, respectively. The turbulent kinetic energy and its dissipation are calculated using the standard turbulence model k - e . A semi-empirical model that solves the second-order longitudinal structure function based on an interpolation function is coupled to CFD via UDF (User Defined Functions) code. CFD results are compared with experimental data obtained from Sauter mean diameter measurements at different bioreactor positions and stirred by a Rushton turbine. A reasonable prediction is obtained in comparison with the original Coulaloglou and Tavlarides (Break up) and Prince and Blanch (Coalescence) model. Further, the generalized model was extended to other stirring and aeration geometries using the same 10 litter tank bioreactor. The latter for evaluating strategies for overcoming gas-liquid mass transfer problems commonly found in bioreactors and a significant effect of the energy spectrum is reached in the geometries studied. The above, explained by the k L a oxygen transfer rate and bubble size determinations. It is numerically demonstrated that flow patterns and bubble size significantly influence the average k L a mass transfer in a bioreactor.",211,,,https://www.sciencedirect.com/science/article/pii/S0009250919307626,http://dx.doi.org/10.1016/j.ces.2019.115272,0,,10.1016/j.ces.2019.115272,2980837028,,007-924-273-344-218; 014-587-025-332-436; 021-024-113-268-248; 022-006-168-206-164; 030-108-960-829-901; 031-373-509-573-335; 032-782-056-728-958; 032-848-488-879-740; 035-813-349-915-309; 040-795-409-126-77X; 042-349-424-071-271; 047-002-234-571-434; 051-198-415-940-480; 058-836-565-497-873; 067-940-051-429-992; 073-150-382-775-794; 074-797-168-514-191; 080-623-470-714-458; 083-035-179-259-881; 093-098-334-074-221; 099-099-244-380-527; 101-032-677-602-619; 107-480-485-337-678; 110-279-940-771-761; 118-455-238-246-458; 119-718-237-252-600; 120-210-024-508-80X; 120-361-652-846-592; 126-432-512-398-613; 133-372-500-296-769; 150-131-723-384-909; 152-939-672-532-610; 157-802-706-471-938; 163-750-197-500-686; 174-783-226-349-47X; 178-281-747-071-907,0
158-259-378-758-159,,,,,"“Narrativa colombiana contemporánea” (Ediciones Tercer Mundo, 1962-1967): valor y cambio literario dentro del espacio editorial colombiano de los años sesenta",Art; Literary criticism; Humanities; Colombian literature; Consecration,2020-01-01,2020,,,,46,139,158,Danilo Penagos Jaramillo,"This article studies the “Narrativa Colombiana contemporanea” series, published by Ediciones Tercer Mundo in 1960 decade, and its importance for the Colombian literature in the second half of the twentieth century. A look to the series’ history shows how the literary critic legitimated the works and the authors published in the series. This fact meant a rupture in the appreciation of national literature and the some authors’ consecration, especially in manuals and literature histories, throughout the years.",,,,https://aprendeenlinea.udea.edu.co/revistas/index.php/elc/article/view/339482/20795523,https://aprendeenlinea.udea.edu.co/revistas/index.php/elc/article/view/339482/20795523,0,,,2999156454,,,0
158-982-865-021-229,,,,,Perspectivas y retos de las técnicas de inteligencia artificial en el ámbito de las ciencias sociales y de la comunicación,Communication sciences; Data science; Human knowledge; Algorithmics,2020-01-17,2020,,,,1,,,Raul Ramos Pollán,"In the last ten years, artificial intelligence (AI ) methods and techniques have witnessed great advances and they already make part of the usual landscape from where new or old problems are tackled in different areas of human knowledge. Three particular aspects are behind this leap forward: a generalized availability and variety of data; a deeper understanding of the mathematics governing the underlying algorithmics; and hardware capabilities allowing wide and deep experimental pipelines over data. The main challenge in each problem and context of application now lies on understanding how can these technologies can be used, their reach and limitations so that the can be aligned with the aims of each specific problem at hand. Social and communication sciences are no exception, but show particularities that define which ai technologies and methods are most appropriate (i.e. natural language processing). This works presents an introduction to the methodology under which ai models are built, to potentially useful ai services in the field and, finally, some examples of applications illustrating practical and technical considerations in this respect.",13,,,https://revistas.urosario.edu.co/index.php/disertaciones/article/view/7774,https://revistas.urosario.edu.co/index.php/disertaciones/article/view/7774,0,,,3000918739,,,0
162-562-905-277-08X,Netherlands,15684946,Elsevier BV,Applied Soft Computing,Two cluster validity indices for the LAMDA clustering method,Multivariable calculus; Machine learning; Artificial intelligence; Covariance; Pattern recognition; Cluster validity index; Data partitioning; Mathematics; Cluster analysis; Coefficient of variation,2020-01-01,2020,journal article,,Universidad de Antioquia,,106102,,Javier Fernando Botia Valderrama; Diego José Luis Botia Valderrama,"Abstract The learning algorithm and multivariable data analysis (LAMDA) is an algorithm to group quantitative and qualitative data, applying self-learning and/or directed learning. Usually, LAMDA automatically generates classes by assigning the best data partition to a class. To evaluate the data partitions generated by LAMDA, the internal evaluation is used to find the optimal number of clusters. For the LAMDA algorithm, the cluster validity (CV) is the most popular index which is based on inter-class contrast (ICC). However, other indices have not been defined for LAMDA and a comparative analysis is required to evaluate its performance. In this paper, two metrics called cluster validity index based on granulation error and the ratio of the distance (CVGED) and cluster validity index based on the ratios of covariance and distance (CVCOD) are proposed. Such indices are compared with the CV and ICC indices for two experiments: using a databases repository and selected open data and experimental laboratory data. According to the main results, CVGED and CVCOD have a better performance in compactness, separation, and coefficient of variation than ICC and CV for most of the selected repository databases but the accuracy is limited for the four indices. Nevertheless, CVCOD improves the quality of data partition when the open data and experimental laboratory data are used.",89,,,https://api.elsevier.com/content/article/PII:S1568494620300429?httpAccept=text/xml https://www.sciencedirect.com/science/article/pii/S1568494620300429?dgcid=rss_sd_all,http://dx.doi.org/10.1016/j.asoc.2020.106102,0,,10.1016/j.asoc.2020.106102,3002497026,,006-186-041-044-20X; 006-566-880-520-419; 007-044-469-706-510; 007-186-314-670-246; 007-264-355-421-386; 008-525-179-330-889; 010-324-034-721-900; 013-395-507-068-962; 016-909-966-954-255; 020-786-724-464-031; 020-989-853-413-783; 022-666-611-701-228; 029-004-736-470-517; 031-940-413-106-976; 034-929-999-599-14X; 036-832-217-890-701; 049-775-617-404-446; 050-041-252-243-055; 052-423-244-611-635; 055-329-314-374-590; 056-550-957-590-122; 056-945-504-074-877; 057-643-229-561-840; 062-076-890-619-227; 068-348-813-395-519; 082-088-953-594-404; 083-943-766-425-761; 091-980-924-745-940; 094-159-592-916-885; 098-068-833-666-576; 101-895-956-722-561; 107-630-046-738-972; 108-403-174-213-077; 108-947-800-106-435; 110-553-818-163-518; 111-834-871-216-073; 116-299-186-583-860; 118-644-328-968-510; 119-464-283-091-708; 128-928-076-479-143; 130-369-989-249-696; 143-571-987-885-235; 147-703-534-390-632; 161-579-877-198-169; 182-743-566-384-013; 183-868-980-686-186; 185-206-537-612-035; 193-074-287-190-068,0
162-658-928-741-814,,,,,"Relaciones entre proyecto de vida y organizaciones: una mirada metafórica desde la planeación, la formación y la contabilidad",,2020-01-14,2020,,,,2,,,Ana María Mejía; Juan Carlos Agudelo Restrepo; Julián Esteban Flórez Correa; Carlos Eduardo Castaño Ríos,"Es importante que las empresas realicen una debida planeacion y formacion con el proposito de tener resultados financieros favorables. Asi, se planteo como objetivo analizar las relaciones entre la planeacion, la formacion de las empresas y el proceso contable en los resultados financieros, utilizando el proyecto de vida del ser humano como metafora para las organizaciones. Se realizaron entrevistas a siete empresarios de organizaciones del municipio de Andes (Antioquia) ubicadas en cuatro grupos denominados emprendimiento, crecimiento, sostenibilidad y consolidacion. Finalmente se concluyo que si existe la metafora propuesta de organizacion en relacion con el proyecto de vida del ser humano, partiendo de relacionar los procesos de planeacion y formacion para la obtencion de resultados financieros positivos.",4,,,https://www.funlam.edu.co/revistas/index.php/SHA/article/view/3497,https://www.funlam.edu.co/revistas/index.php/SHA/article/view/3497,0,,,2999872654,,,0
182-586-871-251-608,,11266708,,Journal of High Energy Physics,Search for a charged Higgs boson decaying into top and bottom quarks in events with electrons or muons in proton-proton collisions at s$$ \sqrt{\mathrm{s}} $$ = 13 TeV,Particle physics; Physics; Bottom quark; Higgs boson; Lepton; Muon; Top quark; Standard Model; Quark; Large Hadron Collider,2020-01-01,2020,journal article,,,1,96,,A. M. Sirunyan; Armen Tumasyan; Wolfgang Adam; Federico Ambrogi; Thomas Bergauer; Johannes Brandstetter; Marko Dragicevic; Janos Erö; A. Escalante Del Valle; Martin Flechl; R. Frühwirth; Manfred Jeitler; Natascha Krammer; Ilse Krätschmer; Dietrich Liko; Thomas Madlener; Ivan Mikulec; Navid Rad; Jochen Schieck; Robert Schöfbeck; Markus Spanring; Daniel Spitzbart; Wolfgang Waltenberger; Claudia-Elisabeth Wulz; Mateusz Zarucki; Vladimir Drugakov; V. Mossolov; J. Suarez Gonzalez; Mohamed Rashad Darwish; E. A. De Wolf; D. Di Croce; Xavier Janssen; Jasper Lauwers; Aleksandra Lelek; Maxim Pieters; H. Rejeb Sfar; H. Van Haevermaet; P. Van Mechelen; S. Van Putte; N. Van Remortel; Freya Blekman; Emil Sørensen Bols; Simranjit Singh Chhibra; Jorgen D'Hondt; J. De Clercq; Denys Lontkovskyi; Steven Lowette; Ivan Marchesini; Seth Moortgat; Lieselotte Moreels; Quentin Python; K. Skovpen; Stefaan Tavernier; W. Van Doninck; P. Van Mulders; I. Van Parijs; Diego Beghin; Bugra Bilin; Hugues Brun; Barbara Clerbaux; G. De Lentdecker; Hugo Delannoy; Brian Dorney; Laurent Favart; Anastasia Grebenyuk; Amandeep Kaur Kalsi; Jelena Luetic; Andrey Popov; Nicolas Postiau; Elizabeth Starling; Laurent Thomas; C. Vander Velde; Pascal Vanlaer; David Vannerom; Qun Wang; Tom Cornelis; Didar Dobur; Illia Khvastunov; Christos Roskas; Daniele Trocino; Michael Tytgat; Willem Verbeke; Basile Vermassen; Martina Vit; N. Zaganidis; O. Bondu; Giacomo Bruno; Claudio Caputo; Pieter David; Christophe Delaere; Martin Delcourt; Andrea Giammanco; Vincent Lemaitre; Alessio Magitteri; Jessica Prisciandaro; Alessia Saggio; M. Vidal Marono; Pietro Vischia; Joze Zobec; Fábio Lúcio Alves; G. A. Alves; G. Correia Silva; C. Hensel; Arthur Moraes; P. Rebello Teles; E. Belchior Batista Das Chagas; W. Carvalho; Jose Chinellato; Eduardo Coelho; E. M. Da Costa; G. G. Da Silveira; D. De Jesus Damiao; C. De Oliveira Martins; S. Fonseca De Souza; L. M. Huertas Guativa; Helena Malbouisson; Jordan Martins; D. Matos Figueiredo; M. Medina Jaime; M. Melo De Almeida; C. Mora Herrera; Luiz Mundim; Helio Nogima; W. L. Prado Da Silva; L. J. Sanchez Rosas; A. Santoro; A. Sznajder; Mauricio Thiel; E. J. Tonelli Manganote; F. Torres Da Silva De Araujo; A. Vilela Pereira; Sudha Ahuja; Cesar Augusto Bernardes; Luigi Calligaris; T. R. Fernandez Perez Tomei; Eduardo De Moraes Gregores; D. De Souza Lemos; P. G. Mercadante; S. F. Novaes; SandraS. Padula; Aleksandar Aleksandrov; Georgy Antchev; R. Hadjiiska; P. Iaydjiev; Andrey Marinov; Milena Misheva; M. Rodozov; Mariana Shopova; G. Sultanov; Miroslav Bonchev; A. Dimitrov; Todor Ivanov; Leander Litov; B. Pavlov; P. Petkov; Wenxing Fang; Xinlei Gao; Li Yuan; M. Ahmad; G. M. Chen; H. S. Chen; M. Chen; C. H. Jiang; Duncan Leggat; H. Liao; Z. K. Liu; Sarmad Masood Shaheen; Aniello Spiezia; J. Tao; E. Yazgan; H. Zhang; Sijing Zhang; J. Zhao; Antonis Agapitos; Y. Ban; G. Chen; Andrew Levin; Jing Li; Liang Li; Q. Li; Y. J. Mao; S. J. Qian; Dong Wang; Zhen Hu; Y. Wang; C. Avila; A. Cabrera; L. F. Chaparro Sierra; C. Florez; C. F. González Hernández; M. A. Segura Delgado; J. Mejia Guisao; J. D. Ruiz Alvarez; C. A. Salazar González; N. Vanegas Arbelaez; Duje Giljanović; Nikola Godinovic; Damir Lelas; Ivica Puljak; Toni Sculac; Z. Antunovic; Marko Kovac; V. Brigljevic; Sasa Ceci; D. Ferencek; K. Kadija; Benjamin Mesic; Matej Roguljic; Andrei Starodumov; Tatjana Susa; Mohsan Waseem Ather; Alexandros Attikis; Eleni Erodotou; Aimilios Ioannou; Marina Kolosova; Sotiroulla Konstantinou; Georgios Mavromanolakis; Jehad Mousa; C. Nicolaou; Fotios Ptochos; P. A. Razis; Hans Rykaczewski; Demetra Tsiakkouri; M. Finger; Antonin Kveton; Jan Tomsa; Edy Ayala; E. Carrera Jarrin; Hassan Abdalla; Ahmed Ali Abdelalim; Sandeep Bhowmik; A. Carvalho Antunes De Oliveira; Ram Krishna Dewanjee; Karl Ehataht; M. Kadastik; M. Raidal; Christian Veelken; Paula Eerola; Laurent Forthomme; Henning Kirschenmann; K. Osterberg; M. Voutilainen; Francisco Garcia; Joona Havukainen; Jaana Kristiina Heikkilä; Terhi Jarvinen; Veikko Karimäki; Ritva Kinnunen; Tapio Lampén; Kati Lassila-Perini; Santeri Laurila; Sami Lehti; Tomas Lindén; Panja-Riina Luukka; Teppo Mäenpää; Hannu Siikonen; Eija Tuominen; Jorma Tuominiemi; Tuure Tuuva; Marc Besancon; Fabrice Couderc; M. Dejardin; D. Denegri; B. Fabbro; Jérôme Faure; F. Ferri; S. Ganjour; A. Givernaud; P. Gras; G. Hamel de Monchenault; P. Jarry; Clément Leloup; E. Locci; J. Malcles; J. Rander; A. Rosowsky; M. Ö. Sahin; Aurore Savoy-Navarro; M. Titov; Chiara Amendola; F. Beaudette; P. Busson; C. Charlot; Batoul Diab; Guillaume Falmagne; R. Granier de Cassagnac; Inna Kucher; Artur Lobanov; C. Martin Perez; Matthew Nguyen; C. Ochando; P. Paganini; Jonas Rembser; R. Salerno; J. B. Sauvan; Y. Sirois; A. Zabi; Amina Zghiche; J. L. Agram; J. Andrea; D. Bloch; Guillaume Bourgatte; J. M. Brom; E. C. Chabert; Caroline Collard; E. Conte; J. C. Fontaine; D. Gelé; U. Goerlach; Markéta Jansová; A. C. Le Bihan; Nicolas Tonon; P. Van Hove; Sébastien Gadrat; Stephanie Beauceron; Colin Bernet; G. Boudoul; Camille Camen; N. Chanon; R. Chierici; D. Contardo; P. Depasse; H. El Mamouni; J. Fay; S. Gascon; Maxime Gouzevitch; B. Ille;  Jain; Francois Lagarde; I. B. Laktineh; Hugues Lattaud; M. Lethuillier; L. Mirabito; S. Perries; V. Sordini; Gaël Touquet; M. Vander Donckt; Sébastien Viret; Arsen Khvedelidze; Zviad Tsamalaidze; C. Autermann; L. Feld; M. K. Kiesel; K. Klein; Martin Lipinski; Danilo Meuser; Alexander Pauls; Marius Preuten; Max Philip Rauch; Christian Schomakers; Johannes Schulz; Marius Teroerde; B. Wittmer; Andreas Albert; M. Erdmann; Sören Erdweg; Thomas Esch; Benjamin Fischer; R. Fischer; Saranya Ghosh; T. Hebbeker; K. Hoepfner; Henning Keller; Luca Mastrolorenzo; Markus Merschmeyer; Andreas Bernhard Meyer; Philipp Millet; Giovanni Mocellin; Spandan Mondal; Swagata Mukherjee; Dennis Noll; Andrzej Novak; Tobias Pook; Andrey Pozdnyakov; Thorben Quast; Markus Radziej; Yannik Rath; H. Reithler; Marcel Rieger; Jonas Roemer; Alexander Schmidt; Simon Christoph Schuler; Archana Sharma; Sebastian Thüer; Sebastian Wiedenbeck; G. Flügge; W. Haj Ahmad; Olena Hlushchenko; T. Kress; Thomas Müller; Alexander Nehrkorn; A. Nowack; Claudia Pistone; O. Pooth; Dennis Roy; Hale Sert; Achim Stahl; M. Aldaya Martin; Paul Asmuss; Illia Babounikau; H. Bakhshiansohi; Kelly Beernaert; Olaf Behnke; U. Behrens; A. Bermúdez Martínez; David Bertsche; A. A. Bin Anuar; Kerstin Borras; Valeria Botta; A. J. Campbell; Andrea Cardini; Patrick Connor; S. Consuegra Rodríguez; Christian Contreras-Campana; Vladyslav Danilov; A. De Wit; Matteo Maria Defranchis; C. Diez Pardos; D. Domínguez Damiani; G. Eckerlin; D. Eckstein; Thomas Eichhorn; Adam Elwood; Engin Eren; Elisabetta Gallo; A. Geiser; J. M. Grados Luyando; Alexander Grohsjean; Moritz Guthoff; Mykyta Haranko; Ali Harb; A. Jafari; Nur Zulaiha Jomhari; H. Jung; A. Kasem; M. Kasemann; Hessamoddin Kaveh; James Keaveney; C. Kleinwort; Joscha Knolle; D. Krücker; W. Lange; Teresa Lenz; J. Leonard; Jindrich Lidrych; K. Lipka; W. Lohmann; R. Mankel; Isabell-Alissandra Melzer-Pellmann; A. B. Meyer; M. Meyer; Marino Missiroli; Gregor Mittag; J. Mnich; A. Mussgiller; Volodymyr Myronenko; D. Pérez Adán; Svenja Karen Pflitsch; D. Pitzl; Alexei Raspereza; Andrej Saibel; Mykola Savitskyi; Valerie Scheurer; Paul Schütze; C. Schwanenberger; Rostyslav Shevchenko; A. P. Singh; Heiner Tholen; Oleksii Turkot; Antonio Vagnerini; M. Van De Klundert; G. P. Van Onsem; R. Walsh; Y. Wen; Katarzyna Wichmann; Christoph Wissing; O. Zenaiev; Radek Zlebcik; Robin Aggleton; Samuel Bein; Lisa Benato; Anna Benecke; Volker Blobel; Torben Dreyer; Aliakbar Ebrahimi; Alexander Fröhlich; Christoph Garbers; Erika Garutti; D. Gonzalez; P. Gunnellini; Johannes Haller; Andreas Hinzmann; Anastasia Karavdina; Gregor Kasieczka; R. Klanner; Roman Kogler; Nataliia Kovalchuk; Simon Kurz; Viktor Kutzner; J. C. Lange; Torben Lange; Andrea Malara; Daniele Marconi; Jens Multhaup; Marek Niedziela; C. E. N. Niemeyer; Dominik Nowatschin; Adrian Perieanu; Arne Reimers; Oliver Rieger; Christian Scharf; P. Schleper; Svenja Schumann; J. Schwandt; Jory Sonneveld; Hartmut Stadie; G. Steinbrück; F. M. Stober; Marc Stöver; Benedikt Vormwald; Irene Zoi; Melike Akbiyik; C. Barth; Marta Baselga; Sebastian Baur; Thomas Berger; Erik Butz; René Caspart; Thorsten Chwalek; W. De Boer; A. Dierlamm; K. El Morabit; Nils Faltermann; M. Giffels; Pablo Goldenzweig; Artur Gottmann; Marco Alexander Harrendorf; F. Hartmann; U. Husemann; Simon Kudella; Soureek Mitra; M. U. Mozer; Th. Müller; M. Musich; Andreas Nürnberg; G. Quast; Klaus Rabbertz; M. Schröder; Ivan Shvetsov; H. J. Simonis; Ralf Ulrich; M. Weber; Clemens Wöhrmann; Roger Wolf; G. Anagnostou; Patrick Asenov; G. Daskalakis; T. Geralis; A. Kyriakis; D. Loukas; Garyfallia Paspalaki; Magda Diamantopoulou; George Karathanasis; Pantelis Kontaxakis; A. D. Panagiotou; Ioanna Papavergou; Niki Saoulidou; Anna Stakia; Konstantinos Theofilatos; Konstantinos Vellidis; Georgios Bakas; Konstantinos Kousouris; Ioannis Papakrivopoulos; Georgios Tsipolitis; I. Evangelou; C. Foudas; Paraskevas Gianneios; Panagiotis Katsoulis; P. Kokkas; Stavros Mallios; Kalliopi Manitara; N. Manthos; I. Papadopoulos; John Strologas; Frixos A Triantis; Dimitrios Tsitsonis; Márton Bartók; Mate Csanad; Péter Major; Koushik Mandal; Ankita Mehta; Marton Imre Nagy; Gabriella Pasztor; Olivér Surányi; Gabor Istvan Veres; G. Bencze; C. Hajdu; D. Horvath; F. Sikler; Tamás Álmos Vámi; Viktor Veszpremi; G. Vesztergombi; N. Beni; S. Czellar; János Karancsi; Alajos Makovec; J. Molnar; Z. Szillasi; P. Raics; Daniel Teyssier; Z. L. Trocsanyi; Balazs Ujvari; T. Csorgo; Wj Metzger; Frigyes Nemes; Tamas Novak; Samrat Choudhury; Jyothsna Rani Komaragiri; Praveen Chandra Tiwari; Seema Bahinipati; Chandiprasad Kar; Gouranga Kole; Prolay Mal; V. K. Muraleedharan Nair Bindhu; A. Nayak; D. K. Sahoo; S. K. Swain; Sunil Bansal; S. B. Beri; V. Bhatnagar; Shubhanshu Chauhan; Ridhi Chawla; Nitish Dhingra; Ruchi Gupta; A. Kaur; M. Kaur; Sandeep Kaur; Priyanka Kumari; Manisha Lohan; Meena Meena; Kaur Sandeep; Samandeep Sharma; J. B. Singh; A. K. Virdi; A. Bhardwaj; B. C. Choudhary; R. B. Garg; Mohit Gola; Sumit Keshri; Ashok Kumar; Shivali Malhotra; M. Naimuddin; Priyanka Priyanka; K. Ranjan; Aashaq Shah; R. Sharma; Rishika Bhardwaj; Monika Bharti; Rajarshi Bhattacharya; S. Bhattacharya; U. Bhawandeep; Debabrata Bhowmik; Sourav Dey; Suchandra Dutta; M. Maity; Kuntal Mondal; Saswati Nandan; Arnab Purohit; Prasant Kumar Rout; Gourab Saha; S. Sarkar; Tanmay Sarkar; Manoj Sharan; Bipen Singh; Shalini Thakur; Prafulla Kumar Behera; Pritam Kalbhor; Alibordi Muhammad; Prabhat Ranjan Pujahari; Anup Kumar Sikdar; Ruchi Chudasama; D. Dutta; Vishwajeet Jha; V. Kumar; Dipak Kumar Mishra; Pawan Kumar Netrakanti; L. M. Pant; P. Shukla; T. Aziz; Muzamil Ahmad Bhat; S. R. Dugad; G. B. Mohanty; Nairit Sur; RavindraKumar Verma; Sunanda Banerjee; S. Chatterjee; Pallabi Das; M. Guchait; Saikat Karmakar; Sanjeev Kumar; G. Majumder; K. Mazumdar; Niladribihari Sahoo; Siddhesh Sawant; Sourabh Dube; Vinay Hegde; A. Kapoor; Kunal Kothekar; Shubham Pandey; Aditee Rane; Angira Rastogi; Shirin Chenarani; E. Eskandari Tadavani; S. M. Etesami; Mohsen Khakzad; M. Mohammadi Najafabadi; M. Naseri; F. Rezaei Hosseinabadi; M. Felcini; M. W. Grünewald; M. Abbrescia; C. Calabria; A. Colaleo; D. Creanza; Leonardo Cristella; N. De Filippis; M. De Palma; A. Di Florio; L. Fiore; Andrea Gelmi; G. Iaselli; Merve Ince; Samet Lezki; G. Maggi; Mario Maggi; Giorgia Miniello; S. My; S. Nuzzo; Alexis Pompili; Gabriella Pugliese; R. Radogna; A. Ranieri; G. Selvaggi; L. Silvestris; R. Venditti; P. Verwilligen; G. Abbiendi; Carlo Battilana; D. Bonacorsi; Lisa Borgonovi; S. Braibant-Giacomelli; Renato Campanini; P. Capiluppi; A. Castro; F. R. Cavallo; Claudia Ciocca; G. Codispoti; M. Cuffiani; G. M. Dallavalle; F. L. Fabbri; A. Fanfani; Elisa Fontanesi; P. Giacomelli; C. Grandi; L. Guiducci; Fabio Iemmi; S. Lo Meo; S. Marcellini; Gianni Masetti; F. L. Navarria; Andrea Perrotta; Federica Primavera; A. M. Rossi; T. Rovelli; G. P. Siroli; Nicolò Tosi; Sebastiano Albergo; S. Costa; A. Di Mattia; Renato Potenza; A. Tricomi; C. Tuve; Giuseppe Barbagli; R. Ceccarelli; Kalyanmoy Chatterjee; V. Ciulli; C. Civinini; R. D'Alessandro; E. Focardi; Giuseppe Latino; P. Lenzi; M. Meschini; S. Paoletti; G. Sguazzoni; D. M. Strom; Lorenzo Viliani; L. Benussi; Stefano Bianco; D. Piccolo; M. Bozzo; Fabrizio Ferro; Roberto Mulargia; Enrico Robutti; S. Tosi; Andrea Benaglia; Andrea Beschi; Francesco Brivio; Vincenzo Ciriolo; S. Di Guida; Mauro Emanuele Dinardo; Paolo Dini; Sara Fiorendi; S. Gennai; A. Ghezzi; P. Govoni; Luca Guzzi; M. Malberti; S. Malvezzi; D. Menasce; Fabio Monti; L. Moroni; Giacomo Ortona; M. Paganoni; D. Pedrini; S. Ragazzi; T. Tabarelli de Fatis; Davide Zuolo; S. Buontempo; N. Cavallo; A. De Iorio; A. Di Crescenzo; Francesco Fabozzi; Francesco Fienga; Giuliana Galati; Alberto Orso Maria Iorio; L. Lista; Sabino Meola; P. Paolucci; Biagio Rossi; C. Sciacca; Elena Voevodina; Patrizia Azzi; Nicola Bacchetta; Alessio Boletti; Alberto Bragagnolo; Roberto Carlin; P. Checchia; P. De Castro Manzano; T. Dorigo; Umberto Dosselli; F. Gasparini; Ugo Gasparini; Andrea Gozzelino; S. Y. Hoh; Paul Lujan; Martino Margoni; A. T. Meneguzzo; Jacopo Pazzini; Nicola Pozzobon; Matteo Presilla; P. Ronchese; Roberto Rossin; Franco Simonetto; Andres Tiko; Mia Tosi; Marco Zanetti; P. Zotto; Gianni Zumerle; Alessandro Braghieri; Paolo Montagna; S. P. Ratti; V. Re; Martina Ressegotti; C. Riccardi; Paola Salvini; I. Vai; P. Vitulo; M. Biasini; G. M. Bilei; Claudia Cecchi; Diego Ciangottini; L. Fanò; Paolo Lariccia; Roberto Leonardi; Elisa Manoni; G. Mantovani; Valentina Mariani; M. Menichelli; Antonio Rossi; Attilio Santocchia; Daniele Spiga; Konstantin Androsov; P. Azzurri; G. Bagliesi; Valerio Bertacchi; L. Bianchini; T. Boccali; R. Castaldi; Ma Ciocci; R. Dell'Orso; G. Fedi; Leonardo Giannini; A. Giassi; M. T. Grippo; F. Ligabue; Elisabetta Manca; Giulio Mandorli; A. Messineo; Fabrizio Palla; A. Rizzi; G. Rolandi; S. Roy Chowdhury; A. Scribano; P. Spagnolo; R. Tenchini; G. Tonelli; N. Turini; A. Venturi; P. G. Verdini; F. Cavallari; Marco Cipriani; D. Del Re; E. Di Marco; M. Diemoz; Egidio Longo; Badder Marzocchi; P. Meridiani; G. Organtini; F. Pandolfi; R. Paramatti; Claudio Quaranta; S. Rahatlou; Carlo Rovelli; Francesco Santanastasio; Livia Soffi; N. Amapane; R. Arcidiacono; S. Argiro; M. Arneodo; Nazar Bartosik; R. Bellan; C. Biino; Alessandra Cappati; N. Cartiglia; Simona Cometti; M. Costa; R. Covarelli; Natale Demaria; Bilal Kiani; C. Mariotti; S. Maselli; E. Migliore; V. Monaco; Ennio Monteil; M. Monteno; M. M. Obertino; Luca Pacher; N. Pastrone; Mario Pelliccioni; G. L. Pinna Angioni; A. Romero; M. Ruspa; R. Sacchi; Riccardo Salvatico; Valentina Sola; Ada Solano; Dario Soldi; A. Staiano; S. Belforte; V. Candelise; M. Casarsa; F. Cossutti; A. Da Rold; G. Della Ricca; Federico Vazzoler; A. Zanetti; Bobae Kim; Dh Kim; G. N. Kim; Min Suk Kim; Jsh Lee; S. W. Lee; C. S. Moon; Y. D. Oh; S. I. Pak; Sezen Sekmen; D. C. Son; Y. C. Yang; Hyunyong Kim; Dong Ho Moon; Geonhee Oh; Brieuc Francois; Tae Jeong Kim; Jaebeom Park; Sungwoong Cho; S. Choi; Yeonju Go; Dooyeon Gyun; Seungkyu Ha; B. Hong; K. S. Lee; Kisung Lee; J. K. Lim; S. K. Park; Youn Roh; Junghwan Goh; H. S. Kim; John Almond; Ji Hwan Bhyun; Junho Choi; Sihyun Jeon; J. S. Kim; Jongjeong Kim; H. S. Lee; S. H. Lee; Kyungwook Nam; Minseok Oh; S. B. Oh; Benjamin Charles Radburn-Smith; U. K. Yang; H. D. Yoo; Inseok Yoon; Geum Bong Yu; D. Jeon; J. H. Kim; J. S. H. Lee; I. C. Park; Ian Watson; Y. Choi; Chanwook Hwang; Yongho Jeong; Y. Lee; I. Yu; Viesturs Veckalns; Vytautas Dudenas; Andrius Juodagalvis; J. Vaitkus; Z. A. Ibrahim; F. Mohamad Idris; W. A. T. Wan Abdullah; Mohd Nizam Yusli; Zukhaimira Zolkapli; Jose F Benitez; A. M. Castaneda Hernandez; J. A. Murillo Quijada; L. Valencia Palomo; Heriberto Castilla-Valdez; E. De La Cruz-Burelo; I. Heredia-De La Cruz; Ricardo Lopez-Fernandez; A. Sanchez-Hernandez; S. Carrillo Moreno; C. Oropeza Barrera; M. Ramirez-Garcia; F. Vazquez Valencia; Jan Eysermans; Isabel Pedraza; H. A. Salazar Ibarguen; C. Uribe Estrada; A. Morelos Pineda; Natasa Raicevic; D. Krofcheck; Srinidhi Bheesette; P. H. Butler; Ashfaq Ahmad; Qamar Hassan; H. R. Hoorani; W. A. Khan; Mehar Ali Shah; Muhammad Shoaib; Muhammad Waqas; Valentina Avati; Leszek Grzanka; Maciej Malawski; Helena Bialkowska; M. Bluj; Bozena Boimska; M. Górski; Malgorzata Kazana; Michal Szleper; P. Zalewski; K. Bunkowski; Adrian Byszuk; K. Doroba; A. Kalinowski; M. Konecki; J. Krolikowski; Maciej Misiura; M. Olszewski; Andrzej Pyskir; Marek Walczak; Mariana Araujo; Pedrame Bargassa; Diogo Bastos; A. Di Francesco; P. Faccioli; Bruno Galinhas; M. Gallinaro; Jj Hollar; Nuno Leonardo; J. Seixas; Ksenia Shchelina; Giles Strong; Oleksii Toldaiev; Joao Varela; Vadim Alexakhin; Pavel Bunin; Y. Ershov; I. Golutvin; Ilya Gorbunov; Vladimir Karjavine; Vladimir Korenkov; A. Lanev; Alexander Malakhov; V. A. Matveev; P. Moisenz; V. Palichik; V. Perelygin; Maria Savina; S. Shmatov; Siarhei Shulha; Oleg Teryaev; Nikolay Voytishin; Bekhzod S Yuldashev; A. Zarubin; Leonid Chtchipounov; V. Golovtsov; Y. Ivanov; Victor Kim; Ekaterina Kuznetsova; P. Levchenko; Victor Murzin; Vadim Oreshkin; I. Smirnov; Dmitry Sosnov; V. Sulimov; L. Uvarov; A. Vorobyev; Yu. Andreev; Alexander Dermenev; S. Gninenko; N. Golubev; Anton Karneyeu; M. Kirsanov; N. Krasnikov; A. Pashenkov; D. Tlisov; A. Toropin; Vladimir Epshteyn; Vladimir Gavrilov; Natalia Lychkovskaya; A. Nikitenko; Vladimir Popov; Ivan Pozdnyakov; Grigory Safronov; Alexander Spiridonov; Anton Stepennov; Maria Toms; Evgueni Vlasov; Alexander Zhokin; T. Aushev; Oksana Bychkova; Ruslan Chistov; Mikhail Danilov; Sergey Polikarpov; Evgenii Tarkovskii; Valeri Andreev; Maksim Azarkin; Igor Dremin; Martin Kirakosyan; Adel Terkulov; Alexey Baskakov; Alexander Belyaev; E. E. Boos; V. Bunichev; Mikhail Dubinin; L. V. Dudko; Vyacheslav Klyukhin; O. Kodolova; I. Lokhtin; Stepan Obraztsov; Maxim Perfilov; S. Petrushanko; V. Savrin; Alexander Barnyakov; V. E. Blinov; Tatyana Dimova; L. V. Kardapoltsev; Yuri Skovpen; Igor Azhgirey; Igor Bayshev; Sergei Bitioukov; Vassili Kachanov; Dmitri Konstantinov; Petr Mandrik; V. Petrov; Roman Ryutin; Sergei Slabospitskii; Andrei Sobol; Sergey Troshin; Nikolay Tyurin; Andrey Uzunian; A.E. Volkov; Anton Babaev; Aleksandr Iuzhakov; Vitalii Okhotnikov; Vladislav Borchsh; V. Ivanchenko; Evgueni Tcherniaev; P. Adzic; Predrag Cirkovic; Damir Devetak; Milos Dordevic; Predrag Milenovic; Jovan Milosevic; Milan Stojanovic; M Aguilar Benitez; J. Alcaraz Maestre; A. Álvarez Fernández; Irene Bachiller; M. Barrio Luna; J. A. Brochero Cifuentes; C. A. Carrillo Montoya; M. Cepeda; Marcos Cerrada; N. Colino; B. De La Cruz; A. Delgado Peris; C. Fernandez Bedoya; J. P. Fernández Ramos; Jose Flix; M. C. Fouz; O. Gonzalez Lopez; S. Goy Lopez; J. M. Hernandez; M. I. Josa; Dermot Moran; Á. Navarro Tobar; A. Pérez-Calero Yzquierdo; J. Puerta Pelayo; I. Redondo; L. Romero; S. Sánchez Navas; Mara Senghi Soares; Andrea Triossi; Carlos Willmott; C. Albajar; J. F. de Trocóniz; B. Alvarez Gonzalez; J. Cuevas; Carlos Erice; J. Fernandez Menendez; Santiago Folgueras; I. Gonzalez Caballero; J. R. González Fernández; E. Palencia Cortezon; V. Rodríguez Bouza; S. Sanchez Cruz; Iban Jose Cabrillo; A. Calderon; B. Chazin Quero; J. Duarte Campderros; M. Fernandez; P. J. Fernández Manteca; A. García Alonso; G. Gomez; C. Martinez Rivero; P. Martinez Ruiz del Arbol; F. Matorras; J. Piedra Gomez; Cédric Prieels; T. Rodrigo; Alberto Ruiz-Jimeno; Lorenzo Russo; L. Scodellaro; Nicolò Trevisani; Ivan Vila; J. M. Vizan Garcia; Kithsiri Malagalage; Welathantri Gd Dharmaratna; Nadeesha Wickramage; D. Abbaneo; Bora Akgun; Etiennette Auffray; Georg Auzinger; Joachim Baechler; Paul Baillon; A. H. Ball; David Barney; Joshua Bendavid; Michele Bianco; Andrea Bocci; Edoardo Bossini; C. Botta; Erica Brondolin; Tiziano Camporesi; Alessandro Caratelli; Gianluca Cerminara; Emilien Chapon; Giacomo Cucciati; D. d’Enterria; A. Dabrowski; Nadir Daci; Vincenzo Daponte; A. David; Olivier Davignon; A. De Roeck; Nikkie Deelen; Mario Deile; Marc Dobson; Marc Dünser; Niels Dupont; A. Elliott-Peisert; Francesco Fallavollita; Daniele Fasanella; G. Franzoni; J. Fulcher; W. Funk; S. Gianì; D. Gigi; Andrew Gilbert; K. Gill; F. Glege; Marek Gruchala; Maxime Guilbaud; Doga Gulhan; Jeroen Hegeman; Constantin Heidegger; Yutaro Iiyama; V. Innocente; P. Janot; Olena Karacheban; Jan Kaspar; Jan Kieseler; Manfred Krammer; Clemens Lange; P. Lecoq; Carlos Lourenco; L. Malgeri; M. Mannelli; A. Massironi; F. Meijers; J. A. Merlin; S. Mersi; E. Meschi; F. Moortgat; M. Mulders; Jennifer Ngadiuba; Shervin Nourbakhsh; Styliani Orfanelli; L. Orsini; Felice Pantaleo; L. Pape; Emmanuelle Perez; M. Peruzzi; A. Petrilli; G. Petrucciani; Andreas Pfeiffer; M. Pierini; Florian Michael Pitters; Dinyar Rabady; A. Racz; M. Rovere; H. Sakulin; C. Schäfer; C. Schwick; Michele Selvaggi; Pedro Silva; Walter Snoeys; P. Sphicas; Jan Steggemann; Vittorio Raoul Tavolaro; D. Treille; A. Tsirou; Adish Vartak; Mauro Verzetti; Wolfram Dietrich Zeuner; Lea Caminada; K. Deiters; W. Erdmann; R. Horisberger; Q. Ingram; H. C. Kaestli; D. Kotlinski; U. Langenegger; T. Rohe; Stephan Albert Wiederkehr; Malte Backhaus; Pirmin Berger; Nadezda Chernyavskaya; G. Dissertori; M. Dittmar; M. Donegà; Christian Dorfer; T. A. Gómez Espinosa; Christoph Grab; D. Hits; Thomas Klijnsma; W. Lustermann; Riccardo Andrea Manzoni; M. Marionneau; Maren Tabea Meinhard; F. Micheli; P. Musella; F. Nessi-Tedaldi; F. Pauss; Gaël Perrin; L. Perrozzi; Simone Pigazzini; Michael Reichmann; Christina Reissel; Thomas Reitenspiess; Daniele Ruini; D. A. Sanz Becerra; Myriam Schönenberger; Lesya Shchutska; M. L. Vesterbacka Olsson; R. Wallny; D. H. Zhu; T. K. Aarrestad; C. Amsler; Danyyl Brzhechko; M. F. Canelli; A. De Cosa; R. Del Burgo; Silvio Donato; B. Kilminster; Stefanos Leontsinis; Vinicius Massami Mikuni; Izaak Neutelings; Giorgia Rauco; P. Robmann; Daniel Salerno; Korbinian Schweiger; Claudia Seitz; Yuta Takahashi; Sébastien Wertz; Alberto Zucchetta; Thi Hien Doan; C. M. Kuo; W.T. Lin; Ashim Roy; S. S. Yu; P. Chang; Y. Chao; K. F. Chen; Po-Hsun Chen; W. S. Hou; You-ying Li; R.-S. Lu; Efstathios Paganis; Andreas Psallidas; Arnaud Steen; Burin Asavapibhop; Chayanit Asawatangtrakuldee; Norraphat Srimanobhas; Narumon Suwonjandee; A. Bat; Fatma Boran; Serdal Damarseckin; Zuhal Seyma Demiroglu; Furkan Dolek; Candan Dozen; Gul Gokbulut; EmineGurpinar Guler; Yalcin Guler; Ilknur Hos; Candan Isik; E. E. Kangal; Ozgun Kara; A. Kayis Topaksu; Ugur Kiminsu; Mehmet Oglakci; Gulsen Onengut; Kadri Ozdemir; Sertac Ozturk; A. Polatoz; Ali Eren Simsek; D. Sunar Cerci; Bayram Tali; Ufuk Guney Tok; Semra Turkcapar; Ibrahim Soner Zorbakir; Caglar Zorbilmez; B. Isildak; Guler Karapinar; Metin Yalvac; Ismail Okan Atakisi; E. Gülmez; M. Kaya; O. Kaya; Berkan Kaynak; Özlem Özçelik; Sevgi Tekten; Elif Asli Yetkin; Altan Cakir; Kerem Cankocak; Yildiray Komurcu; S. Sen; Suat Ozkorucuklu; Boris Grynyov; L. Levchuk; Fionn Ball; Eshwen Bhal; Simone Bologna; J. J. Brooke; Dustin Burns; Emyr Clement; D. Cussans; Henning Flacher; J. Goldstein; G. P. Heath; H. F. Heath; L. Kreczko; Sudarshan Paramesvaran; Bjoern Penning; T. Sakuma; S. Seif El Nasr storey; David J. Smith; V. J. Smith; Joseph Taylor; Alexander Titterton; K. W. Bell; C. Brew; R. M. Brown; Davide Cieri; David Ja Cockerill; J. A. Coughlan; Kristian Harder; S. Harper; Jacob Linacre; Konstantinos Manolopoulos; Dave M Newbold; E. O. Olaiya; David Petyt; Thomas Reis; Thomas Schuh; C. H. Shepherd-Themistocleous; Alessandro Thea; I. R. Tomalin; Thomas Williams; William John Womersley; R. Bainbridge; Philippe Bloch; Johan Borg; Shane Breeze; O. Buchmuller; Aaron Bundock; GurpreetSingh Chahal; D. Colling; P. D. Dauncey; G. Davies; M. Della-Negra; R. Di Maria; Pieter Everaerts; G. Hall; G. Iles; Thomas James; Matthias Komm; Christian Laner; L. Lyons; Anne-Marie Magnan; S. Malik; Arabella Martelli; Vukasin Milosevic; J. A. Nash; Vito Palladino; M. Pesaresi; D. M. Raymond; Alexander Richards; A. Rose; Edward Scott; C. Seez; Antoni Shtipliyski; M. Stoye; Thomas Strebler; Sioni Summers; A. Tapper; Kirika Uchida; Tejinder Virdee; N. Wardle; Daniel Winterbottom; Jack Wright; Angelo Giacomo Zecchinelli; Seth Conrad Zenz; J. E. Cole; Peter R Hobson; A. Khan; Paul Kyberd; C. K. Mackay; Alexander Morton; I. D. Reid; L. Teodorescu; Sema Zahid; Kenneth Call; J. R. Dittmann; K. Hatakeyama; Christopher Madrid; Brooks McMaster; Nathaniel Pastika; Caleb Smith; Rachel Bartek; A. Dominguez; Rishabh Uniyal; Andrew Buccilli; Seth Cooper; C. Henderson; P. Rumerio; C. West; Daniel Arcaro; T. Bose; Zeynep Demiragli; Daniel Gastler; Semiray Girgis; Deborah Pinna; Clint Richardson; J. Rohlf; D. Sperka; Indara Suarez; L. R. Sulak; David Zou; Gabriele Benelli; Bjorn Burkle; Xavier Coubez; D. Cutts; Yi-ting Duh; Mary Hadley; John Hakala; U. Heintz; Julie Managan Hogan; K. H. M. Kwok; E. Laird; G. Landsberg; Z. Mao; M. Narain; Sinan Sagir; Rizki Syarif; Emanuele Usai; David Yu; Reyer Band; Christopher Brainerd; R. Breedon; M. Calderon De La Barca Sanchez; M. Chertok; J. Conway; Rylan Conway; P. T. Cox; R. Erbacher; Chad Flores; Garrett Funk; Frank Jensen; W. Ko; Ota Kukral; R. L. Lander; Michael Mulhearn; D. E. Pellett; J. Pilot; M. Shi; Dustin Stolp; Devin Taylor; Kyle Tos; M. Tripathi; Zhixing Wang; Fengwangdong Zhang; Michail Bachtis; Cameron Bravo; R. Cousins; Abhigyan Dasgupta; Alice Florent; J. Hauser; M. Ignatenko; Nickolas Mccoll; William Arthur Nash; Simon Regnard; D. Saltzberg; Christian Schnaible; Brent Stone; V. Valuev; Kira Burt; R. Clare; J. W. Gary; S. M. A. Ghiasi Shirazi; Gail Hanson; Georgia Karapostoli; Elizabeth Kennedy; O. R. Long; M. Olmedo Negrete; Mirena Ivova Paneva; W. Si; Long Wang; H. Wei; S. J. Wimpenny; Brent Yates; Yi Zhang; J. G. Branson; S. Cittolin; Mark Derdzinski; Raffaele Gerosa; Dylan Gilbert; Bobak Hashemi; Daniel Klein; V. Krutelyov; J. Letts; Mario Masciovecchio; S. May; Sanjay Padhi; M. Pieri; V. Sharma; Matevz Tadel; F. Würthwein; A. Yagil; G. Zevi Della Porta; Nick Amin; Rohan Bhandari; C. Campagnari; Matthew Citron; Valentina Dutta; M. Franco Sevilla; Loukas Gouskos; J. Incandela; Bennett Marsh; Hualin Mei; Ana Ovcharova; H. Qu; J. D. Richman; Ulascan Sarica; D. Stuart; Sicheng Wang; J. Yoo; Dana Z. Anderson; A. Bornheim; Olmo Cerri; Irene Dutta; Jay Mathew Lawhorn; Nan Lu; Jiajing Mao; H. B. Newman; Thong Nguyen; Joosep Pata; Maria Spiropulu; J. R. Vlimant; Si Xie; Zhicai Zhang; R. Y. Zhu; Michael Benjamin Andrews; T. Ferguson; Tanmay Mudholkar; Manfred Paulini; M. Sun; I. Vorobiev; M. Weinberg; J. P. Cumalat; W. T. Ford; Andrew Johnson; Emily MacDonald; Troy Mulholland; Rishi Patel; Alexx Perloff; K. Stenson; K. A. Ulmer; S. R. Wagner; J. P. Alexander; Jorge Chaves; Yangyang Cheng; J. Chu; Abhisek Datta; Andre Frankenthal; Kevin Mcdermott; Nathan Mirman; J. R. Patterson; D. Quach; Aurelijus Rinkevicius; A. Ryd; S. M. Tan; Z. Tao; J. Thom; P. Wittich; Margaret Zientek; S. Abdullin; Michael Albrow; Maral Alyari; Giorgio Apollinari; Artur Apresyan; A. Apyan; L. A. T. Bauerdick; A. Beretvas; Jeffrey Berryhill; P. C. Bhat; K. Burkett; J. N. Butler; A. Canepa; Giuseppe Benedetto Cerati; H. W. K. Cheung; Frank Chlebana; Matteo Cremonesi; Javier Duarte; V. D. Elvira; J. C. Freeman; Zoltan Gecse; Erik Gottschalk; L. Gray; D. R. Green; Stefan Grünendahl; O. Gutsche; AllisonReinsvold Hall; J. Hanlon; R. M. Harris; S. Hasegawa; Ryan Heller; James Hirschauer; Bodhitha Jayatilaka; S. Jindariani; M. Johnson; U. Joshi; B. Klima; Matti J. Kortelainen; Benjamin Kreis; S. Lammel; Jd Lewis; Don Lincoln; R. Lipton; Miaoyuan Liu; T. Liu; J. Lykken; Kaori Maeshima; John Michael Marraffino; D. Mason; P. McBride; P. Merkel; S. Mrenna; S. Nahn; V. O'Dell; V. Papadimitriou; Kevin Pedro; Cristian Pena; G. Rakness; Fabio Ravera; L. Ristori; Basil Schneider; E. Sexton-Kennedy; Nicholas Smith; Aron Soha; W. J. Spalding; L. Spiegel; S. Stoynev; James Strait; Nadja Strobbe; L. Taylor; S. Tkaczyk; N. V. Tran; Lorenzo Uplegger; E. W. Vaandering; Caterina Vernieri; Marco Verzocchi; R. Vidal; M. H. L. S. Wang; Hannsjoerg Artur Weber; D. Acosta; P. Avery; Pierluigi Bortignon; D. Bourilkov; Andrew Brinkerhoff; Luca Cadamuro; A. Carnes; Vladimir Cherepanov; D. Curry; Filippo Errico; R. D. Field; Sergei Gleyzer; Bhargav Madhusudan Joshi; M. Kim; J. Konigsberg; A. Korytov; Kin Ho Lo; P. Ma; K. Matchev; Nicholas Menendez; G. Mitselmakher; Daniel Rosenzweig; K. Shi; Jing Wang; X. Zuo; Yagya Raj Joshi; Todd Adams; Andrew Askew; S. Hagopian; V. Hagopian; K. F. Johnson; Raman Khurana; Ted Kolberg; German Martinez; T. Perry; H. B. Prosper; Catherine Schiber; Rachel Yohay; Jingyu Zhang; M. M. Baarmand; Vallary Bhopatkar; Marcus Hohlmann; D. Noonan; Mehdi Rahmani; Mark Saunders; F. Yumiceva; M. R. Adams; Leonard Apanasevich; Douglas Berry; R. R. Betts; R. Cavanaugh; Xuan Chen; Susan Dittmer; O. Evdokimov; C. E. Gerber; Dhanush Anil Hangal; D. J. Hofman; Kurt Jung; Corrinne Mills; Titas Roy; Marguerite Tonjes; N. Varelas; Hui Wang; Xiao Wang; Z. Wu; Mohammad Alhusseini; Burak Bilki; Warren Clarida; Kamuran Dilsiz; Süleyman Durgut; R. P. Gandrajula; Maksat Haytmyradov; Viktor Khristenko; Ohannes Kamer Köseyan; Jean-Pierre Merlo; A. Mestvirishvili; Anthony Moeller; J. Nachtman; Hasan Ogul; Y. Onel; Ferhat Ozok; A. Penzo; Christina Snyder; E. Tiras; James Wetzel; B. Blumenfeld; Alice Cocoros; Nicholas Eminizer; David Fehling; Lei Feng; A. V. Gritsan; W. T. Hung; P. Maksimovic; Jeffrey Roskes; Melody A. Swartz; Meng Xiao; C. Baldenegro Barrera; Philip Baringer; A. Bean; Samuel Boren; James Bowen; Alexander Bylinkin; Tommaso Isidori; S. Khalil; Jack King; Georgios Krintiras; Anna Kropivnitskaya; Cole Lindsey; Devdatta Majumder; William Mcbrayer; Nicola Minafra; M. Murray; Christopher Rogan; Christophe Royon; S. Sanders; Erich Schmitz; J. D. Tapia Takaki; J. Williams; G. W. Wilson; Senka Duric; Andrew Ivanov; Ketino Kaadze; Doyeong Kim; Yurii Maravin; Dalath Rachitha Mendis; Tyler Mitchell; Atanu Modak; Abdollah Mohammadi; Finn Rebassoo; D. M. Wright; A. Baden; Owen Baron; Alberto Belloni; S. C. Eno; Y. Feng; N. J. Hadley; Shabnam Jabeen; Geng-Yuan Jeng; R. G. Kellogg; Joshua Kunkle; A. C. Mignerey; Sara Nabili; Francesca Ricci-Tam; Markus Seidel; Y. H. Shin; Andris Skuja; Suresh C Tonwar; Kak Wong; Daniel Abercrombie; Brandon Allen; Austin Baty; Ran Bi; Stephanie Brandt; Wit Busza; I. A. Cali; Mariarosaria D'Alfonso; G. Gomez Ceballos; Maxim Goncharov; Philip Harris; Dylan Hsu; Miao Hu; Markus Klute; Dmytro Kovalskyi; Yen-Jie Lee; P. D. Luckey; Benedikt Maier; Andrea Carlo Marini; Christopher Mcginn; Camelia Mironov; Siddharth Narayanan; Xinmei Niu; C. Paus; Dylan Rankin; C. Roland; G. Roland; Z. Shi; George Stephans; Konstanty Sumorok; Kaya Tatar; Dragos Velicanu; T. W. Wang; Bolek Wyslouch; A. C. Benvenuti; Rajdeep Mohan Chatterjee; Andrew Evans; Sergey Guts; Peter Hansen; Joshua Hiltbrand; Sh. Jain; Sean Kalafut; Y. Kubota; Zachary Lesko; J. Mans; R. Rusack; Mohammad Abrar Wadud; John Gabriel Acosta; Sandra Oliveros; Kenneth Bloom; D. R. Claes; Caleb Fangmeier; Linda Finco; Frank Golf; R. Gonzalez Suarez; Rami Kamalieddin; I. Kravchenko; Joaquin Emilo Siado; G. R. Snow; Benjamin Stieger; Garvita Agarwal; Charles Harrington; I. Iashvili; Avto Kharchilava; Christine Mclean; Duong Nguyen; A. Parker; Juska Pekkanen; S. Rappoccio; Bahareh Roozbahani; G. Alverson; E. Barberis; Chad Freer; Yacine Haddad; Apichart Hortiangtham; Gabriel Madigan; D. M. Morse; T. Orimoto; Louise Skinnari; Abraham Tishelman-Charny; Tanvi Wamorkar; Baokai Wang; Andrew Wisecarver; D. R. Wood; James Bueghly; Thoth Gunter; Kristan Allan Hahn; Nathaniel Odell; Michael Henry Schmitt; Kevin Sung; Marco Trovato; M. Velasco; Rachael Bucci; Nabarun Dev; Reza Goldouzian; M. D. Hildreth; K. Hurtado Anampa; Colin Jessop; D. J. Karmgard; K. Lannon; Wei Li; Nikitas Loukas; N. Marinelli; Ian Mcalister; F. Meng; Charles Mueller; Y. Musienko; Michael Planer; R. Ruchti; Prasanna Siddireddy; Graeme Smith; Silvia Taroni; M. Wayne; Andrew Wightman; M. Wolf; Anna Woodard; Juliette Alimena; Ben Bylsma; L. S. Durkin; Sean Flowers; B. Francis; C. Hill; Weifeng Ji; Anthony Lefeld; T. Y. Ling; Brian L Winer; Stephane Cooperstein; Gage Dezoort; P. Elmer; Joshua Hardenbrook; Nicholas Haubrich; Samuel Higginbotham; Alexis Kalogeropoulos; Stephanie Kwan; D. Lange; Marco Toliman Lucchini; J. Luo; Daniel Marlow; Kelvin Mei; Isabel Ojalvo; James Olsen; C. Palmer et al.,"A search is presented for a charged Higgs boson heavier than the top quark, produced in association with a top quark, or with a top and a bottom quark, and decaying into a top-bottom quark-antiquark pair. The search is performed using proton-proton collision data collected by the CMS experiment at the LHC at a center-of-mass energy of 13 TeV, corresponding to an integrated luminosity of 35.9 fb−1. Events are selected by the presence of a single isolated charged lepton (electron or muon) or an opposite-sign dilepton (electron or muon) pair, categorized according to the jet multiplicity and the number of jets identified as originating from b quarks. Multivariate analysis techniques are used to enhance the discrimination between signal and background in each category. The data are compatible with the standard model, and 95% confidence level upper limits of 9.6–0.01 pb are set on the charged Higgs boson production cross section times branching fraction to a top-bottom quark-antiquark pair, for charged Higgs boson mass hypotheses ranging from 200 GeV to 3 TeV. The upper limits are interpreted in different minimal supersymmetric extensions of the standard model.",2020,,,https://publikationen.bibliothek.kit.edu/1000105319,https://publikationen.bibliothek.kit.edu/1000105319,0,,,3002501686,,003-649-105-078-142; 009-735-818-639-519; 013-901-225-195-006; 014-002-676-540-400; 014-410-352-633-208; 016-546-466-418-421; 017-193-576-454-314; 024-491-646-673-723; 024-541-234-790-977; 026-845-226-315-688; 037-696-337-690-360; 040-612-410-048-233; 049-404-766-382-401; 050-267-269-752-739; 052-947-110-986-738; 059-929-850-971-983; 061-598-183-587-555; 070-700-643-164-073; 077-947-724-400-057; 078-733-337-744-522; 082-120-576-225-562; 086-506-566-507-408; 086-696-023-784-337; 092-490-282-673-176; 116-966-766-685-122; 135-973-600-029-840; 147-398-702-033-901; 150-793-811-452-011; 160-813-316-281-938; 165-242-375-572-618; 183-088-376-803-393; 186-699-916-242-163,0
